

GenCore version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: February 4, 2003, 09:38:23 ; Search time 38 Seconds
(without alignments)
995.873 Million cell updates/sec

Title: US-09-704-272-6

Perfect score: 1525

Sequence: 1 FGKPSLELPQWYNEQYTF.....PLNLTKQQLSEVALMTTSVD 284

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_101002.*

- 1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT.*
- 2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT.*
- 3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT.*
- 4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT.*
- 5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT.*
- 6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT.*
- 7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT.*
- 8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT.*
- 9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT.*
- 10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT.*
- 11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT.*
- 12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT.*
- 13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT.*
- 14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT.*
- 15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT.*
- 16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT.*
- 17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT.*
- 18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT.*
- 19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT.*
- 20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT.*
- 21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT.*
- 22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT.*
- 23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Match	Score	Length	ID	Description
1	1525	100.0	284	22	AA62695
2	1525	100.0	2143	21	AA638113
3	1525	100.0	2259	21	AA638116
4	1525	100.0	2260	21	AA638117
5	1525	100.0	2261	21	AA638118
6	1525	100.0	2261	21	AA638119
7	1525	100.0	2261	21	AA638120
8	1525	100.0	2261	21	AA638121
9	1525	100.0	2261	21	AA638122
10	1525	100.0	2261	21	AA638123

11	1525	100.0	2261	21	AA638113	Human ABC1 cholest
12	1525	100.0	2261	21	AA638114	Human ABC1 cholest
13	1525	100.0	2261	21	AA638116	Human ABC1 cholest
14	1525	100.0	2261	21	AA638117	Human ABC1 cholest
15	1525	100.0	2261	21	AA638118	Human ABC1 cholest
16	1525	100.0	2261	21	AA638119	Human ABC1 cholest
17	1525	100.0	2261	21	AA638120	Human ABC1 cholest
18	1525	100.0	2261	21	AA638121	Human ABC1 cholest
19	1525	100.0	2261	21	AA638122	Human ABC1 cholest
20	1525	100.0	2261	21	AA638123	Human ABC1 cholest
21	1525	100.0	2261	21	AA638124	Human ABC1 cholest
22	1525	100.0	2261	21	AA638125	Human ABC1 cholest
23	1525	100.0	2261	21	AA638126	Human ABC1 cholest
24	1525	100.0	2261	21	AA638127	Human ABC1 cholest
25	1525	100.0	2261	21	AA638128	Human ABC1 cholest
26	1525	100.0	2261	21	AA638129	Human ABC1 cholest
27	1525	100.0	2261	21	AA638130	Human ABC1 cholest
28	1525	100.0	2261	21	AA638131	Human ABC1 cholest
29	1525	100.0	2261	21	AA638132	Human ABC1 cholest
30	1525	100.0	2261	21	AA638133	Human ABC1 cholest
31	1525	100.0	2261	21	AA638134	Human ABC1 cholest
32	1525	100.0	2261	21	AA638135	Human ABC1 cholest
33	1525	100.0	2261	21	AA638136	Human ABC1 cholest
34	1525	100.0	2261	21	AA638137	Human ABC1 cholest
35	1525	100.0	2261	21	AA638138	Human ABC1 cholest
36	1525	100.0	2261	21	AA638139	Human ABC1 cholest
37	1525	100.0	2261	21	AA638140	Human ABC1 cholest
38	1525	100.0	2261	21	AA638141	Human ABC1 cholest
39	1525	100.0	2261	21	AA638142	Human ABC1 cholest
40	1525	100.0	2261	21	AA638143	Human ABC1 cholest
41	1525	100.0	2261	21	AA638144	Human ABC1 cholest
42	1525	100.0	2261	21	AA638145	Human ABC1 cholest
43	1525	100.0	2261	21	AA638146	Human ABC1 cholest
44	1525	100.0	2261	21	AA638147	Human ABC1 cholest
45	1525	100.0	2261	21	AA638148	Human ABC1 cholest

ALIGNMENTS

RESULT 1

AA62695

ID AA62695 standard; peptide; 284 AA.

AC AA62695;

DT 06-AUG-2001 (first entry)

DE ABC1 protein external domain TM7-TM8 fragment (residues 1371-1654).

KW ABC1; antilipemic; cholesterol; inhibitor; low density lipoprotein; LDL.

OS Homo sapiens.

PN WO200132184-A2.

PD 10-MAY-2001.

PF 01-NOV-2000; 2000WO-US30109.

PR 01-NOV-1999; 99US-0162803.

PR 30-JUN-2000; 2000US-0215564.

XX (WISC) WISCONSIN ALUMNI RES FOUND.

XX Attle AD, Cook M, Gray-Keller MP, Hayden MR, Plimstone S;

PI Brooks-Willson A;

XX WPI; 2001-335779/35.

XX New method for inhibiting cholesterol uptake in the gut comprises administration of an inhibitor of an ABC1 protein -

XX

PS Disclosure: Page 9; 41pp; English.

XX The invention relates to a new method for inhibiting cholesterol uptake

CC in the gut that comprises administration of an inhibitor of an ABC1

CC protein. The method is useful for: lowering levels of LDL (low density

CC lipoprotein) cholesterol by reducing the activity of ABC1 protein in the

CC intestinal cells and the abundance of the ABC1 protein in the individual

CC by inhibiting the activity of the protein; identifying drugs that can

CC lower serum cholesterol and LDL levels comprising assaying the drug to

CC test if it can bind to an ABC1 protein; testing LDL cholesterol lowering

CC agents; and for modulation of ABC1 biological activity. Sequences

CC AAB62692-97 represent predicted external domain of ABC1 protein.

XX

XX Sequence 284 AA;

XX

Query Match 100.0%; Score 1525; DB 22; Length 284;

Best Local Similarity 100.0%; Pred. No. 2.3e-144;

Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FGKYPSELEQPMWYNEQYTFVSNDAEDTGTLELLNALTDPGFGTRCMGPNIPDTPCQ 60

DB 1 FGKYPSELEQPMWYNEQYTFVSNDAEDTGTLELLNALTDPGFGTRCMGPNIPDTPCQ 60

QY 61 AGEETWTAPVPQTIMDLFQNGNWTMNPSPACQSSDKTKKMLPVCPCAGGLPPPPQRK 120

DB 61 AGEETWTAPVPQTIMDLFQNGNWTMNPSPACQSSDKTKKMLPVCPCAGGLPPPPQRK 120

QY 121 QNTADILQDLTGRNLSYLVKTYVQIIAKSLKNIWNEFRYGFSLGVSNTQALPPSOE 180

DB 121 QNTADILQDLTGRNLSYLVKTYVQIIAKSLKNIWNEFRYGFSLGVSNTQALPPSOE 180

QY 181 VNDATKQMKKKHLKAKDSSADRFNLNGLRFTMTGLDTRNNYKVFNNKGWHAISSEFLNWIN 240

DB 181 VNDATKQMKKKHLKAKDSSADRFNLNGLRFTMTGLDTRNNYKVFNNKGWHAISSEFLNWIN 240

QY 241 NAILRANLQKGNPSHYGITAFNPLNLTQOOLSEVALMTTSVD 284

DB 241 NAILRANLQKGNPSHYGITAFNPLNLTQOOLSEVALMTTSVD 284

RESULT 2

AAB38108

ID AAB38108 standard; Protein: 2143 AA.

AC AAB38108;

XX

XX 29-JAN-2001 (first entry)

XX

XX Human ABC1 cholesterol transporter PHA-1 mutant protein (R2144STOP).

DE

XX Human ABC1 cholesterol transporter; chromosome 9q31;

KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;

KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;

KW cardiovascular disease; coronary artery disease; coronary stenosis;

KW cerebrovascular disease; peripheral vascular disease;

KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;

KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;

KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;

KW mutin.

XX

XX Homo sapiens.

OS

XX

XX WO200055318-A2.

PN

XX

XX 21-SEP-2000.

PD

XX

XX 15-MAR-2000; 2000WO-IB00532.

PF

XX

XX 15-MAR-1999; 99US-0124702.

PR

XX 08-JUN-1999; 99US-0138048.

PR

XX 17-JUN-1999; 99US-0139600.

PR

XX 01-SEP-1999; 99US-0151977.

PR

XX

PA (UYBR-) UNIV BRITISH COLUMBIA.

PA (XENO-) XENON BIORESEARCH INC.

XX

XX Hayden MR, Willson AR, Pimstone SN;

XX

XX WPI: 2000-587528/55.

DR N-PSDB; AAC69389.

XX

XX New ABC1 polypeptide is useful for treating diseases associated with

PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's

PT disease and cancer -

XX

XX Examples; Page -: 229pp; English.

XX

XX The invention relates to the human ABC1 cholesterol transporter protein

CC (B38082) and to nucleic acid sequences (CG9120) which encode it. ABC1 is

CC a member of the ATP-binding cassette (ABC transporter) superfamily of

CC proteins, and plays a crucial role in cholesterol transport, particularly

CC intracellular cholesterol trafficking in monocytes and fibroblasts, being

CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is

CC located on chromosome 9q31, and mutations in this gene are associated

CC with two genetic HDL (high density lipoprotein) deficiency disorders,

CC tangier disease (TD) and familial HDL deficiency (FHA). These diseases

CC are distinguishable in that TD is an autosomal recessive disorder, while

CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good

CC cholesterol") in the blood correlate with a high risk of cardiovascular

CC disease, particularly coronary artery disease, but also cerebrovascular

CC disease, coronary stenosis, and peripheral vascular disease.

CC Conversely, a high level of HDL has protective effects against

CC cardiovascular disease. The invention provides genetic constructs and

CC transgenic cells and non-human animals comprising human ABC1 nucleic

CC acids, and methods of gene therapy for the treatment or prevention of

CC cardiovascular disease comprising the administration of an expression

CC vector encoding ABC1 or an active fragment thereof. The invention also

CC encompasses compounds which mimic ABC1 activity, compounds which

CC stimulate ABC1 expression and methods of screening for such compounds.

CC It further relates to methods for determining whether a patient has an

CC increased risk for cardiovascular disease due to polymorphisms in the

CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat

CC or prevent cardiovascular disease, especially coronary artery disease,

CC cerebrovascular disease, coronary stenosis or peripheral vascular

CC disease. They may also be used in the treatment of diseases associated

CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick

CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.

CC The invention specifically excludes proteins with the exact amino acid

CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic

CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The

CC present sequence represents a mutant human ABC1 cholesterol transporter

CC associated with an altered cholesterol level and therefore an altered

CC risk of cardiovascular disease.

CC Note: The present sequence is not shown in the specification, but is

CC derived from the native human ABC1 shown on pages 152-157.

XX

XX Sequence 2143 AA;

XX

Query Match 100.0%; Score 1525; DB 21; Length 2143;

Best Local Similarity 100.0%; Pred. No. 4.7e-143;

Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FGKYPSELEQPMWYNEQYTFVSNDAEDTGTLELLNALTDPGFGTRCMGPNIPDTPCQ 60

DB 1371 FGKYPSELEQPMWYNEQYTFVSNDAEDTGTLELLNALTDPGFGTRCMGPNIPDTPCQ 1430

QY 61 AGEETWTAPVPQTIMDLFQNGNWTMNPSPACQSSDKTKKMLPVCPCAGGLPPPPQRK 120

DB 1431 AGEETWTAPVPQTIMDLFQNGNWTMNPSPACQSSDKTKKMLPVCPCAGGLPPPPQRK 1490

QY 121 QNTADILQDLTGRNLSYLVKTYVQIIAKSLKNIWNEFRYGFSLGVSNTQALPPSOE 180

DB 1491 QNTADILQDLTGRNLSYLVKTYVQIIAKSLKNIWNEFRYGFSLGVSNTQALPPSOE 1550

QY 181 VNDATKQMKKKHLKAKDSSADRFNLNGLRFTMTGLDTRNNYKVFNNKGWHAISSEFLNWIN 240

Db 1551 VNDATKQMKHKLAKDSSADRLNSLGRFMTGLDTRNNVWVFNKQWHAISSEFLNVIN 1610

QY 241 NAILRANLQKGENPSHYGITAFNHPNLNTKQOLSEVALMTTSVD 284

Db 1611 NAILRANLQKGENPSHYGITAFNHPNLNTKQOLSEVALMTTSVD 1654

RESULT 3

AAB38107

XX AAB38107 standard; Protein; 2259 AA.

AC AAB38107;

XX

DT 29-JAN-2001 (first entry)

XX

DE Human ABC1 FHA-3 mutant protein (delta-E1893, D1894).

XX

KW Human ABC1 cholesterol transporter; chromosome 9q31;

KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;

KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;

KW cardiovascular disease; coronary artery disease; coronary restenosis;

KW cerebrovascular disease; peripheral vascular disease;

KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;

KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;

KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;

KW mtein.

XX

OS Homo sapiens.

XX

PN WO200055318-A2.

XX

PD 21-SEP-2000.

XX

PF 15-MAR-2000; 2000WO-IB00532.

XX

PR 15-MAR-1999; 99US-0124702.

PR 08-JUN-1999; 99US-0138048.

PR 17-JUN-1999; 99US-0139600.

PR 01-SEP-1999; 99US-0151977.

XX

PA (UYBR-) UNIV BRITISH COLUMBIA.

PA (XENO-) XENON BIORESEARCH INC.

XX

PI Haydén MR, Wilson AR, Pimstone SN;

XX

DR WPI; 2000-587528/55.

DR N-PSDB; AAC69388.

XX

PT New ABC1 polypeptide is useful for treating diseases associated with

PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's

PT disease and cancer -

XX

PS Examples; Page -: 229pp; English.

XX

CC The invention relates to the human ABC1 cholesterol transporter protein

CC (G38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is

CC a member of the ATP-binding cassette (ABC transporter) superfamily of

CC proteins, and plays a crucial role in cholesterol transport, particularly

CC intracellular cholesterol trafficking in monocytes and fibroblasts, being

CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is

CC located on chromosome 9q31, and mutations in this gene are associated

CC with two genetic HDL (high density lipoprotein) deficiency disorders,

CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases

CC are distinguishable in that TD is an autosomal recessive disorder, while

CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good

CC cholesterol") in the blood correlate with a high risk of cardiovascular

CC disease, particularly coronary artery disease, but also cerebrovascular

CC disease, coronary restenosis, and peripheral vascular disease.

CC Conversely, a high level of HDL has protective effects against

CC cardiovascular disease. The invention provides genetic constructs and

CC transgenic cells and non-human animals comprising human ABC1 nucleic

CC acids, and methods of gene therapy for the treatment or prevention of

CC cardiovascular disease comprising the administration of an expression

CC vector encoding ABC1 or an active fragment thereof. The invention also

CC encompasses compounds which mimic ABC1 activity, compounds which

CC stimulate ABC1 expression and methods of screening for such compounds.

CC It further relates to methods for determining whether a patient has an

CC increased risk for cardiovascular disease due to polymorphisms in the

CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat

CC or prevent cardiovascular disease, especially coronary artery disease,

CC cerebrovascular disease, coronary restenosis or peripheral vascular

CC disease. They may also be used in the treatment of diseases associated

CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick

CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.

CC The invention specifically excludes proteins with the exact amino acid

CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic

CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The

CC present sequence represents a mutant human ABC1 cholesterol transporter

CC associated with an altered cholesterol level and therefore an altered

CC risk of cardiovascular disease.

CC Note: The present sequence is not shown in the specification, but is

CC derived from the native human ABC1 shown on pages 152-157.

XX

SQ Sequence 2259 AA;

Query Match 100.0%; Score 1525; DB 21; Length 2259;

Best Local Similarity 100.0%; Pred. No. 5e-143;

Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FKYPSELEQPMWYNEQYTFVSNDAPEDEGTLELLNALT KDPGFTRCMEGNPIDPTPCQ 60

|||||

Db 1371 FKYPSELEQPMWYNEQYTFVSNDAPEDEGTLELLNALT KDPGFTRCMEGNPIDPTPCQ 1430

QY 61 AGESEWTTAPVPTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120

|||||

Db 1431 AGESEWTTAPVPTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 1490

QY 121 QNTADILQDLTGRNISDYLVKTYVQIIAKSLANKIWNVEFRYGGFSLGVSNTQALPPSQE 180

|||||

Db 1491 QNTADILQDLTGRNISDYLVKTYVQIIAKSLANKIWNVEFRYGGFSLGVSNTQALPPSQE 1550

QY 181 VNDATKQMKHKLAKDSSADRLNSLGRFMTGLDTRNNVWVFNKQWHAISSEFLNVIN 240

|||||

Db 1551 VNDATKQMKHKLAKDSSADRLNSLGRFMTGLDTRNNVWVFNKQWHAISSEFLNVIN 1610

QY 241 NAILRANLQKGENPSHYGITAFNHPNLNTKQOLSEVALMTTSVD 284

|||||

Db 1611 NAILRANLQKGENPSHYGITAFNHPNLNTKQOLSEVALMTTSVD 1654

RESULT 4

AAB38106

ID AAB38106 standard; Protein; 2260 AA.

XX

AC AAB38106;

XX

DT 29-JAN-2001 (first entry)

XX

DE Human ABC1 cholesterol transporter FHA-1 mutant protein (delta-L693).

XX

KW Human ABC1 cholesterol transporter; chromosome 9q31;

KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;

KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;

KW cardiovascular disease; coronary artery disease; coronary restenosis;

KW cerebrovascular disease; peripheral vascular disease;

KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;

KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;

KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;

KW mtein.

XX

OS Homo sapiens.

XX

PN WO200055318-A2.

XX

PD 21-SEP-2000.

XX

```

PF 15-MAR-2000; 2000WO-IB00532.
XX
PR 15-MAR-1999; 99US-0124702.
PR 08-JUN-1999; 99US-0138048.
PR 17-JUN-1999; 99US-0139600.
PR 01-SEP-1999; 99US-0151977.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (XENO-) XENON BIORESEARCH INC.
XX
PI Hayden MR, Wilson AR, Pimstone SN;
XX
XX WPI: 2000-587528/55.
XX N-PSDB; AAC69387.
XX
XX New ABC1 polypeptide is useful for treating diseases associated with
PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
PT disease and cancer -
XX
XX Examples; Page -: 229pp; English.
XX
XX The invention relates to the human ABC1 cholesterol transporter protein
CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
CC a member of the ATP-binding cassette (ABC transporter) superfamily of
CC proteins, and plays a crucial role in cholesterol transport, particularly
CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
CC located on chromosome 9q31, and mutations in this gene are associated
CC with two genetic HDL (high density lipoprotein) deficiency disorders,
CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
CC are distinguishable in that TD is an autosomal recessive disorder, while
CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
CC cholesterol") in the blood correlate with a high risk of cardiovascular
CC disease, particularly coronary artery disease, but also cerebrovascular
CC disease, coronary restenosis, and peripheral vascular disease.
CC Conversely, a high level of HDL has protective effects against
CC cardiovascular disease. The invention provides genetic constructs and
CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC vector encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary restenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.
XX
SQ Sequence 2260 AA;
Query Match 100.0%; Score 1525; DB 21; Length 2260;
Best Local Similarity 100.0%; Pred. No. 5e-143;
Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 FGKYPSELQPMWYNGQYTVSNDAEDTGTLELLNALTKDGFGRCMEGNPIDPTPCQ 60
DB 1370 FGKYPSELQPMWYNGQYTVSNDAEDTGTLELLNALTKDGFGRCMEGNPIDPTPCQ 1429
QY 61 AGEEWTTAPVQTIIMDLFONGNWTWQNPSPACQSSDKIKKMLPVCPCAGGLPPQQR 120
DB 1430 AGEEWTTAPVQTIIMDLFONGNWTWQNPSPACQSSDKIKKMLPVCPCAGGLPPQQR 1489

```

```

QY 121 QNTADIIQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
DB 1490 QNTADIIQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 1549
QY 181 VNDAIKQMKKHLKLAKDSSADRFNLSLGRPMTGLDTRNNYKVFNNKNGWHAISSFLNVIN 240
DB 1550 VNDAIKQMKKHLKLAKDSSADRFNLSLGRPMTGLDTRNNYKVFNNKNGWHAISSFLNVIN 1609
QY 241 NAILRANLQKGENPSHYGITAFNHLPLNLTKOQLSEVALMTTSVD 284
DB 1610 NAILRANLQKGENPSHYGITAFNHLPLNLTKOQLSEVALMTTSVD 1653
RESULT 5
AAB38082
ID AAB38082 standard; Protein; 2261 AA.
XX
AC AAB38082;
XX
XX 29-JAN-2001 (first entry)
XX
XX Human ABC1 cholesterol transporter.
DE
XX
XX Human ABC1 cholesterol transporter; chromosome 9q31.
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal.
XX
OS Homo sapiens.
XX
XX WO2000055318-A2.
XX
XX 21-SEP-2000.
XX
XX 15-MAR-2000; 2000WO-IB00532.
XX
XX 15-MAR-1999; 99US-0124702.
XX 08-JUN-1999; 99US-0138048.
XX 17-JUN-1999; 99US-0139600.
XX 01-SEP-1999; 99US-0151977.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX (XENO-) XENON BIORESEARCH INC.
XX
XX Hayden MR, Wilson AR, Pimstone SN;
XX
XX WPI: 2000-587528/55.
XX N-PSDB; AAC69120.
XX
XX New ABC1 polypeptide is useful for treating diseases associated with
PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
PT disease and cancer -
XX
XX Claim 5; Page 152-157; 229pp; English.
XX
XX The invention relates to the human ABC1 cholesterol transporter protein
CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
CC a member of the ATP-binding cassette (ABC transporter) superfamily of
CC proteins, and plays a crucial role in cholesterol transport, particularly
CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
CC located on chromosome 9q31, and mutations in this gene are associated
CC with two genetic HDL (high density lipoprotein) deficiency disorders,
CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
CC are distinguishable in that TD is an autosomal recessive disorder, while
CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
CC cholesterol") in the blood correlate with a high risk of cardiovascular
CC disease, particularly coronary artery disease, but also cerebrovascular

```

CC disease, coronary restenosis, and peripheral vascular disease.
CC Conversely, a high level of HDL has protective effects against
CC cardiovascular disease. The invention provides genetic constructs and
CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC vector encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary restenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents the human ABC1 cholesterol transporter.
XX
SQ Sequence 2261 AA;

Query Match 100.0%; Score 1525; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 5e-143;
Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLLELNALTKDPGFGTRCMGPNIPDTPCQ 60
DB 1371 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLLELNALTKDPGFGTRCMGPNIPDTPCQ 1430
QY 61 AGEEWTTAPVQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPPPPQK 120
DB 1431 AGEEWTTAPVQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPPPPQK 1490
QY 121 QNTADILQDLTGRTSDYLVKTVYQIIAKSLKNIWNEFRYGGSLGVSNTQALPPSQE 180
DB 1491 QNTADILQDLTGRTSDYLVKTVYQIIAKSLKNIWNEFRYGGSLGVSNTQALPPSQE 1550
QY 181 VNDIAIKMKHLKLAKDSSADRLNSLGRFMTGLDTRNNVKWFNKGWHAISFLNLIN 240
DB 1551 VNDIAIKMKHLKLAKDSSADRLNSLGRFMTGLDTRNNVKWFNKGWHAISFLNLIN 1610
QY 241 NAILRANLQGENPSHYGTAFNHPNLTKQQLSEVALMTTSVD 284
DB 1611 NAILRANLQGENPSHYGTAFNHPNLTKQQLSEVALMTTSVD 1654

RESULT 6
AAB38105
ID AAB38105 standard; Protein; 2261 AA.
XX
AC AAB38105;
XX
DT 29-JAN-2001 (first entry)
XX
DE Human ABC1 cholesterol transporter TD-2 mutant protein (Q597R).
XX
KW Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cerebrovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
mucin.
XX
OS Homo sapiens.
XX
PN WO200055318-A2.
XX

PD 21-SEP-2000.
XX
PF 15-MAR-2000; 2000WO-IB00532.
XX
PR 15-MAR-1999; 99US-0124702.
PR 08-JUN-1999; 99US-0138048.
PR 17-JUN-1999; 99US-0139600.
PR 01-SEP-1999; 99US-0151977.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (XENO-) XENON BIORESEARCH INC.
XX
PI Hayden MR, Wilson AR, Pimstone SN;
XX
DR WPI; 2000-587528/55.
DR N-PSDB; AAC69386.
XX
PT New ABC1 polypeptide is useful for treating diseases associated with
PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
PT disease and cancer -
XX
PS Examples; Page -: 229pp; English.
XX

CC The invention relates to the human ABC1 cholesterol transporter protein
CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
CC a member of the ATP-binding cassette (ABC transporter) superfamily of
CC proteins, and plays a crucial role in cholesterol transport, particularly
CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
CC located on chromosome 9q31, and mutations in this gene are associated
CC with two genetic HDL (high density lipoprotein) deficiency disorders,
CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
CC are distinguishable in that TD is an autosomal recessive disorder, while
CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
CC cholesterol") in the blood correlate with a high risk of cardiovascular
CC disease, particularly coronary artery disease, but also cerebrovascular
CC disease, coronary restenosis, and peripheral vascular disease.
CC Conversely, a high level of HDL has protective effects against
CC cardiovascular disease. The invention provides genetic constructs and
CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC vector encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary restenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.
XX
SQ Sequence 2261 AA;

Query Match 100.0%; Score 1525; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 5e-143;
Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLLELNALTKDPGFGTRCMGPNIPDTPCQ 60
DB 1371 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLLELNALTKDPGFGTRCMGPNIPDTPCQ 1430
QY 61 AGEEWTTAPVQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPPPPQK 120

Db 1431 AGESEWTTAPVQQTIMDLFQNGNWTMQNPSPACQCSDDKIKKMLPVCPPGAGGLPPQPK 1490
Qy 121 QNTADILQDLTGRNLSYLVKTYVQIIIAKSLKNIWNEFRYGGFSLGVSNQALPPSQE 180
Db 1491 QNTADILQDLTGRNLSYLVKTYVQIIIAKSLKNIWNEFRYGGFSLGVSNQALPPSQE 1550
Qy 181 VNDATIKQMKHKLAKDSSADRFNLSLGRFMTGLDTRNNVWVFNKNGWHAISFLNIN 240
Db 1551 VNDATIKQMKHKLAKDSSADRFNLSLGRFMTGLDTRNNVWVFNKNGWHAISFLNIN 1610
Qy 241 NAILRANLQKGENPSHYGITAFNHPNLNLTQKQSEVALMTTSVD 284
Db 1611 NAILRANLQKGENPSHYGITAFNHPNLNLTQKQSEVALMTTSVD 1654
RESULT 7
AAB38109
ID AAB38109 standard; Protein: 2261 AA.
XX AC AAB38109;
XX DT 29-JAN-2001 (first entry)
XX DE Human ABC1 cholesterol transporter mutant, R219K.
XX KW Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW mutelin.
XX OS Homo sapiens.
XX PN WO2000055318-A2.
XX PD 21-SEP-2000.
XX PF 15-MAR-2000; 2000WO-IB00532.
XX PR 15-MAR-1999; 99US-0124702.
PR 08-JUN-1999; 99US-0138048.
PR 17-JUN-1999; 99US-0139600.
PR 01-SEP-1999; 99US-0151977.
XX {UYBR-} UNIV BRITISH COLUMBIA.
PA {XENO-} XENON BIORESEARCH INC.
XX Hayden MR, Wilson AR, Pimstone SN;
PI WPI; 2000-587528/55.
XX New ABC1 polypeptide is useful for treating diseases associated with
PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
PT disease and cancer -
XX Examples; Page -: 229pp; English.
XX The invention relates to the human ABC1 cholesterol transporter protein
CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
CC a member of the ATP-binding cassette (ABC transporter) superfamily of
CC proteins, and plays a crucial role in cholesterol transport, particularly
CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
CC located on chromosome 9q31, and mutations in this gene are associated
CC with two genetic HDL (high density lipoprotein) deficiency disorders,
CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
CC are distinguishable in that TD is an autosomal recessive disorder, while
CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good

cholesterol") in the blood correlate with a high risk of cardiovascular
disease, particularly coronary artery disease, but also cerebrovascular
disease, coronary restenosis, and peripheral vascular disease.
Conversely, a high level of HDL has protective effects against
cardiovascular disease. The invention provides genetic constructs and
transgenic cells and non-human animals comprising human ABC1 nucleic
acids, and methods of gene therapy for the treatment or prevention of
cardiovascular disease comprising the administration of an expression
vector encoding ABC1 or an active fragment thereof. The invention also
encompasses compounds which mimic ABC1 activity, compounds which
stimulate ABC1 expression and methods of screening for such compounds.
It further relates to methods for determining whether a patient has an
increased risk for cardiovascular disease due to polymorphisms in the
ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
or prevent cardiovascular disease, especially coronary artery disease,
cerebrovascular disease, coronary restenosis or peripheral vascular
disease. They may also be used in the treatment of diseases associated
with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
The invention specifically excludes proteins with the exact amino acid
sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
acid with the exact sequence as GenBank Accession No: AJ012376.1. The
present sequence represents a mutant human ABC1 cholesterol transporter
associated with an altered cholesterol level and therefore an altered
risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.
XX Sequence 2261 AA;
SQ
Query Match 100.0%; Score 1525; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 5e-143;
Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 FGKYPSELOPQWYNEQYTFVSNDAPEDTGTLELLNALTQDGFGRMCGNPIPDTPCQ 60
Db 1371 FGKYPSELOPQWYNEQYTFVSNDAPEDTGTLELLNALTQDGFGRMCGNPIPDTPCQ 1430
Qy 61 AGESEWTTAPVQQTIMDLFQNGNWTMQNPSPACQCSDDKIKKMLPVCPPGAGGLPPQPK 120
Db 1431 AGESEWTTAPVQQTIMDLFQNGNWTMQNPSPACQCSDDKIKKMLPVCPPGAGGLPPQPK 1490
Qy 121 QNTADILQDLTGRNLSYLVKTYVQIIIAKSLKNIWNEFRYGGFSLGVSNQALPPSQE 180
Db 1491 QNTADILQDLTGRNLSYLVKTYVQIIIAKSLKNIWNEFRYGGFSLGVSNQALPPSQE 1550
Qy 181 VNDATIKQMKHKLAKDSSADRFNLSLGRFMTGLDTRNNVWVFNKNGWHAISFLNIN 240
Db 1551 VNDATIKQMKHKLAKDSSADRFNLSLGRFMTGLDTRNNVWVFNKNGWHAISFLNIN 1610
Qy 241 NAILRANLQKGENPSHYGITAFNHPNLNLTQKQSEVALMTTSVD 284
Db 1611 NAILRANLQKGENPSHYGITAFNHPNLNLTQKQSEVALMTTSVD 1654
RESULT 8
AAB38110
ID AAB38110 standard; Protein: 2261 AA.
XX AC AAB38110;
XX DT 29-JAN-2001 (first entry)
XX DE Human ABC1 cholesterol transporter mutant, V399A.
XX KW Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW

KW mutein.
 OS Homo sapiens.
 XX WO200055318-A2.
 XX 21-SEP-2000.
 XX
 XX 15-MAR-2000; 2000WO-IB00532.
 XX
 XX 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON BIORESEARCH INC.
 PI Hayden MR, Wilson AR, Pimstone SN;
 XX
 XX WPI; 2000-587528/55.
 XX
 XX New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX
 XX Examples; Page -; 229pp; English.
 XX
 XX The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary stenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary stenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of Genbank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as Genbank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.
 XX
 XX Sequence 2261 AA;

Query Match 100.0%; Score 1525; DB 21; Length 2261;
 Best Local Similarity 100.0%; Pred. No. 5e-143;
 Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FGKPSLELQPMWYNEQYTFVSDAPEDTGTLELLNALTQDGFGRGMEGNPIPDTPCQ 60
 DB 1371 FGKPSLELQPMWYNEQYTFVSDAPEDTGTLELLNALTQDGFGRGMEGNPIPDTPCQ 1430
 QY 61 AGESEWTTAPVPTIMDLFONGNWTQNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
 DB 1431 AGESEWTTAPVPTIMDLFONGNWTQNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 1490
 QY 121 QNTADILQDITGRNISDYLVKTYVQIIIAKSLNKKIWNVEFRYGGFSLGVSNTQALPSSQE 180
 DB 1491 QNTADILQDITGRNISDYLVKTYVQIIIAKSLNKKIWNVEFRYGGFSLGVSNTQALPSSQE 1550
 QY 181 VNDIAIKOMKKHLKLAKDSSADREFLSLGRFMTGLDTRNNKVFNNKKGWHAISFLNWIN 240
 DB 1551 VNDIAIKOMKKHLKLAKDSSADREFLSLGRFMTGLDTRNNKVFNNKKGWHAISFLNWIN 1610
 QY 241 NAILRANLQGENPSHYGITAFNHLNLTQKQLSEVALMTTSVD 284
 DB 1611 NAILRANLQGENPSHYGITAFNHLNLTQKQLSEVALMTTSVD 1654

RESULT 9

AAB38111

ID AAB38111 standard; Protein; 2261 AA.

XX

AC AAB38111;

XX

DT 29-JAN-2001 (first entry)

XX

DE Human ABC1 cholesterol transporter mutant, V771M.

XX

KW Human ABC1 cholesterol transporter; chromosome 9q31;

KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;

KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;

KW cerebrovascular disease; coronary artery disease; coronary stenosis;

KW cerebrovascular disease; peripheral vascular disease;

KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;

KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;

KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;

XX

OS Homo sapiens.

XX

PN WO200055318-A2.

XX

PD 21-SEP-2000.

XX

PF 15-MAR-2000; 2000WO-IB00532.

XX

PR 15-MAR-1999; 99US-0124702.

PR

PR 08-JUN-1999; 99US-0138048.

PR

PR 17-JUN-1999; 99US-0139600.

PR

PR 01-SEP-1999; 99US-0151977.

XX

PA (UYBR-) UNIV BRITISH COLUMBIA.

XX

PA (XENO-) XENON BIORESEARCH INC.

XX

PI Hayden MR, Wilson AR, Pimstone SN;

XX

DR WPI; 2000-587528/55.

XX

XX New ABC1 polypeptide is useful for treating diseases associated with

PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's

PT disease and cancer -

XX

PS Examples; Page -; 229pp; English.

XX

CC The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is

CC located on chromosome 9q31, and mutations in this gene are associated
CC with two genetic HDL (high density lipoprotein) deficiency disorders,
CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
CC are distinguishable in that TD is an autosomal recessive disorder, while
CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
CC cholesterol") in the blood correlate with a high risk of cardiovascular
CC disease, particularly coronary artery disease, but also cerebrovascular
CC disease, coronary restenosis, and peripheral vascular disease.
CC Conversely, a high level of HDL has protective effects against
CC cardiovascular disease. The invention provides genetic constructs and
CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC vector encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary restenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.
XX
SQ Sequence 2261 AA;
Query Match 100.0%; Score 1525; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 5e-143;
Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 FGKPSLELPQWYNEQTFVSNAPEDTGTLELLNALTDPGFGTRCMEGNPIDTPCQ 60
DB 1371 FGKPSLELPQWYNEQTFVSNAPEDTGTLELLNALTDPGFGTRCMEGNPIDTPCQ 1430
QY 61 AGEETWTPAPVQTMDLFGNGNWTMNPSPACOCSSDKTKKMLPVCPPGAGLPPQQR 120
DB 1431 AGEETWTPAPVQTMDLFGNGNWTMNPSPACOCSSDKTKKMLPVCPPGAGLPPQQR 1490
QY 121 QNTADILQDLTGRNISDYLKTYVQIIAKSLKNIWNEFRYGFSLGVSNTOALPPSQE 180
DB 1491 QNTADILQDLTGRNISDYLKTYVQIIAKSLKNIWNEFRYGFSLGVSNTOALPPSQE 1550
QY 181 VNDAIKQMKHLKLAKDSSADRFNLNLSGRFMTGLDTRNNKVFNNKNGWHAISSFLNVTN 240
DB 1551 VNDAIKQMKHLKLAKDSSADRFNLNLSGRFMTGLDTRNNKVFNNKNGWHAISSFLNVTN 1610
QY 241 NATLRANLQKGNPSHYGTTAFNHPNLNLTQKQLSEVALMTTSVD 284
DB 1611 NATLRANLQKGNPSHYGTTAFNHPNLNLTQKQLSEVALMTTSVD 1654
RESULT 10
AAB38112
ID AAB38112 standard; Protein: 2261 AA.
XX
XX AAB38112;
XX
DT 29-JAN-2001 (first entry)
XX Human ABC1 cholesterol transporter mutant, T774P.
DE
XX Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW

KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW mutin.
XX
OS Homo sapiens.
XX
PN WO200055318-A2.
XX
PD 21-SEP-2000.
XX
PF 15-MAR-2000; 2000WO-IB00532.
XX
XX 15-MAR-1999; 99US-0124702.
PR 08-JUN-1999; 99US-0138048.
PR 17-JUN-1999; 99US-0139600.
PR 01-SEP-1999; 99US-0151977.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA (XENO-) XENON BIORESEARCH INC.
XX
XX Hayden MR, Wilson AR, Pimstone SN;
PI WPI; 2000-587528/55.
XX
XX New ABC1 polypeptide is useful for treating diseases associated with
PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
PT disease and cancer -
XX
XX Examples; Page -: 229pp; English.
XX
CC The invention relates to the human ABC1 cholesterol transporter protein
CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
CC a member of the ATP-binding cassette (ABC transporter) superfamily of
CC proteins, and plays a crucial role in cholesterol transport, particularly
CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
CC located on chromosome 9q31, and mutations in this gene are associated
CC with two genetic HDL (high density lipoprotein) deficiency disorders,
CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
CC are distinguishable in that TD is an autosomal recessive disorder, while
CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
CC cholesterol") in the blood correlate with a high risk of cardiovascular
CC disease, particularly coronary artery disease, but also cerebrovascular
CC disease, coronary restenosis, and peripheral vascular disease.
CC Conversely, a high level of HDL has protective effects against
CC cardiovascular disease. The invention provides genetic constructs and
CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC vector encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary restenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.
XX
SQ Sequence 2261 AA;


```

Query Match      100.0%; Score 1525; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 5e-143;
Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLLELNALTKDPGFGTRCMENPIPDTPCQ 60
Db 1371 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLLELNALTKDPGFGTRCMENPIPDTPCQ 1430

Qy 61 AGESEWTTAPVQTIIMDLFQNGWNTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
Db 1431 AGESEWTTAPVQTIIMDLFQNGWNTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 1490

Qy 121 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
Db 1491 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 1550

Qy 181 VNDAIKMKKHLKLAQSSADREFLSLGRFMTGLDTRNNKVKWFNKKGWHAISFLNWIN 240
Db 1551 VNDAIKMKKHLKLAQSSADREFLSLGRFMTGLDTRNNKVKWFNKKGWHAISFLNWIN 1610

Qy 241 NAILRANLQGENPSHYGITAFNHNPLNTKQOLSEVALMTTSD 284
Db 1611 NAILRANLQGENPSHYGITAFNHNPLNTKQOLSEVALMTTSD 1654

RESULT 11
AAB38113
ID AAB38113 standard; Protein; 2261 AA.
XX AC AAB38113;
XX DT 29-JAN-2001 (first entry)
XX DE Human ABC1 cholesterol transporter mutant, K776N.
XX KW Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW muretin.
XX OS Homo sapiens.
XX WO200005318-A2.
XX PN 21-SEP-2000.
XX PD 15-MAR-2000; 2000WO-IB00532.
XX PF 15-MAR-1999; 99US-0124702.
XX PR 08-JUN-1999; 99US-0138048.
XX PR 17-JUN-1999; 99US-0139600.
XX PR 01-SEP-1999; 99US-0151977.
XX XX (UYBR-) UNIV BRITISH COLUMBIA.
XX PA (XENO-) XENON BIORESEARCH INC.
XX PI Hayden MR, Wilson AR, Pimstone SN;
XX DR WPI; 2000-587528/55.
XX XX New ABC1 polypeptide is useful for treating diseases associated with
XX PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
XX PT disease and cancer -
XX XX Examples; Page -, 229pp; English.
XX PS The invention relates to the human ABC1 cholesterol transporter protein
XX CC

```

```

CC (B38082) and to nucleic acid sequences (c69120) which encode it. ABC1 is
CC a member of the ATP-binding cassette (ABC transporter) superfamily of
CC proteins, and plays a crucial role in cholesterol transport, particularly
CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
CC located on chromosome 9q31, and mutations in this gene are associated
CC with two genetic HDL (high density lipoprotein) deficiency disorders,
CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
CC are distinguishable in that TD is an autosomal recessive disorder, while
CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
CC cholesterol") in the blood correlate with a high risk of cardiovascular
CC disease, particularly coronary artery disease, but also cerebrovascular
CC disease, coronary restenosis, and peripheral vascular disease.
CC Conversely, a high level of HDL has protective effects against
CC cardiovascular disease. The invention provides genetic constructs and
CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC vector encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary restenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: A7012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.
XX Qy Sequence 2261 AA;

```

```

Query Match      100.0%; Score 1525; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 5e-143;
Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLLELNALTKDPGFGTRCMENPIPDTPCQ 60
Db 1371 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLLELNALTKDPGFGTRCMENPIPDTPCQ 1430

Qy 61 AGESEWTTAPVQTIIMDLFQNGWNTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
Db 1431 AGESEWTTAPVQTIIMDLFQNGWNTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 1490

Qy 121 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
Db 1491 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 1550

Qy 181 VNDAIKMKKHLKLAQSSADREFLSLGRFMTGLDTRNNKVKWFNKKGWHAISFLNWIN 240
Db 1551 VNDAIKMKKHLKLAQSSADREFLSLGRFMTGLDTRNNKVKWFNKKGWHAISFLNWIN 1610

Qy 241 NAILRANLQGENPSHYGITAFNHNPLNTKQOLSEVALMTTSD 284
Db 1611 NAILRANLQGENPSHYGITAFNHNPLNTKQOLSEVALMTTSD 1654

RESULT 12
AAB38114
ID AAB38114 standard; Protein; 2261 AA.
XX AC AAB38114;
XX DT 29-JAN-2001 (first entry)
XX DT
XX

```

DE Human ABC1 cholesterol transporter mutant, E1172D.
XX
KW Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary stenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW
XX
OS Homo sapiens.
XX
PN WO200055318-A2.
XX
XX
PD 21-SEP-2000.
XX
XX 15-MAR-2000; 2000WO-IB00532.
XX
XX 15-MAR-1999; 99US-0124702.
PR 08-JUN-1999; 99US-0138048.
PR 17-JUN-1999; 99US-0139600.
PR 01-SEP-1999; 99US-0151977.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA (XENO-) XENON BIORESEARCH INC.
XX
XX Hayden MR, Wilson AR, Pimstone SN;
PI
XX WPI; 2000-587528/55.
XX
XX New ABC1 polypeptide is useful for treating diseases associated with
PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
PT disease and cancer -
XX
XX Examples; Page -: 229pp; English.
XX
XX The invention relates to the human ABC1 cholesterol transporter protein
CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
CC a member of the ATP-binding cassette (ABC transporter) superfamily of
CC proteins, and plays a crucial role in cholesterol transport, particularly
CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
CC located on chromosome 9q31, and mutations in this gene are associated
CC with two genetic HDL (high density lipoprotein) deficiency disorders,
CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
CC are distinguishable in that TD is an autosomal recessive disorder, while
CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
CC cholesterol") in the blood correlate with a high risk of cardiovascular
CC disease, particularly coronary artery disease, but also cerebrovascular
CC disease, coronary stenosis, and peripheral vascular disease.
CC Conversely, a high level of HDL has protective effects against
CC cardiovascular disease. The invention provides genetic constructs and
CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC vector encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary stenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered

CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.
XX
XX Sequence 2261 AA;
SQ
Query Match 100.0%; Score 1525; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 5e-143;
Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLLELNALTKDPGFGTRCMGEGNPIPTPCQ 60
DB 1371 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLLELNALTKDPGFGTRCMGEGNPIPTPCQ 1430
QY 61 AGEETWTAPVQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPGAGGLPPPPQRK 120
DB 1431 AGEETWTAPVQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPGAGGLPPPPQRK 1490
QY 121 QNTADTLQDLTGRNISDYLVKTYVOIIIAKSLKNKIWNERYGSGFSLGVSNTQALPPSOE 180
DB 1491 QNTADTLQDLTGRNISDYLVKTYVOIIIAKSLKNKIWNERYGSGFSLGVSNTQALPPSOE 1550
QY 181 VNDIAIKOMKKHLKLAKDSSADRLNSLGRFMTGLDTRNNVKVWNNKGWHAISFLNVIN 240
DB 1551 VNDIAIKOMKKHLKLAKDSSADRLNSLGRFMTGLDTRNNVKVWNNKGWHAISFLNVIN 1610
QY 241 NATLRANLQGENPNSHYGITAFNHPNLTKOOLSEVALMTTSVD 284
DB 1611 NATLRANLQGENPNSHYGITAFNHPNLTKOOLSEVALMTTSVD 1654
RESULT 13
AAB38116
ID AAB38116 standard; Protein; 2261 AA.
XX
AC AAB38116;
XX
DT 29-JAN-2001 (first entry)
XX
XX Human ABC1 cholesterol transporter mutant, S1731C.
DE
XX
XX Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary stenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW
XX
XX Homo sapiens.
OS
XX WO200055318-A2.
PN
XX 21-SEP-2000.
PD
XX 15-MAR-2000; 2000WO-IB00532.
PF
XX 15-MAR-1999; 99US-0124702.
PR 08-JUN-1999; 99US-0138048.
PR 17-JUN-1999; 99US-0139600.
PR 01-SEP-1999; 99US-0151977.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA (XENO-) XENON BIORESEARCH INC.
XX
XX Hayden MR, Wilson AR, Pimstone SN;
PI
XX WPI; 2000-587528/55.
XX
XX New ABC1 polypeptide is useful for treating diseases associated with
PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
PT

disease and cancer -
 Examples: Page -, 229pp; English.
 The invention relates to the human ABC1 cholesterol transporter protein (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is a member of the ATP-binding cassette (ABC transporter) superfamily of proteins, and plays a crucial role in cholesterol transport, particularly intracellular cholesterol trafficking in monocytes and fibroblasts, being involved in cholesterol efflux from the cell. The gene encoding ABC1 is located on chromosome 9q31, and mutations in this gene are associated with two genetic HDL (high density lipoprotein) deficiency disorders, Tangier disease (TD) and familial HDL deficiency (FHA). These diseases are distinguishable in that TD is an autosomal recessive disorder, while FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good cholesterol") in the blood correlate with a high risk of cardiovascular disease, particularly coronary artery disease, but also cerebrovascular disease, coronary restenosis, and peripheral vascular disease. Conversely, a high level of HDL has protective effects against cardiovascular disease. The invention provides genetic constructs and transgenic cells and non-human animals comprising human ABC1 nucleic acids, and methods of gene therapy for the treatment or prevention of cardiovascular disease comprising the administration of an expression vector encoding ABC1 or an active fragment thereof. The invention also encompasses compounds which mimic ABC1 activity, compounds which stimulate ABC1 expression and methods of screening for such compounds. It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary restenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.

Query Match 100.0%; Score 1525; DB 21: Length 2261;
 Best Local Similarity 100.0%; Pred. No. 5e-143;
 Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 FGKPSLELPQWNYEQYTFVSNADPDTGTLLELNALTKDPGFGTRCMENPIPTPCQ 60
 DB 1371 FGKPSLELPQWNYEQYTFVSNADPDTGTLLELNALTKDPGFGTRCMENPIPTPCQ 1430
 QY 61 AGEETWTPAPVOTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGLPPPPQR 120
 DB 1431 AGEETWTPAPVOTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGLPPPPQR 1490
 QY 121 QNTADILQDLTGRNISDYLVKTVYVQIIAKSLKNKWTWNEFRYGFSLGVSNQTALPPSQE 180
 DB 1491 QNTADILQDLTGRNISDYLVKTVYVQIIAKSLKNKWTWNEFRYGFSLGVSNQTALPPSQE 1550
 QY 181 VNDAIQMKKHLKLAKDSSADFLNSLGRFTMGDLTRNNKVFNNKGNHAISSFLNVIN 240
 DB 1551 VNDAIQMKKHLKLAKDSSADFLNSLGRFTMGDLTRNNKVFNNKGNHAISSFLNVIN 1610
 QY 241 NAILRANLQGENPSHYGTAFFNHPNLINTKQQLSEVALMTTTSVD 284
 DB 1611 NAILRANLQGENPSHYGTAFFNHPNLINTKQQLSEVALMTTTSVD 1654
 RESULT 14
 AD AAB38117
 DD AAB38117 standard; Protein; 2261 AA.

XX AC AAB38117;
 XX DT 29-JAN-2001 (first entry)
 XX DE Human ABC1 cholesterol transporter mutant, 1883M.
 XX KW Human ABC1 cholesterol transporter; chromosome 9q31;
 XX KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 XX KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 XX KW cerebrovascular disease; coronary artery disease; coronary restenosis;
 XX KW cerebrovascular disease; peripheral vascular disease;
 XX KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 XX KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 XX KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 XX KW mutin.
 XX OS Homo sapiens.
 XX FN WO2000055318-A2.
 XX PD 21-SEP-2000.
 XX PF 15-MAR-2000; 2000WO-IB00532.
 XX PR 15-MAR-1999; 99US-0124702.
 XX PR 08-JUN-1999; 99US-0138048.
 XX PR 17-JUN-1999; 99US-0139600.
 XX PR 01-SEP-1999; 99US-0151977.
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 XX (XENO-) XENON BIORESEARCH INC.
 XX PI Hayden MR, Wilson AR, Pimstone SN;
 XX WPI: 2000-587528/55.
 XX New ABC1 polypeptide is useful for treating diseases associated with
 XX ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 XX disease and cancer -
 XX Examples; Page -, 229pp; English.
 XX The invention relates to the human ABC1 cholesterol transporter protein
 XX (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 XX a member of the ATP-binding cassette (ABC transporter) superfamily of
 XX proteins, and plays a crucial role in cholesterol transport, particularly
 XX intracellular cholesterol trafficking in monocytes and fibroblasts, being
 XX involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 XX located on chromosome 9q31, and mutations in this gene are associated
 XX with two genetic HDL (high density lipoprotein) deficiency disorders,
 XX Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 XX are distinguishable in that TD is an autosomal recessive disorder, while
 XX FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 XX cholesterol") in the blood correlate with a high risk of cardiovascular
 XX disease, particularly coronary artery disease, but also cerebrovascular
 XX disease, coronary restenosis, and peripheral vascular disease. Conversely,
 XX a high level of HDL has protective effects against
 XX cardiovascular disease. The invention provides genetic constructs and
 XX transgenic cells and non-human animals comprising human ABC1 nucleic
 XX acids, and methods of gene therapy for the treatment or prevention of
 XX cardiovascular disease comprising the administration of an expression
 XX vector encoding ABC1 or an active fragment thereof. The invention also
 XX encompasses compounds which mimic ABC1 activity, compounds which
 XX stimulate ABC1 expression and methods of screening for such compounds.
 XX It further relates to methods for determining whether a patient has an
 XX increased risk for cardiovascular disease due to polymorphisms in the
 XX ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 XX or prevent cardiovascular disease, especially coronary artery disease,
 XX cerebrovascular disease, coronary restenosis or peripheral vascular
 XX disease. They may also be used in the treatment of diseases associated
 XX with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 XX disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 XX The invention specifically excludes proteins with the exact amino acid
 XX sequences of GenBank Accession No: CAA10005.1 and X75946, and the nucleic
 XX acid with the exact sequence as GenBank Accession No: A012376.1. The
 XX present sequence represents a mutant human ABC1 cholesterol transporter
 XX associated with an altered cholesterol level and therefore an altered
 XX risk of cardiovascular disease.
 XX Note: The present sequence is not shown in the specification, but is
 XX derived from the native human ABC1 shown on pages 152-157.
 XX
 XX Sequence 2261 AA;
 Query Match 100.0%; Score 1525; DB 21: Length 2261;
 Best Local Similarity 100.0%; Pred. No. 5e-143;
 Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 FGKPSLELPQWNYEQYTFVSNADPDTGTLLELNALTKDPGFGTRCMENPIPTPCQ 60
 DB 1371 FGKPSLELPQWNYEQYTFVSNADPDTGTLLELNALTKDPGFGTRCMENPIPTPCQ 1430
 QY 61 AGEETWTPAPVOTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGLPPPPQR 120
 DB 1431 AGEETWTPAPVOTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGLPPPPQR 1490
 QY 121 QNTADILQDLTGRNISDYLVKTVYVQIIAKSLKNKWTWNEFRYGFSLGVSNQTALPPSQE 180
 DB 1491 QNTADILQDLTGRNISDYLVKTVYVQIIAKSLKNKWTWNEFRYGFSLGVSNQTALPPSQE 1550
 QY 181 VNDAIQMKKHLKLAKDSSADFLNSLGRFTMGDLTRNNKVFNNKGNHAISSFLNVIN 240
 DB 1551 VNDAIQMKKHLKLAKDSSADFLNSLGRFTMGDLTRNNKVFNNKGNHAISSFLNVIN 1610
 QY 241 NAILRANLQGENPSHYGTAFFNHPNLINTKQQLSEVALMTTTSVD 284
 DB 1611 NAILRANLQGENPSHYGTAFFNHPNLINTKQQLSEVALMTTTSVD 1654
 RESULT 14
 AD AAB38117
 DD AAB38117 standard; Protein; 2261 AA.

CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.

XX
SQ Sequence 2261 AA;
Query Match 100.0%; Score 1525; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 5e-143;
Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLELLNALT KDPCGTRCMEGNPIDTPCQ 60
DB 1371 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLELLNALT KDPCGTRCMEGNPIDTPCQ 1430
QY 61 AGEETWTTAPVPQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
DB 1431 AGEETWTTAPVPQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 1490
QY 121 QNTADILQDLTGRNISDYLVKTYVQIIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
DB 1491 QNTADILQDLTGRNISDYLVKTYVQIIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 1550
QY 181 VNDATKQMKKHLKLAKDSSADRFNLNSLGRFMTGLDTRNNKYVFNKNGHAISSFLNWIN 240
DB 1551 VNDATKQMKKHLKLAKDSSADRFNLNSLGRFMTGLDTRNNKYVFNKNGHAISSFLNWIN 1610
QY 241 NAILRANLQKGENPSHYGITAFNHLNLTQKQLEVALMTTSVD 284
DB 1611 NAILRANLQKGENPSHYGITAFNHLNLTQKQLEVALMTTSVD 1654

RESULT 15
AAB71749
ID AAB71749 standard; protein; 2261 AA.
AC AAB71749;
XX
DT 17-MAY-2001 (first entry)
XX
DE Human ABC1 protein.
XX
KW High density lipoprotein-cholesterol; HDL-C; cardiovascular; ABC1.
XX
OS Homo sapiens.
XX
PN WO200115676-A2.
XX
PD 08-MAR-2001.
XX
PF 01-SEP-2000; 2000WO-1801492.
XX
PR 01-SEP-1999; 99US-0151977.
PR 15-MAR-2000; 2000US-0526193.
PR 23-JUN-2000; 2000US-0213958.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (XENO-) XENON GENETICS INC.
XX
PI Hayden MR, Brooks-Wilson AR, Pimstone SN, Clee SM;
XX
DR WPI; 2001-244356/25.
XX
PT Treating a lower than normal high density lipoprotein-cholesterol
PT (HDL-C) level, a higher than normal triglyceride level, or a
PT cardiovascular disease, by administering a compound that modulates LXR-
PT or RXR-mediated transcriptional activity -
XX
PS Claim 16; Fig 2; 317pp; English.

XX
CC The present invention relates to a method for treating a patient
CC diagnosed as having a lower than normal high density
CC lipoprotein-cholesterol (HDL-C) level, a higher than normal
CC triglyceride level, or a cardiovascular disease, involving
CC administering a compound that modulates LXR- or RXR-mediated
CC transcriptional activity or ABC1 expression or activity.
CC The LXR gene product may be used in an assay to identify
CC compounds useful for the treatment of a disease or condition selected a
CC lower than normal HDL cholesterol level, a higher than normal
CC triglyceride level, and a cardiovascular disease.

XX
SQ Sequence 2261 AA;
Query Match 100.0%; Score 1525; DB 22; Length 2261;
Best Local Similarity 100.0%; Pred. No. 5e-143;
Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLELLNALT KDPCGTRCMEGNPIDTPCQ 60
DB 1371 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLELLNALT KDPCGTRCMEGNPIDTPCQ 1430
QY 61 AGEETWTTAPVPQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
DB 1431 AGEETWTTAPVPQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 1490
QY 121 QNTADILQDLTGRNISDYLVKTYVQIIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
DB 1491 QNTADILQDLTGRNISDYLVKTYVQIIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 1550
QY 181 VNDATKQMKKHLKLAKDSSADRFNLNSLGRFMTGLDTRNNKYVFNKNGHAISSFLNWIN 240
DB 1551 VNDATKQMKKHLKLAKDSSADRFNLNSLGRFMTGLDTRNNKYVFNKNGHAISSFLNWIN 1610
QY 241 NAILRANLQKGENPSHYGITAFNHLNLTQKQLEVALMTTSVD 284
DB 1611 NAILRANLQKGENPSHYGITAFNHLNLTQKQLEVALMTTSVD 1654

Search completed: February 4, 2003, 09:39:19
Job time : 48 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: February 4, 2003, 09:39:23 ; Search time 14 seconds
(without alignments)
596.865 Million cell updates/sec

Title: US-09-704-272-6
Perfect score: 1525
Sequence: 1 FGKYPSELQPMYNEQYTF.....PLNLTQQLSEVALMTSVD 284

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 262574 seqs, 29422922 residues

Total number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_AA.*
1: /cgn2.6/ptodata/1/iaa/5A_COMB.pep.*
2: /cgn2.6/ptodata/1/iaa/5B_COMB.pep.*
3: /cgn2.6/ptodata/1/iaa/6A_COMB.pep.*
4: /cgn2.6/ptodata/1/iaa/6B_COMB.pep.*
5: /cgn2.6/ptodata/1/iaa/PCTUS_COMB.pep.*
6: /cgn2.6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1423	93.3	1375	3	US-08-665-259-26
2	1423	93.3	1375	3	US-08-762-500-26
3	257	16.9	1457	3	US-08-665-259-27
4	257	16.9	1457	3	US-08-762-500-27
5	94.5	6.2	884	6	5208144-8
6	92	6.0	2511	4	US-09-261-907-2
7	89.5	5.9	596	4	US-08-481-150-8
8	89.5	5.9	596	5	PCT-US93-00869-8
9	89	5.8	903	3	US-08-804-439A-22
10	89	5.8	903	3	US-08-720-229-22
11	88.5	5.8	903	1	US-08-220-151-8
12	88.5	5.8	903	1	US-08-413-118-8
13	88.5	5.8	903	3	US-08-473-446-8
14	88	5.8	888	2	US-08-861-464-6
15	88	5.8	888	2	US-08-396-001-6
16	88	5.8	888	4	US-09-323-433A-6
17	86.5	5.7	967	4	US-09-139-802-201
18	86	5.6	2509	1	US-08-469-005A-10
19	85.5	5.6	953	4	US-09-245-281-43
20	85.5	5.6	953	4	US-09-207-359B-43
21	83.5	5.5	339	4	US-09-125-619-14
22	83.5	5.5	969	4	US-09-206-942-32
23	83.5	5.5	975	4	US-09-206-942-30
24	83.5	5.5	3224	2	US-08-705-660-34
25	83.5	5.5	3224	3	US-08-989-045-34
26	83	5.4	913	1	US-08-220-151-6
27	83	5.4	913	1	US-08-413-118-6

28 83 5.4 913 3 US-08-473-446-6 Sequence 6, Appli
29 83 5.4 10182 4 US-09-134-001C-3159 Sequence 3159, Ap
30 82.5 5.4 736 1 US-07-688-352C-24 Sequence 24, Appl
31 82.5 5.4 736 2 US-08-474-379C-24 Sequence 24, Appl
32 82.5 5.4 736 3 US-09-146-249A-24 Sequence 24, Appl
33 82.5 5.4 736 3 US-08-208-188B-24 Sequence 24, Appl
34 82.5 5.4 736 5 PCT-US91-02714-23 Patent No. 5244792
35 82 5.4 904 6 5244792-4 Patent No. 5244792
36 82 5.4 913 6 5196516-8 Patent No. 5196516
37 81.5 5.3 820 4 US-09-173-914-2 Sequence 2, Appli
38 81.5 5.3 885 1 US-08-042-747A-8 Sequence 8, Appli
39 81.5 5.3 885 3 US-08-804-439A-23 Sequence 23, Appl
40 81.5 5.3 885 3 US-08-720-229-23 Sequence 23, Appl
41 80 5.2 464 4 US-09-025-580-28 Sequence 28, Appl
42 80 5.2 464 4 US-09-457-040B-5 Sequence 5, Appli
43 80 5.2 605 2 US-08-752-307B-8 Sequence 8, Appli
44 80 5.2 605 4 US-09-707-802-8 Sequence 8, Appli
45 80 5.2 605 4 US-09-991-326-8 Sequence 8, Appli

ALIGNMENTS

RESULT 1
US-08-665-259-26
; Sequence 26, Application US/08665259
; Patent No. 6028173
; GENERAL INFORMATION:
; APPLICANT: Landes, Gregory M.
; APPLICANT: Burn, Timothy C.
; APPLICANT: Connors, Timothy D.
; APPLICANT: Dackowski, William R.
; APPLICANT: Van Raay, Terence J.
; APPLICANT: Klinger, Katherine W.
; TITLE OF INVENTION: NOVEL HUMAN CHROMOSOME 16 GENES,
; NUMBER OF SEQUENCES: 73
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: GENZYME CORPORATION
; STREET: One Mountaint Road
; CITY: Framingham
; STATE: Massachusetts
; COUNTRY: United States of America
; ZIP: 01701

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/665,259
; FILING DATE: 17-JUN-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Dugan, Deborah A.
; REGISTRATION NUMBER: 37,315
; REFERENCE/DOCKET NUMBER: IG5-9.1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (508) 872-8400
; TELEFAX: (508) 872-5415
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1375 amino acids
; TYPE: amino acid
; STRANDEDNESS: not relevant
; TOPOLOGY: unknown
; MOLECULE TYPE: protein
; US-08-665-259-26

Query Match 93.3%; Score 1423; DB 3; Length 1375;
Best Local Similarity 93.0%; Pred. No. 6.2e-141;
Matches 264; Conservative 10; Mismatches 10; Indels 0; Gaps 0;

QY 1 FGKPSLEQPMYNEQYTFVSNDAPEDTGTLELLNALT KDPGGTRCMGPNIPDTPCQ 60
Db 485 FGKPSLEQPMYNEQYTFVSNDAPEDMGTQELLNALT KDPGGTRCMGPNIPDTPCL 544
QY 61 AGEEDWTAPVOTIMDLFQNGNWTMKNPSPACQSSDKIKKMLPVCPGAGGLPPPPQK 120
Db 545 AGEEDWTISVPQSIVDLFQNGNWTMKNPSPACQSSDKIKKMLPVCPGAGGLPPPPQK 604
QY 121 ONTADILQDLTGRTNISDYLVKTYVQIIAKSLKNKIWNNEFRYGFSLGVSNTQALPPSQE 180
Db 605 QKTADILQNLGTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGFSLGVSNSQALPPSHE 664
QY 181 VNDAIKQMKHKLAKDSSADRFSLGRTMTGLDTRNNKVVFNNGKWHAISSFLNVIN 240
Db 665 VNDAIKQMKHKLAKDSSADRFSLGRTMTGLDTRNNKVVFNNGKWHAISSFLNVIN 724
QY 241 NAILRANLQGENPSHYGITAFAFNHPLNLT KQOLSEVALMTTTSVD 284
Db 725 NAILRANLQGENPSHYGITAFAFNHPLNLT KQOLSEVALMTTTSVD 768
RESULT 2
US-08-762-500-26
; Sequence 26, Application US/08762500
; Patent No. 6030806
; GENERAL INFORMATION:
; APPLICANT: Landes, Gregory M.
; APPLICANT: Burn, Timothy C.
; APPLICANT: Connors, Timothy D.
; APPLICANT: Dackowski, William R.
; APPLICANT: Van Raay, Terence J.
; APPLICANT: Klinger, Katherine W.
; TITLE OF INVENTION: NOVEL HUMAN CHROMOSOME 16 GENES,
; METHODS OF MAKING AND USING SAME
; NUMBER OF SEQUENCES: 83
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: GENZYME CORPORATION
; STREET: One Mountain Road
; CITY: Framingham
; STATE: Massachusetts
; COUNTRY: United States of America
; ZIP: 01701
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/762,500
; FILING DATE: 08-DEC-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/665,259
; FILING DATE: 17-JUN-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/10469
; FILING DATE: 17-JUN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Dugan, Deborah A.
; REGISTRATION NUMBER: 37,315
; REFERENCE/DOCKET NUMBER: IGS-9.3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (508) 872-8400
; TELEFAX: (508) 872-5415
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1375 amino acids
; TYPE: amino acid
; STRANDEDNESS: not relevant
; TOPOLOGY: unknown
; MOLECULE TYPE: protein
US-08-762-500-26

Query Match 93.3%; Score 1423; DB 3; Length 1375;
Best Local Similarity 93.0%; Pred. No. 6.2e-141;
Matches 264; Conservative 10; Mismatches 10; Indels 0; Gaps 0;
QY 1 FGKPSLEQPMYNEQYTFVSNDAPEDTGTLELLNALT KDPGGTRCMGPNIPDTPCQ 60
Db 485 FGKPSLEQPMYNEQYTFVSNDAPEDMGTQELLNALT KDPGGTRCMGPNIPDTPCL 544
QY 61 AGEEDWTAPVOTIMDLFQNGNWTMKNPSPACQSSDKIKKMLPVCPGAGGLPPPPQK 120
Db 545 AGEEDWTISVPQSIVDLFQNGNWTMKNPSPACQSSDKIKKMLPVCPGAGGLPPPPQK 604
QY 121 ONTADILQDLTGRTNISDYLVKTYVQIIAKSLKNKIWNNEFRYGFSLGVSNTQALPPSQE 180
Db 605 QKTADILQNLGTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGFSLGVSNSQALPPSHE 664
QY 181 VNDAIKQMKHKLAKDSSADRFSLGRTMTGLDTRNNKVVFNNGKWHAISSFLNVIN 240
Db 665 VNDAIKQMKHKLAKDSSADRFSLGRTMTGLDTRNNKVVFNNGKWHAISSFLNVIN 724
QY 241 NAILRANLQGENPSHYGITAFAFNHPLNLT KQOLSEVALMTTTSVD 284
Db 725 NAILRANLQGENPSHYGITAFAFNHPLNLT KQOLSEVALMTTTSVD 768
RESULT 3
US-08-665-259-27
; Sequence 27, Application US/08665259
; Patent No. 6028173
; GENERAL INFORMATION:
; APPLICANT: Landes, Gregory M.
; APPLICANT: Burn, Timothy C.
; APPLICANT: Connors, Timothy D.
; APPLICANT: Dackowski, William R.
; APPLICANT: Van Raay, Terence J.
; APPLICANT: Klinger, Katherine W.
; TITLE OF INVENTION: NOVEL HUMAN CHROMOSOME 16 GENES,
; METHODS OF MAKING AND USING SAME
; NUMBER OF SEQUENCES: 73
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: GENZYME CORPORATION
; STREET: One Mountain Road
; CITY: Framingham
; STATE: Massachusetts
; COUNTRY: United States of America
; ZIP: 01701
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/665,259
; FILING DATE: 17-JUN-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Dugan, Deborah A.
; REGISTRATION NUMBER: 37,315
; REFERENCE/DOCKET NUMBER: IGS-9.1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (508) 872-8400
; TELEFAX: (508) 872-5415
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1457 amino acids
; TYPE: amino acid
; STRANDEDNESS: not relevant
; TOPOLOGY: unknown
; MOLECULE TYPE: protein
US-08-665-259-27
Query Match 16.9%; Score 257; DB 3; Length 1457;
Best Local Similarity 24.9%; Pred. No. 8.6e-18;

```
Matches 91; Conservative 40; Mismatches 98; Indels 136; Gaps 15;
QY 2 GKPSLELOPMWYNEQY-----FVSNDAPE-----DTGTELLNALTDPGFGT 46
Db 504 GDLPLVLSPQYH-NYTPRGNFIPYANEERQYRLRLSPDASPOQLVSTFLPSGVGA 562
QY 47 RCM-----EGNPI----- 54
Db 563 TCVLKSPANGSLGPMNLSSGESLLAARFDSMCLESTQGLPLSNFVPPPPSPAPSDS 622
QY 55 ---PD-----TPCQAGEEWTAP-VPQTIMDLFQNGNWTMONPSPACQSSDKI 100
Db 623 PVXPDDESLQAWNSLPTAGPETWTSAPSLRLVHEPVR-----CTCSAQGT 670
QY 101 KMLPVCPPGAGLPPQPKONTADILQDITGRNISDYLVKTYVQIIAKSLKNKIWNNEF 160
Db 671 GFS---CPSSVGG-HPQMRVVTGDILTITGHNVSEYLLFTSDRF-----RLH 715
QY 161 RYGFSLGVSTQALPPSQEVNDIAIKOMKKHLKLAKDSSADRLNSLGRFMTGLDTRNNV 220
Db 716 RYGAITFG--NVQKSIPAS-----FGARVPPMVRKIAVRVA 750
QY 221 KWFNNKGWHAISFLNINNAILRANLQKE-NPSHYGITAFNHPNLTKOOLS-EVAL 278
Db 751 QVLYNNKGYHSMPTYLSNLNAILRANLPKSGNPAAYXIYTNHPMNKTSASLSLDYLL 810
QY 279 MTSV 283
Db 811 QGTDV 815

RESULT 4
US-08-762-500-27
; Sequence 27, Application US/08762500
; Patent No. 6030806
; GENERAL INFORMATION:
; APPLICANT: Landes, Gregory M.
; APPLICANT: Burn, Timothy C.
; APPLICANT: Connors, Timothy D.
; APPLICANT: Dackowski, William J.
; APPLICANT: Van Raay, Terence R.
; APPLICANT: Klinger, Katherine W.
; TITLE OF INVENTION: NOVEL HUMAN CHROMOSOME 16 GENES,
; TITLE OF INVENTION: COMPOSITIONS, METHODS OF MAKING AND USING SAME
; NUMBER OF SEQUENCES: 83
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: GENZYME CORPORATION
; STREET: One Mountain Road
; CITY: Framingham
; STATE: Massachusetts
; COUNTRY: United States of America
; ZIP: 01701
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/762,500
; FILING DATE: 09-DEC-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/665,259
; FILING DATE: 17-JUN-1996
; PRIOR APPLICATION DATA: RCT/US96/10469
; APPLICATION NUMBER: 17-JUN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Dugan, Deborah A.
; REGISTRATION NUMBER: 37,315
; REFERENCE/DOCKET NUMBER: IG5-9.3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (508) 872-8400
```

```
TELEFAX: (508) 872-5415
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1457 amino acids
; TYPE: amino acid
; STRANDEDNESS: not relevant
; TOPOLOGY: unknown
; MOLECULE TYPE: protein
US-08-762-500-27

Query Match 16.9%; Score 257; DB 3; Length 1457;
Best Local Similarity 24.9%; Pred. No. 8.6e-18;
Matches 91; Conservative 40; Mismatches 98; Indels 136; Gaps 15;
QY 2 GKPSLELOPMWYNEQY-----FVSNDAPE-----DTGTELLNALTDPGFGT 46
Db 504 GDLPLVLSPQYH-NYTPRGNFIPYANEERQYRLRLSPDASPOQLVSTFLPSGVGA 562
QY 47 RCM-----EGNPI----- 54
Db 563 TCVLKSPANGSLGPMNLSSGESLLAARFDSMCLESTQGLPLSNFVPPPPSPAPSDS 622
QY 55 ---PD-----TPCQAGEEWTAP-VPQTIMDLFQNGNWTMONPSPACQSSDKI 100
Db 623 PVXPDDESLQAWNSLPTAGPETWTSAPSLRLVHEPVR-----CTCSAQGT 670
QY 101 KMLPVCPPGAGLPPQPKONTADILQDITGRNISDYLVKTYVQIIAKSLKNKIWNNEF 160
Db 671 GFS---CPSSVGG-HPQMRVVTGDILTITGHNVSEYLLFTSDRF-----RLH 715
QY 161 RYGFSLGVSTQALPPSQEVNDIAIKOMKKHLKLAKDSSADRLNSLGRFMTGLDTRNNV 220
Db 716 RYGAITFG--NVQKSIPAS-----FGARVPPMVRKIAVRVA 750
QY 221 KWFNNKGWHAISFLNINNAILRANLQKE-NPSHYGITAFNHPNLTKOOLS-EVAL 278
Db 751 QVLYNNKGYHSMPTYLSNLNAILRANLPKSGNPAAYXIYTNHPMNKTSASLSLDYLL 810
QY 279 MTSV 283
Db 811 QGTDV 815

RESULT 5
5208144-8
; Patent No. 5208144
; APPLICANT: SMITH, JOHN A.; RAYCHOWHURY, RAKTIMA; NILES, JOHN L.
; TITLE OF INVENTION: METHOD FOR DETECTION OF HUMAN DNA
; CONTAINING THE GENE ENCODING LOW DENSITY LIPOPROTEIN RECEPTOR
; NUMBER OF SEQUENCES: 42
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/396,697
; FILING DATE: 22-AUG-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 313,682
; FILING DATE: 22-FEB-1989
; APPLICATION NUMBER: 235,211
; FILING DATE: 23-AUG-1988
; SEQ ID NO: 8:
; LENGTH: 884
5208144-8

Query Match 6.2%; Score 94.5; DB 6; Length 884;
Best Local Similarity 23.6%; Pred. No. 0.57;
Matches 70; Conservative 37; Mismatches 111; Indels 79; Gaps 19;
QY 1 FGKYP-----LELOPMW-----YNEQYTFVSNDAPEDTGTELLNALTDPGFGT 47
Db 551 FGKENKERVLVNVNPLTQVRIFHQLRYNQS---VSNPKQVCVSHLCLL---RPGYSCA 603
QY 48 CMENGPNI---PDTPCQAGEEWTAPVPQTIMDLFQNGN-WTMONPSPACQSSDKIKM 103
Db 604 CPQGSDFVTGTVQCDAASELPLVTMPPPCRM---HGGNCYFDENELPKCKSSGSGE- 659
```



```
;
; 104 LPVCPGP-AGGLPPQKONTADILQDLTGRTNISDYLVKTVQIIAKSLNKIWNNEFY 162
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 660 --YCEVGLSRGIPP-----GTTMA-VLLTFVVIIVGAL---VLVGLPHY 698
;
; 163 GGFSLGVSTQALPPSQVBNDAIKOMKKHLKLAKDSSADRLNSLG-RPMTGLDTRNNVK 221
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 699 -----RKTGSLT-----LPKLPSSLAKPSE-----NGNGVTRSGADV--NND 738
;
; 222 VWFNKNKGWHAISFLNVLNNAILRANLQKGNPSHYGITAFNHPNLTLTKQQLSEVAL 278
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 739 IGVSPFGPETIDRSWANNEHFV---MEVGKQP-----VIFENPMYAAKNDTSKVAL 787
;
```

RESULT 6

```
US-09-261-907-2
; Sequence 2, Application US/09261907A
; Patent No. 6294364
; GENERAL INFORMATION:
; APPLICANT: ELLIS, CATHERINE
; APPLICANT: LONSDALE, JOHN
; APPLICANT: BERGSMAN, DEBK J.
; APPLICANT: MOONEY, JEFFREY L.
; APPLICANT: DEPIERA, MEGAN E.
; APPLICANT: CHAPMAN, CONRAD
; TITLE OF INVENTION: HUMAN FAS
; FILE REFERENCE: GP-70603
; CURRENT APPLICATION NUMBER: US/09/261.907A
; CURRENT FILING DATE: 1999-03-03
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 2511
; TYPE: PRT
; ORGANISM: HOMO SAPIENS
US-09-261-907-2
```

```
Query Match 6.08; Score 92; DB 4; Length 2511;
Best Local Similarity 23.28; Pred. No. 5.3;
Matches 39; Conservative 27; Mismatches 60; Indels 42; Gaps 7;
```

```
QY 107 CPPGAGLPPQKONTADILQDLTGRTNISDYLVKTVQIIAKSLNKIWNNEFYGGFS 166
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 634 CPPGV--VPACHNSKDTVI---SGQAPVF-----EFVEQLRKEGVFAKEVRUGNA 681
;
; 167 LGVSTQALPPS--QEVNDATKQMK-----HLKLAKDSSADRLNSLGR 209
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 682 FHSYFMEAIAPLQLQELKKVIREPKRSARWLSTSIPEAQWHSLSARTSSAEYNNVLVS 741
;
; 210 FMTGLDTRNNVKVFNKNGWHA--ISSFLNVLNNAILRANLQKGNPS 255
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 742 -----PVLQFQALNHWPEHAVVLEIAPHALLQAVLKRGLKPS 778
;
```

RESULT 7

```
US-08-481-190-8
; Sequence 8, Application US/08481190
; Patent No. 6160204
; GENERAL INFORMATION:
; APPLICANT: John C. Steffens
; TITLE OF INVENTION: Polyphenol Oxidase cDNA
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Yahwak & Associates
; STREET: 25 Skytop Drive
; CITY: Trumbull
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06611
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: Macintosh
; OPERATING SYSTEM: MS-DOS
```

```
;
; SOFTWARE: Microsoft Word 4.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/481.190
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 203.533
; FILING DATE: 02-24-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: George M. Yahwak
; REGISTRATION NUMBER: 26.824
; REFERENCE/DOCKET NUMBER: UA 816 CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203)268-1951
; TELEFAX: (203)268-1951
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 596 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-481-190-8
;
; Query Match 5.9%; Score 89.5; DB 4; Length 596;
; Best Local Similarity 23.0%; Pred. No. 1;
; Matches 63; Conservative 32; Mismatches 128; Indels 51; Gaps 12;
```

```
QY 13 MYNEQYT-----FVSNDAPEDTGYLELLNALTDPGFGTRCMGPNIPDTPCQ 60
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 293 MYRQWVTNAPCLLFFGAPYVLGNVNEAPGTTIPIPHVHWAGT--VRGSKFPGNDVS 350
;
; 61 AGESEWTTAPVQPTIMDLFQNGNWTMNPSPACQCSSDKIKKMLPVCPPGAGGLPPPPQR 120
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 351 YGED-----MGNFYSAGLDPVFYCHHGNVDRMNEW-KAIGG---KRRD 390
;
; 121 QNTADILQD---LTGNISDYLVKTVQIIAKSLNKI-----WVNEFRYGGFSLGVSN 171
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 391 ISBKDWLNSEFFYDEHKNPYRVKVRDCLDTKMGYDYAPMPTWRNFKPKSKASGVKNV 450
;
; 172 TQALPPSQVBNDAIKOMKKHLKLAKDSSADRLNSLGRFMTGLDTRNNVKVFNKNGWHA 231
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 451 TSTLPANVEFVLAK-MDKTISFAINRPASSRTOOEKNEQEMLTFNNIR--YDNRGIYR 507
;
; 232 ISSFLNVLNNAILRAN-LQKGNPSHYGITAFNH 264
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 508 FDFVLNVDNN--VNANELDKAEFAGSY--TSLPH 537
;
```

RESULT 8

```
PCT-US93-00869-8
; Sequence 8, Application PC/TUS9300869
; GENERAL INFORMATION:
; APPLICANT: John C. Steffens
; TITLE OF INVENTION: Polyphenol Oxidase cDNAs: Cloning
; TITLE OF INVENTION: and Applications
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Yahwak & Associates
; STREET: 25 Skytop Drive
; CITY: Trumbull
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06611
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: Macintosh
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: Microsoft Word 4.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/00869
; FILING DATE: 19930129
; CLASSIFICATION:
```

```
; ATTORNEY/AGENT INFORMATION:
; NAME: George M. Yahwak
; REGISTRATION NUMBER: 26,824
; REFERENCE/DOCKET NUMBER: CRF D-1057
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203)268-1951
; TELEFAX: (203)268-1951
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 596 amino acids
; TYPE: AMINO ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; PCT-US93-00869-8

Query Match          5.9%; Score 89.5; DB 5; Length 596;
Best Local Similarity 23.0%; Pred. No. 1;
Matches 63; Conservative 32; Mismatches 128; Indels 51; Gaps 12;

QY 13 MYNQYT-----FVSNDAPEDTGTTLELNLTKDPGFGTRCMENPIPTPCQ 60
DB 293 MYRQWVNAPCPLLFTGAPVILGNVNEAPGTIETIPHPVHAWGT--VRGSKFPNGDVS 350
QY 61 AGESEWTTAPVQTIIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
DB 351 YGED-----MGNFYSAGLDPVFYCHGNVDMMNEW-KAIGG---KRRD 390
QY 121 QNTADILQD---LTGRNISDLYKTVQIIAKSLNKTI-----WVNEFRYGGFSLGVS 171
DB 391 ISEKDWLNSFFFEYDEHKNPYRVKVRDCLDTKKMGYDYAPMPTWRNFKEPKSASVGKVN 450
QY 172 TOALPPSQEVDNAIKOMKHLKLAKDSSADRLNSLGRMTGLDTRNNVKNWNNKGWHA 231
DB 451 TSTLPPANEVFLAK-MDKTISEFAINRPASSRTQOEKNEQEEMLTFFNNIR--YDNRGYIR 507
QY 232 ISSPLNINNAILRAN-LOKGENPSHYGITAFNH 264
DB 508 FDVFLNVDNN--VNANELOKAEPAGSY--TSLPH 537

RESULT 9
US-08-804-439A-22
; Sequence 22, Application US/08804439A
; Patent No. 6015565
; GENERAL INFORMATION:
; APPLICANT: Rose, Timothy M.
; APPLICANT: Bosch, Marnix L.
; TITLE OF INVENTION: GLYCOPROTEIN B OF THE RFHV/KSHV
; NUMBER OF SEQUENCES: 113
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 4225 Executive Square, Ste 1400
; CITY: La Jolla
; STATE: CA
; COUNTRY: USA
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/804,439A
; FILING DATE: February 21, 1997
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Haile, Lisa A.
; REGISTRATION NUMBER: 38,347
; REFERENCE/DOCKET NUMBER: 09176/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 494-0792
; TELEFAX: (415) 494-0792
; INFORMATION FOR SEQ ID NO: 22:

; ATTORNEY/AGENT INFORMATION:
; NAME: George M. Yahwak
; REGISTRATION NUMBER: 26,824
; REFERENCE/DOCKET NUMBER: CRF D-1057
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203)268-1951
; TELEFAX: (203)268-1951
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 903 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-804-439A-22

Query Match          5.8%; Score 89; DB 3; Length 903;
Best Local Similarity 20.2%; Pred. No. 2.2;
Matches 57; Conservative 28; Mismatches 115; Indels 82; Gaps 11;

QY 21 VSNDAPEDTGTTLELNLTKDPGFGTRCMENPIPTPCQAGEEWTAPVQTIIMDLFQ 80
DB 26 VASAAPSSFGT-----ECVAAATQAANGGFATPA-----PPAPGPAPTGDTRP 68
QY 81 NGNWTMNPSP-----ACQCSSDKIKKMLPVCPPGAGG----- 113
DB 69 KKKKPKNP PPPRPGADNATVAAGHATLREHLRDIKAENTDANFYVCPPTGATVVQFEQ 128
QY 114 ---LPPQKQNTADILQDLTGRNISDLYKTV--YVQIIAKSLKNKIWNNEFRYGGFSLG 168
DB 129 PRCPTRPQGQNTGEGIAVVFKEINAPYKATWYKDVTVS---QVMFGH-RYSQF-MG 183
QY 169 VSNTQALPPSQEVDNAI-----KOMKKHLKLAKDSSADRLNSLGRMTGLDTRN 218
DB 184 IFEDRAPVPEEVIDKINAKGVCRSTAKYVRNNLETTAFHRDDH-----ETDMELKP 235
QY 219 NVKWNENKQWHAISSEFLNVLNAILRANLOKGENPSHYGIT 260
DB 236 ANAATRTSRGHTD-----LKNPSTRVEAFHRYGTT 267

RESULT 10
US-08-720-229-22
; Sequence 22, Application US/08720229
; Patent No. 6022542
; GENERAL INFORMATION:
; APPLICANT: Rose, Timothy M.
; APPLICANT: Bosch, Marnix L.
; TITLE OF INVENTION: GLYCOPROTEIN B OF THE RFHV/KSHV
; NUMBER OF SEQUENCES: 100
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 755 Page Mill Road
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/720,229
; FILING DATE: 26-SEP-1996
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Schiff, J. Michael
; REGISTRATION NUMBER: 40,253
; REFERENCE/DOCKET NUMBER: 29938-20002.00
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 813-5600
; TELEFAX: (415) 494-0792
; INFORMATION FOR SEQ ID NO: 22:
```

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 903 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-720-229-22
Query Match 5.8%; Score 89; DB 3; Length 903;
Best Local Similarity 20.2%; Pred. No. 2.2;
Matches 57; Conservative 28; Mismatches 115; Indels 82; Gaps 11;

Qy 21 VSDAPEDTGTLELLNALTQDFGFCRMEGNIPDTPCOAGEEWTAPVPQTIIMDLFQ 80
Db 26 VASAAPSSPGT-----PGVAATQAANGGATPA-----PPAPGAPTGDTPK 68
Qy 81 NGNWTQNPSP-----ACOCSSDKIKKMLPVCPPGAGG----- 113
Db 69 KKKKKPNPPPPRPGADNATVAAGHATLREHLRDIKAENTDANFYVCPPTGATVVQFEQ 128
Qy 114 ---LPPQRKQNTADILQDLTGRNISDYLVKT--YVQIIAKSLKNIWVNEFRYGGFSLG 168
Db 129 PRCPTRPEQONTGEGIAVVFKEKNIAPYKFKATMYKDVTVS---QVWFGH-RYSQF-MG 183
Qy 169 VSNTOALPPSQEVDNDAI-----KOMKKHLKLAKDSSADRFNLSLGRFMTGLDTRN 218
Db 184 IFEDRAPVPFEEVIDKINAKGVCRTAKYVVRNNLETTAFHRDDH-----ETDMELKP 235
Qy 219 NVKVFNNKGWHAISFLNINNAILRANLOKGENPSHYGTT 260
Db 184 IFEDRAPVPFEEVIDKINAKGVCRTAKYVVRNNLETTAFHRDDH-----ETDMELKP 235
Qy 236 ANAATRTSRGWHTTD-----LKNPSRVEAFHRYGTT 267

RESULT 11
US-08-220-151-8
; Sequence 8, Application US/08220151
; Patent No. 5529780
; GENERAL INFORMATION:
; APPLICANT: Paoletti, Enzo
; APPLICANT: Limbach, Keith J.
; TITLE OF INVENTION: NUCLEOTIDE AND AMINO ACID SEQUENCES OF
; TITLE OF INVENTION: CANINE HERPESVIRUS gB, gC AND gD AND USES THEREFOR
; NUMBER OF SEQUENCES: 91
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris & Safford
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/220.151
; FILING DATE: 30-MAR-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Frommer, William S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2540
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 903 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```

```
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: N-terminal
US-08-220-151-8
Query Match 5.8%; Score 88.5; DB 1; Length 903;
Best Local Similarity 20.6%; Pred. No. 2.5;
Matches 58; Conservative 32; Mismatches 109; Indels 83; Gaps 13;

Qy 21 VSDAPEDTGTLELLNALTQDFGFCRMEGNIPDTPCOAGEEWTAPVPQTIIMDLFQ 80
Db 27 VASAAPSSPGT-----PGVARDPG-GER-----GPCHSGAALGAAPTG---DPRP 68
Qy 81 NGNWTQNPSP-----ACOCSSDKIKKMLPVCPPGAGG----- 113
Db 69 KKKKKPNPPPPRPGADNATVAAGHATLREHLRDIKAENTDANFYVCPPTGATVVQFEQ 128
Qy 114 ---LPPQRKQNTADILQDLTGRNISDYLVKT--YVQIIAKSLKNIWVNEFRYGGFSLG 168
Db 129 PRCPTRPEQONTGEGIAVVFKEKNIAPYKFKATMYKDVTVS---QVWFGH-RYSQF-MG 183
Qy 169 VSNTOALPPSQEVDNDAI-----KOMKKHLKLAKDSSADRFNLSLGRFMTGLDTRN 218
Db 184 IFEDRAPVPFEEVIDKINAKGVCRTAKYVVRNNLETTAFHRDDH-----ETDMELKP 235
Qy 219 NVKVFNNKGWHAISFLNINNAILRANLOKGENPSHYGTT 260
Db 236 ANAATRTSRGWHTTD-----LKNPSRVEAFHRYGTT 267

RESULT 12
US-08-413-118-8
; Sequence 8, Application US/08413118
; Patent No. 5688920
; GENERAL INFORMATION:
; APPLICANT: Paoletti, Enzo
; APPLICANT: Limbach, Keith J.
; TITLE OF INVENTION: NUCLEOTIDE AND AMINO ACID SEQUENCES OF
; TITLE OF INVENTION: CANINE HERPESVIRUS gB, gC, AND gD AND USES THEREFOR
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CURTIS, MORRIS & SAFFORD, P.C.
; STREET: 530 FIFTH AVENUE, 25TH FLOOR
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/413.118
; FILING DATE: 29-MAR-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/220.151
; FILING DATE: 30-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: FROMMER, WILLIAM S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2670
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 903 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: N-terminal
```

TOPOLOGY: linear

; MOLECULE TYPE: protein
US-08-861-464-6

Query Match 5.8%; Score 88; DB 2; Length 888;
Best Local Similarity 19.4%; Pred. No. 2.8;
Matches 61; Conservative 36; Mismatches 105; Indels

[illegible]

RESULT 15

US-08-396-001-6
 : Sequence 6, Application US/08396001
 : Patent No. 5919618
 : GENERAL INFORMATION:
 : APPLICANT: Guarente, Leonard P.
 : APPLICANT: Austriaco Jr., Nicanor
 : APPLICANT: Claus, James
 : APPLICANT: Cole, Francesca
 : APPLICANT: Kennedy, Brian
 : TITLE OF INVENTION: Genes Determining Cellular Senescence in
 : TIME OF INVENTION: Yeast
 : NUMBER OF SEQUENCES: 16
 : CORRESPONDENCE ADDRESS:
 : ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
 : STREET: Two Militia Drive
 : CITY: Lexington
 : STATE: MA
 : COUNTRY: USA
 : ZIP: 02173
 : COMPUTER READABLE FORM:
 : MEDIUM TYPE: Floppy disk
 : COMPUTER: IBM PC compatible
 : OPERATING SYSTEM: PC-DOS/MS-DOS
 : SOFTWARE: PatentIn Release #1.0, Version #1.30
 : CURRENT APPLICATION DATA:
 : APPLICATION NUMBER: US/08/396,001
 : FILING DATE: 28-FEB-1995
 : CLASSIFICATION: 435
 : ATTORNEY/AGENT INFORMATION:
 : NAME: Granahan, Patricia
 : REGISTRATION NUMBER: 32,227
 : REFERENCE/DOCKET NUMBER: MIT-6408A2
 : TELECOMMUNICATION INFORMATION:
 : TELEPHONE: 617-861-6240
 : TELEFAX: 617-861-9540
 : INFORMATION FOR SEQ ID NO: 6:
 : SEQUENCE CHARACTERISTICS:
 : LENGTH: 888 amino acids
 : TYPE: amino acid
 : TOPOLOGY: linear

GenCore version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: February 4, 2003, 09:40:23 : Search time 13 Seconds
(without alignments)
484,314 Million cell updates/sec

Title: US-09-704-272-6

Perfect score: 1525

Sequence: 1 FGKYPSELEQPMWYNEQYTF.....PLNLTKQQLSEVALMTTSVD 284

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 129505 seqs, 22169297 residues

Total number of hits satisfying chosen parameters: 129505

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published_Applications_AA.*
1: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB pep.*
6: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB pep.*
7: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB pep.*
11: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB pep.*
12: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB pep.*
13: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB pep.*
14: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	1513	99.2	2261	10	US-09-995-542-11
2	1513	99.2	2261	10	US-09-846-456-11
3	1423	93.3	2201	10	US-09-995-542-9
4	733.5	48.1	2273	10	US-09-995-542-12
5	724.5	47.5	2310	10	US-09-995-542-10
6	664	43.5	2121	10	US-09-995-542-3
7	664	43.5	2167	10	US-09-995-542-2
8	663.5	43.5	1550	10	US-09-995-542-8
9	663.5	43.5	2100	10	US-09-995-542-6
10	663.5	43.5	2146	10	US-09-995-542-5
11	662.5	43.4	2144	10	US-09-995-542-4
12	460.5	30.2	199	10	US-09-858-194-2
13	267	17.5	2001	9	US-09-767-870-18
14	267	17.5	2436	10	US-09-795-693-8
15	140	9.2	664	10	US-09-767-870-9
16	88	5.8	888	10	US-09-826-752-6
17	87.5	5.7	522	10	US-09-876-889-353
18	86.5	5.7	969	9	US-09-981-353-122
19	86.5	5.7	977	10	US-09-925-297-797

20	85.5	5.6	953	9	US-10-118-984-43	Sequence 43, Appl
21	85.5	5.6	953	10	US-09-728-721-43	Sequence 43, Appl
22	82.5	5.4	384	9	US-10-029-180-50	Sequence 50, Appl
23	81.5	5.3	172	10	US-09-764-847-551	Sequence 551, App
24	81.5	5.3	774	10	US-09-815-242-12046	Sequence 16, Appl
25	81.5	5.3	972	10	US-09-924-154-16	Sequence 24, Appl
26	80	5.2	426	9	US-09-909-650A-24	Sequence 10, Appl
27	80	5.2	426	9	US-09-165-522-10	Sequence 2, Appl
28	80	5.2	464	9	US-09-165-522-2	Sequence 4, Appl
29	80	5.2	678	9	US-09-895-913A-4	Sequence 5, Appl
30	79.5	5.2	1242	10	US-09-903-248-5	Sequence 5, Appl
31	79.5	5.2	1242	10	US-09-859-604-5	Sequence 5, Appl
32	79.5	5.2	1242	10	US-09-903-063-5	Sequence 5, Appl
33	79.5	5.2	1242	10	US-09-903-216-5	Sequence 5, Appl
34	79.5	5.2	1242	10	US-09-903-199-5	Sequence 5, Appl
35	79.5	5.2	1242	10	US-09-903-023-5	Sequence 5, Appl
36	79.5	5.2	1242	12	US-10-085-027-1	Sequence 1, Appl
37	79	5.2	1848	9	US-09-839-996-6	Sequence 6, Appl
38	78.5	5.1	793	10	US-09-881-752A-362	Sequence 362, App
39	78.5	5.1	2434	10	US-09-815-242-5835	Sequence 5835, Ap
40	78.5	5.1	6281	10	US-09-815-242-12996	Sequence 12996, A
41	78	5.1	704	10	US-09-801-368-218	Sequence 218, App
42	77	5.0	315	10	US-09-764-853-793	Sequence 793, App
43	76.5	5.0	364	10	US-09-756-983-22	Sequence 22, Appl
44	76.5	5.0	378	10	US-09-801-574-38	Sequence 38, Appl
45	76.5	5.0	540	9	US-09-738-626-4450	Sequence 4450, Ap

ALIGNMENTS

RESULT 1

US-09-995-542-11
; Sequence 11, Application US/09995542
; Patent No. US20020127647A1

; GENERAL INFORMATION:

; APPLICANT: Shutter, John

; APPLICANT: Ulias, Learni

; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
; TITLE OF INVENTION: Uses Thereof

; FILE REFERENCE: 00-658-A

; CURRENT APPLICATION NUMBER: US/09/995,542

; CURRENT FILING DATE: 2001-11-28

; PRIOR APPLICATION NUMBER: 60/253,520

; PRIOR FILING DATE: 2000-11-28

; NUMBER OF SEQ ID NOS: 24

; SOFTWARE: Patentin Ver. 2.0

; SEQ ID NO 11

; LENGTH: 2261

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-995-542-11

Query Match 99.2%; Score 1513; DB 10; Length 2261;
Best Local Similarity 99.3%; Pred. No. 2 6e-138;
Matches 282; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY	1	FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLELLNALT	KDPCGFGTRCMEGNP	IPDTPCQ	60
Db	1371	FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLELLNALT	KDPCGFGTRCMEGNP	IPDTPCQ	1430
QY	61	AGEEWTAPVPTIMDLFONGNWTQNPSPACQSSDKTKMLPVC	PGAGGLPPQPK	120	
Db	1431	AGEEWTAPVPTIMDLFONGNWTQNPSPACQSSDKTKMLPVC	PGAGGLPPQPK	1490	
QY	121	QNTADILQDLTGRNISDYLKTYVQIIAKSLKNNK	IWNNEFRYGGFSLGVSN	QALPPSQE	180
Db	1491	QNTADILQDLTGRNISDYLKTYVQIIAKSLKNNK	IWNNEFRYGGFSLGVSN	QALPPSQE	1550
QY	181	VNDAIKQMKHKLAKDSSADREFLNSLGRFWTGLDTRNNV	KVWFKWNNKGNHWA	ISSTFLVNIN	240
Db	1551	VNDATKQMKHKLAKDSSADREFLNSLGRFWTGLDTRNNV	KVWFKWNNKGNHWA	ISSTFLVNIN	1610

QY	241	NAILRANLQKGENSPHYGITAFNHPNLTKQQLSEVALMTTSVD	284
QY	1611	NAILRANLQKGENSPHYGITAFNHPNLTKQQLSEVALMTTSVD	1654
pb			

RESULT 2

```

US-09-846-456-11
; Sequence 11, Application US/09846456
; Patent No. US20020146792A1
; GENERAL INFORMATION:
; APPLICANT: Rosier, Marie
; APPLICANT: Prades, Catherine
; APPLICANT: Lemoine, Cendrine
; APPLICANT: Naudin, Laurent
; APPLICANT: Denefle, Patrice
; APPLICANT: Duvergier, Nicolas
; APPLICANT: Brewer, Bryan
; APPLICANT: Remaley, Alan
; APPLICANT: Fojo, Silvia
; TITLE OF INVENTION: Regulatory Nucleic Acid Sequences
; DATE OF INVENTION: 2000-05-02
; FILE REFERENCE: 3806.0505
; CURRENT APPLICATION NUMBER: US/09/846-456-11
; CURRENT FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: US 60/201111
; PRIOR FILING DATE: 2000-05-02
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 11
; LENGTH: 2261
; TYPE: prt
; ORGANISM: Homo sapiens
US-09-846-456-11

```

Query Match	99.28;	Score 1513;	DB 10;	Length 2261;
Best Local Similarity	99.38;	Pred. No. 2.6e-138;		
Matches 282; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

Qy	1	FGKPSLELPQWMYNEQYTVSNDAPEDTGTLLELNALTKDGFCTRCMEGNPIPDTPCQ	60
Db	1371	FGKPSLELPQWMYNEQYTVSNDAPEDTGTLLELNALTKDGFCTRCMEGNPIPDTPCQ	1430
Qy	61	AGEEWTTAPVPQTIMDLFQNGNWTMQNPSQACSSDKIKKMLPVCPPGAGGLPPQPK	120
Db	1431	AGEEWTTAPVPQTIMDLFQNGNWTMQNPSQACSSDKIKKMLPVCPPGAGGLPPQPK	1490
Qy	121	QNTADILQDLTGRNISDYLVKTYVYQIIAKSLNKKIWNEFRYGGFSLGVNTQALPPSQE	180
Db	1491	QNTADILQDLTGRNISDYLVKTYVYQIIAKSLNKKIWNEFRYGGFSLGVNTQALPPSQE	1550
Qy	181	VNDATJQMKKHLKLAKDSSADRFNLNSLGRPMTGDLTRNNVKVWFNKKGMHAISSFLNVIN	240
Db	1551	VNDATJQMKKHLKLAKDSSADRFNLNSLGRPMTGDLTRNNVKVWFNKKGMHAISSFLNVIN	1610
Qy	241	NAILRANLOKGENPSHYGITAFAHPNLNLTQKQISEVALMTTSDV	284
Db	1611	NAILRANLOKGENPSHYGITAFAHPNLNLTQKQISEVAPMTTSDV	1654

RESULT 3

```

US-09-995-542-9
; Sequence 9, Application US/09995542
; Patent No. US20020127647A1
; GENERAL INFORMATION:
; APPLICANT: Shutter, John
; APPLICANT: Ulias, Jaarni
; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
; TITLE OF INVENTION: Uses Thereof
; FILE REFERENCE: 00-658-A
; CURRENT APPLICATION NUMBER: US/09/995,542
; CURRENT FILING DATE: 2001-11-28
; PRIOR APPLICATION NUMBER: 60/253,520
; PRIOR FILING DATE: 2000-11-28

```

```

: NUMBER OF SEQ ID NOS: 24
: SOFTWARE: PatentIn Ver. 2.0
: SEQ ID NO 9
: LENGTH: 2201
: TYPE: PRT
: ORGANISM: Mus musculus
: FEATURE:
: NAME/KEY: UNSURE
: LOCATION: (115)
: OTHER INFORMATION: amino acid at this position is unknown
: US-09-995-542-9

```

Query Match	93.3%	Score 1423;	DB 10;	Length 2201;
Best Local Similarity	93.0%	Pred. No. 1.4e-129;		
Matches 264:	Conservative	10;	Mismatches 10;	Indels 0;
	Gaps	0;		

Qy	1	FGYPSLEQLQPMWYNEQYTFVSNDAPEDTGTLLELNALTKDPGFGTRCMEGNPIPDTPCQ	60
Db	1311	FGYPSLEQLQPMWYNEQYTFVSNDAPEDKGTQELLNLTAKDPGFGTRCMEGNPIPDTPCL	1370
Qy	61	AGEEWTTPAVPQTIMDLFQNGNWTMQNPSPACQSSDKTKKMLPVCPCGAGLPPQPK	120
Db	1371	AGEEWTTPSPVQISVDLDFQNGNWTMKNPSPACQSSDKTKKMLPVCPCGAGLPPQPK	1430
Qy	121	QNTADTLQDLTGRTNSDYLVKTYVQIIAKSLKNIWNWNEFRYGFSLGVSNQTALPSPQE	180
Db	1431	QKTADTLQNLTGRTNSDYLVKTYVQIIAKSLKNIWNWNEFRYGFSLGVSNQALPSPHE	1490
Qy	181	VNDAIKQMKKHLKLAKDSSADRFSLSGRFTGDLTRNNKVVFNKNGKWHAISSFLNVIN	240
Db	1491	VNDAIKQMKKLLKLKDTSDADRFSLSGRFGAGLDTKNNKVVFNKNGKWHAISSFLNVIN	1550
Qy	241	NATILRANLQKGNPSHYGITAFAFNHPNLNTKQOLSEVALMTTSD	284
Db	1551	NATILRANLQKGNPSYGGITAFNHPNLNTKQOLSEVALMTTSD	1594

RESULT 4

```

RES001
; Sequence 12, Application US/09995542
; Patent No. US20020127647A1
; GENERAL INFORMATION:
; APPLICANT: Shutter, John
; APPLICANT: Ullas, Jaarai
; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
; TITLE OF INVENTION: Uses Thereof
; TITLE OF INVENTION: Uses Thereof
; FILE REFERENCE: 00-658-A
; CURRENT APPLICATION NUMBER: US/09/995,542
; CURRENT FILING DATE: 2001-11-28
; PRIOR APPLICATION NUMBER: 60/253,520
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 12
; LENGTH: 2273
; TYPE: PRT
; ORGANISM: Homo sapiens
; SEQ-09-995-542-12

```

Query Match	48.1%	Score 733.5;	DB 10;	Length 2273;
Best Local Similarity	48.2%	Pred. NO. 2e-62;		
Conservative	35.	Mismatches	83:	Indels 39:
Gaps	4:			

[illegible]


```
Db 1516 QRSTEILDTRNIDSLVKTYPALIRSLKSKFWNEQRYGGISIG----GKLPVWPI 1571
QY 181 VNDAIKQMKHKLAKDSSADRELNSLGR-----FMWGLDTRNNVK 221
Db 1572 TGEALV-----GELSDLGRIMNYSGGPITREASKETPDLKHLKETEDNIK 1616
QY 222 VWFNNKGWHAISSFLNINNAIRANLQGENPSHYGITAFNHNPLNLTQOOLSEVALMTT 281
Db 1617 VWFNNKGWHALVSLFNVAHNAILRASLPKDRSPPEYGITVISQPLNLTKEQLSDITVLT 1676
QY 282 SVD 284
Db 1677 SVD 1679

RESULT 5
US-09-995-542-10
; Sequence 10, Application US/09995542
; Patent No. US20020127647A1
; GENERAL INFORMATION:
; APPLICANT: Shutter, John
; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
; FILE REFERENCE: 00-658-A
; CURRENT APPLICATION NUMBER: US/09/995,542
; PRIOR FILING DATE: 2001-11-28
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 10
; LENGTH: 2310
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-995-542-10

Query Match 47.5%; Score 724.5; DB 10; Length 2310;
Best Local Similarity 47.2%; Pred. No. 1.5e-61;
Matches 143; Conservative 39; Mismatches 82; Indels 39; Gaps 4;

QY 1 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLELLNALTKDPGFGTRCMEGNPIDTPCQ 60
Db 1396 FGEPFALTLPWYGHQYTFVSNDAPEDTGTLELLNALTKDPGFGTRCMEGNPIDTPCQ 1454
QY 61 AGEDEWTTAPVQPTIMDLFQNGWNTMNPSPACQCSDDKIKKMLPVCPPGAGGLPPOR 120
Db 1455 INATSKTPTSPNITLHFKQKWTAAHPSPCKSTREKLTMLPECEGAGGLPPOR 1514
QY 121 QNTADILQDLTGRNIDSLVKTYPVQIIAKSLKNKIWNFRYGGFSLGVSNTQALPPSQ 180
Db 1515 QRSTEVLDLTRNIDSLVKTYPALIRSLKSKFWNEQRYGGISIG-GKLPAPISSE 1573
QY 181 VNDAIKQMKHKLAKDSSADRELNSLGR-----FMWGLDTRNNVK 221
Db 1574 -----ALVGLSLGQMMNVSPPVTRREASKEMDLFLKHLETTDNK 1615
QY 222 VWFNNKGWHAISSFLNINNAIRANLQGENPSHYGITAFNHNPLNLTQOOLSEVALMTT 281
Db 1616 VWFNNKGWHALVSLFNVAHNAILRASLPKDRSPPEYGITVISQPLNLTKEQLSDITVLT 1675
QY 282 SVD 284
Db 1676 SVD 1678

RESULT 6
US-09-995-542-3
; Sequence 3, Application US/09995542
; Patent No. US20020127647A1
; GENERAL INFORMATION:
; APPLICANT: Shutter, John
; APPLICANT: Ullas, Laarni
```

```
; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
; FILE REFERENCE: 00-658-A
; CURRENT APPLICATION NUMBER: US/09/995,542
; PRIOR FILING DATE: 2001-11-28
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 2121
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-995-542-3

Query Match 43.5%; Score 664; DB 10; Length 2121;
Best Local Similarity 45.3%; Pred. No. 1e-55;
Matches 129; Conservative 47; Mismatches 107; Indels 2; Gaps 2;

QY 1 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLELLNALTKDPGFGTRCMEGNPIDTPCQ 60
Db 1228 FGQYPPQLSPAMYGPQVSFFSEADPGDPNRMKLLLEALLGEAGLQEPSMODKARGSECT 1287
QY 61 AGEDEWTTAP-VQPTIMDLFQNGWNTMNPSPACQCSDDKIKKMLPVCPPGAGGLPPOR 119
Db 1288 HSLACYFTVPEVPPDVASILASGNWTPESPSPACQCSQPGARRLLPDCPAGAGGPPPPQA 1347
QY 120 KONTADILQDLTGRNIDSLVKTYPVQIIAKSLKNKIWNFRYGGFSLGVSNTQALPPSQ 179
Db 1348 VAGLGEVYQNTLGRNVSDFLVKTYPVSLVRGLTKTKWVDEVRYGGFSLG-GRDPDLPTGH 1406
QY 180 EVNDAIKOMKKHKLAKDSSADRELNSLGRFMTGLDTRNNVKNWNNKWHAISSFLNVI 239
Db 1407 EVRTLAEIRALLSPQPGNALDRILNLTQWALGDARNLSLKIFWNNKWHAMVAFVNR 1466
QY 240 NNAILRANLQGENPSHYGITAFNHNPLNLTQOOLSEVALMTTSD 284
Db 1467 NGLLHALLPSGPVRHAHSITLHNPLNLTKESLTIASSVD 1511

RESULT 7
US-09-995-542-2
; Sequence 2, Application US/09995542
; Patent No. US20020127647A1
; GENERAL INFORMATION:
; APPLICANT: Shutter, John
; APPLICANT: Ullas, Laarni
; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
; FILE REFERENCE: 00-658-A
; CURRENT APPLICATION NUMBER: US/09/995,542
; PRIOR FILING DATE: 2001-11-28
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 2167
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-995-542-2

Query Match 43.5%; Score 664; DB 10; Length 2167;
Best Local Similarity 45.3%; Pred. No. 1.1e-55;
Matches 129; Conservative 47; Mismatches 107; Indels 2; Gaps 2;

QY 1 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLELLNALTKDPGFGTRCMEGNPIDTPCQ 60
Db 1274 FGQYPPQLSPAMYGPQVSFFSEADPGDPNRMKLLLEALLGEAGLQEPSMODKARGSECT 1333
QY 61 AGEDEWTTAP-VQPTIMDLFQNGWNTMNPSPACQCSDDKIKKMLPVCPPGAGGLPPOR 119
Db 1334 HSLACYFTVPEVPPDVASILASGNWTPESPSPACQCSQPGARRLLPDCPAGAGGPPPPQA 1393
```



```

; NUMBER OF SEQ. ID NOS: 21
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 18
; LENGTH: 199
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-767-870-18

```

Query match:	100.00%	DB: 100.00%	Length: 1597
Best Local Similarity	41.08%	Pred. No. 2.4e-37	
Matches	86	Conservative	40; Mismatches 73; Indels 11; Gaps 2;
QY	22	SNDAEDTGTLELLNALTKDPFGFTRCMEGNPIDPTPCQAGEEHWTTAPVQQTIMDLFQN	81
DB	1	SEDAPGDPGRARLLEALLQEEAG-----LEEPVQHSHSRFSPEVPAEYAKVLAS	50
QY	82	GNWTQMNPSPACQCSSDKIRKMLPVCPPGAGLPPPPQKQNTADILQDLTGRNLSDYLVK	141
DB	51	GNWTPESPSPACQCSRGARRLLDPCPAAGGPPPPQAVTGSGEVQNLTKRNLSDFLVK	110
QY	142	TYVQIIAKSLKNTWNEFRYGGFSLGVSNTQALPPSPQEVNDATIKOMKHLKLAKDSSAD	201
DB	111	TYRLVFRQGLTKKWNVEVRGSGFSLG-GRDPGLPSQGEIGRSVEELWALLSPPLPGGALD	169
QY	202	RFLNSLGRFMTGLDTRNNKVKVWFNNKGWHA	231
DB	170	RVKNLTAWAHSLDAQDSLKTFWNNKGWHS	199

```

US-10-072-621-8
; Sequence 8, Application US/10072621
; Patent No. US20020169137A1
; GENERAL INFORMATION:
; APPLICANT: Reiner, Peter B.
; APPLICANT: Connop, Bruce P.
; APPLICANT: Pollard, Michelle
; TITLE OF INVENTION: REGULATION OF AMYLOID PRECURSOR PROTEIN EXPRESSION
; TITLE OF INVENTION: BY MODIFICATION OF ABC TRANSPORTER EXPRESSION OR ACTIVATION
; FILE REFERENCE: 100103.402
; CURRENT APPLICATION NUMBER: US/10/072.621
; CURRENT FILING DATE: 2002-02-08
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 2001
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: 30, 70, 280, 477, 558, 1471, 1651, 1689, 1724
; OTHER INFORMATION: Xaa = Any Amino Acid
; FEATURE:

```

```

; LOCATION: 307, 707, 2807, 477, 336, 1471, 1631, 1869, 1724
; OTHER INFORMATION: Xaa = Aty Amino Acid
US-10-072-621-8

Query Match      17.5%  Score 267;  DB 9;  Length 2001;
Best Local Similarity 28.8%  Pred. No. 4.3e-17;
Matches 79;  Conservative 41;  Mismatches 68;  Indels 86;  Gaps 13;

QY  44  FGTRCMEG-----NPIP-DTPCQ-----AGEEWMTAP-V 71
      : : : : : : : : : : : : : : : : : : : : : :
Db  1137  FDSWCLESFTOGLPLSNFVPPPPSPAPSDSPASPDIEDLQANNVSLPPTPAGQEWMTSAPSL 1196
      : : : : : : : : : : : : : : : : : : : : : :

QY  72  PQTMDLFPQNGNWTWNPQSPACQSSDKIKMLPYCPGACGLPPQPKQNTADILQDLT 131
      : : : : : : : : : : : : : : : : : : : : : :
      : : : : : : : : : : : : : : : : : : : : : :

Db  1197  PRLVREPVR-----CTCSAQGTGFS---CPNSVGG-HPQQRVVTGDTLTDIT 1240
      : : : : : : : : : : : : : : : : : : : : : :

QY  132  GRNISDLVLKVTYQIIAKSLKNKIWNREFRGFSGLVSNQALPPSQEVNDAIKQMKKH 191
      : : : : : : : : : : : : : : : : : : : : : :
      : : : : : : : : : : : : : : : : : : : : : :

Db  1241  GHNVSEYLLFTSDRF-----RLHRYGATIFG-NVLKSPAS--FGRAPPMVVRK 1286
      : : : : : : : : : : : : : : : : : : : : : :

```


GenCore version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: February 4, 2003, 09:38:27 ; Search time 19 Seconds

(without alignments)

1436.957 Million cell updates/sec

Title: US-09-704-272-6

Perfect score: 1525

Sequence: 1 FGKPSLELPQWYNEQYTF.....PLNLTKQLSEVALMTTSVD 284

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 283224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	1423	93.3	2201	2	A54774	ATP binding casset
2	267	17.5	1529	2	A59189	ATP binding casset
3	257	16.9	1472	2	B54774	ATP binding casset
4	215.5	14.1	1447	2	T15200	hypothetical prote
5	108.5	7.1	432	2	T14292	glutamate-ammonia
6	100.5	6.6	434	1	AJBHQ	glutamate-ammonia
7	98	6.4	877	2	F90070	Clumping factor B
8	97	6.4	908	2	T16057	hypothetical prote
9	95.5	6.3	429	1	AJF8QD	glutamate-ammonia
10	94.5	6.2	263	2	C64339	hypothetical prote
11	94.5	6.2	430	2	S18600	glutamate-ammonia
12	94.5	6.2	4660	2	T42737	gp330 protein prec
13	92.5	6.1	428	1	AJRZQD	glutamate-ammonia
14	91	6.0	459	2	B83793	hypothetical prote
15	90.5	5.9	428	2	S32228	glutamate-ammonia
16	90	5.9	773	2	F90537	lipoprotein [impor
17	89.5	5.9	423	2	S39482	glutamate-ammonia
18	89.5	5.9	596	1	S33540	catechol oxidase (
19	89.5	5.9	649	2	B96729	hypothetical prote
20	89	5.8	903	1	VGBE1	glycoprotein B pre
21	88.5	5.8	363	2	S38154	hypothetical prote
22	88.5	5.8	865	2	AG2023	hypothetical prote
23	88.5	5.8	903	1	VGBEK1	glycoprotein B pre
24	88.5	5.8	982	2	T43676	hunchback-related
25	88.5	5.8	1071	2	T18597	hypothetical prote
26	88.5	5.8	1650	2	S53457	dominant autoantig
27	88	5.8	678	2	S12456	virD3 protein - Ag
28	88	5.8	791	2	S67265	hypothetical prote
29	88	5.8	888	2	S64016	probable regulator

30	87.5	5.7	578	2	G84015	maltoogenic amylase
31	86.5	5.7	407	2	A85191	probable serine pr
32	86.5	5.7	944	2	D82926	hypothetical prote
33	86.5	5.7	967	2	A30325	membrane alanyl am
34	86	5.6	506	2	AB3411	cysteine-tRNA liga
35	86	5.6	633	2	S48956	hypothetical prote
36	86	5.6	739	2	T156187	transcription fact
37	86	5.6	1309	1	BVBYD9	RAD9 protein - yea
38	86	5.6	2509	2	G01880	glutathione-S-trans
39	85.5	5.6	430	1	AJPMQ2	glutamate-ammonia
40	85.5	5.6	2329	2	S44625	C50C3.6 protein -
41	85	5.6	770	1	S30293	transcription fact
42	85	5.6	1566	2	T20058	hypothetical prote
43	84.5	5.5	389	2	S75454	hypothetical prote
44	84	5.5	325	2	JC2008	actin homolog prot
45	83.5	5.5	283	2	D83948	hypothetical prote

ALIGNMENTS

RESULT 1

A54774

ATP binding cassette transporter ABC1 - mouse

C:Species: Mus musculus (house mouse)

C:Date: 05-Apr-1995 #sequence_revision 05-Apr-1995 #text_change 02-Feb-2001

C:Accession: A54774

R.Luciani, M.F.: Denizot, F.; Savary, S.; Mattei, M.G.; Chimini, G.

Genomics 21, 150-159, 1994

A:Title: Cloning of two novel ABC transporters mapping on human chromosome 9.

A:Reference number: A54774; MUID:94375008; PMID:8088782

A:Accession: A54774

A:Molecule type: mRNA

A:Residues: 1-2201 <LUC>

A:Cross-references: GB:X175926; MID:9495256; PIDN:CAA53530.1; PID:9495257

C:Superfamily: unassigned ATP-binding cassette proteins; ATP-binding cassette homolog

C:Keywords: ATP; duplication; nucleotide binding; P-loop

F:856-1047/Domain: ATP-binding cassette binding; P-loop

F:873-880/Region: ATP-binding cassette motif A (P-loop)

F:1869-2060/Domain: ATP-binding cassette homolog <ABC>

F:1886-1893/Region: nucleotide-binding motif A (P-loop)

Query Match

Best Local Similarity 93.3%; Score 1423; DB 2; Length 2201;

Matches 264; Conservative 10; Mismatches 10; Indels 0; Gaps 0;

QY 1 FGKPSLELPQWYNEQYTFVSNDAPEDTGTTLELNALTKDPGFTRCMEGNIPDTPCQ 60

|||||

Db 1311 FGKPSLELPQWYNEQYTFVSNDAPEDMGTQELLNALT KDPGFTRCMEGNIPDTPCL 1370

QY 61 AGEEETTPAPVQPTMDLFQNGNWTMONPSPACQSSDKIKKMLPVCPPGAGLPPPPQK 120

|||||

Db 1371 AGEEDWTISPVQSIVDLFQNGNWTMKNPSPACQSSDKIKKMLPVCPPGAGLPPPPQK 1430

QY 121 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNIWNEFRYGGFSLGVSNTQALPPSQE 180

|||||

Db 1431 QKTADILQNLTCGRNISDYLVKTYVQIIAKSLKNIWNEFRYGGFSLGVSNSQALPPSHE 1490

QY 181 VNDATKQMKHKHLKADSSADRFSLNSLGRFTGLDTRNNKVKWVFNKKGWHAISSFLNIN 240

|||||

Db 1491 VNDATKQMKKKLTKTSDADRFSLSLGRFMAGLDTKNNVKWVFNKKGWHAISSFLNIN 1550

QY 241 NAILRANLQKGNPSHYGITAFAFNHPLNLTQKQSEVALMTTSVD 284

|||||

Db 1551 NAILRANLQKGNPSOYGITAFAFNHPLNLTQKQSEVALMTTSVD 1594

RESULT 2

A59189

ATP-binding cassette transporter - human (fragment)

N:Alternate names: KIAA1062 protein

C:Species: Homo sapiens (man)

C:Date: 18-Feb-2000 #sequence_revision 18-Feb-2000 #text_change 02-Jun-2000

[illegible]

QY 55 ---PD-----TpCOAGEEWTTAP--VPQTIMDLFQNGNWTMQNPSPACQCSSDKI 100
 Db 638 PVXPDEDSLOANNLSLPPPTAGPETWTSAFSLPLRVHEPVR-----CTCSAQGT 685
 QY 101 KMLPVCPPGAGGLPPQPKONTADILQDTLGTNRNISDYLVKTYVQIIAKSLKNKIWNNEF 160
 Db 686 GFS---CPSSVGG-HPQMRVVTGDTLITDIGHNVSEYLLFTSDRF-----RLH 730
 QY 161 RYGGFSLGVSNTOALPPSQEVNDIAIKMKHKLAKDSSADREFLSLGRFMTGLDTRNNV 220
 Db 731 RYGAITFG--NVQKSIPAS-----EGARVPMKRVKIAVRVA 765
 QY 221 KVFNNKGWHAISFLNVIINAILRANLQKE-NPSHYGITAFNHPNLITKQOLS-EVAL 278
 Db 766 QVLYNNKCYHSMPTLYNSLNAAILRANLPSKGNPAAIXITVTHPMNKTASLSLDYLL 825
 QY 279 MTTSV 283
 Db 826 QGTDV 830
 RESULT 4
 T15200
 hypothetical protein F12B6.1 - *Caenorhabditis elegans*
 C:Species: *Caenorhabditis elegans*
 C:Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 17-Mar-2000
 C:Accession: T15200
 R:Pauley, A.; Maggi, L.
 submitted to the EMBL Data Library, May 1997
 A:Description: The sequence of *C. elegans* cosmid F12B6.
 A:Reference number: Z18307
 A:Accession: T15200
 A:Status: preliminary; translated from GB/EMBL/DDBB
 A:Molecule type: DNA
 A:Residues: 1-1447 >X>
 A:Cross-references: EMBL:AF003138; NID:g2088708; PID:g2088709; PIDN:AAB54153.1; GSPDB
 A:Experimental source: strain Bristol N2; clone F12B6
 C:Genetics:
 A:Gene: CESP.F12B6.1
 A:Map position: 1
 A:Introns: 79/2; 114/3; 177/1; 224/3; 331/1; 345/3; 373/2; 417/2; 464/1; 536/1; 659/2
 C:Superfamily: unassigned ATP-binding cassette proteins; ATP-binding cassette homolog
 Query Match 14.1%; Score 215.5; DB 2; Length 1447;
 Best Local Similarity 24.2%; Pred. No. 3.7e-09;
 Matches 86; Conservative 44; Mismatches 105; Indels 121; Gaps 15;
 QY 5 PSLEQPMYNEQYTFVSN--DAPEDGTLELLNALTKDPCGFTRCMEG--NPIDP--- 57
 Db 605 PPLPLETSIMGNHSDFYVNSWDTAENSTANDILHAMFSPGTGPRCAKDVPNLDDTMRR 664
 QY 58 -----PCQ--AGEEWT-----TAPVPQTIMDL- 78
 Db 665 ELMFERNRYGFRGNKAPGVDKSDVNEYQCOINIGEFDYDIEDISNATYNAPIYCCGEDFG 724
 QY 79 ----FONGNWTMQNPSPACQCSSDKIKKMLPVCPPGAGLPPQPKONTADILQDLTGRN 134
 Db 725 WNCILEDKWKNETN-----WLRNLTTRIDFLDTRN 755
 QY 135 ISDY-LVKTYVQIIATAKSLKNKIWNNEFRYGGFSLGVSNTOALPPSQEVND-----AI 185
 Db 756 LTQFLRIYRFAQLANTTA-----PFLGGFSLGHVNQRA--OSQADIDTSKRGWLETI 806
 QY 186 KQMKHKL-----AKDSSADREFLSLGRFMTGLDTRNNVKKVWNN 226
 Db 807 KDIAQSMRIINLTGTGIEPATPKVLDPPAQNLITLNVQVNDL----LQNLDVRENKVVWNN 863
 QY 227 KGWHAISSFLNVIINAILRANLQKGNPSHYGITAFNHPNLIT-KQOLSEVALMTT 281
 Db 864 KTECEPTASNTI SNAILROR-DVAIDPEDIGIITMNHPMNKTITSOTLDONALKFT 918

Db 43 POEIIKLYONG-YTTTEIAIKMKSHETIRRL-----RNNNIDI----- 81
QY 132 GRNISDYLVTYVQIIAKSLN--KIWNNEFRYGGSLGVSNTQALPPSQEVN----- 182
Db 82 -RKSSSLI-----IKNTKKINLPNSESILVTLGLVINGDGSVKNQESNYIELKV 130
QY 183 ---DAIKQMKKHLKLAKDSADRFLNSLGRFMTGLDTRNNVKVWENKNG---WHA---IS 233
Db 131 TDKDFIEFRNLC---ENIGFYINEYVRKFKENKDKQYVVRV--RSKGFYWKSLNVD 184
QY 234 SFLNVI--NNAILRANLOK 251
Db 185 YVMNVIGNNEKLMISWLK 203

RESULT 11
S18600
glutamate-ammonia ligase (EC 6.3.1.2) precursor, chloroplast (clone lambdaaatgs11) - Arab
N;Alternate names: glutamine synthetase
C;Species: Arabidopsis thaliana (mouse-ear cress)
C;Date: 22-Nov-1993 #sequence_revision 12-May-1995 #text_change 03-Jun-2002
C;Accession: S18600
R;Peterson, T.K.; Goodman, H.M.
Mol. Gen. Genet. 230, 145-154, 1991
A;Title: The glutamine synthetase gene family of Arabidopsis thaliana: light-regulation
A;Reference number: S18600; MUID:92079889; PMID:1684022
A;Molecule type: mRNA
A;Residues: 1-430 <PET>
A;Cross-references: EMBL:S69727; NID:9240069; PIDN:AAB20558.1; PID:g240070
A;Experimental source: clone lambdaaatgs11
C;Genetics:
A;Genome: nuclear
C;Superfamily: glutamate-ammonia ligase
C;Keywords: chloroplast; ligase
F;1-51/Domain: transit peptide (chloroplast) #status predicted <TNP>
F;52-430/Product: glutamate-ammonia ligase #status predicted <MAT>

Query Match 6.2%; Score 94.5; DB 2; Length 430;
Best Local Similarity 23.1%; Pred. No. 5.9;
Matches 67; Conservative 25; Mismatches 111; Indels 87; Gaps 14;
QY 5 PSLELPQWYNEQYTFVSNADP-EDTGTLELLNALTDPGFG-----TRCMEGNPI 54
Db 105 PS-ELPKWNYDGSST---GQAPGEDSEVILYPQAFIRDPFRGNNILVICDTWTTPAGEPI 160
QY 55 P-----DTPCQAGEEWTAPVPQTIMDLFQNGNWTMQNPSPACQCSSDKIKKM 103
Db 161 PTNKRKAKEIFSNNKVSGEVWFGTEQYETLLQ--QNVKWLGLWP----- 204
QY 104 LPVCPFGAGLPPQPRKQNTADILQDLTGRNISDYLVTYVQIIAKSLKNIWNEFRYG 163
Db 205 -----VGAFPGQGPYYCGVGADKIWRDLSDAHAKCL-----YA 240
QY 164 GFSLGVSNTQALPPSQEVN-----DAIKQMKKHLKLAKDSADRFLNSLGRFMTGLDT 216
Db 241 GINISGTNGEVMFGQWFOGFSVGIDA---GDHWKCAR-YLLERITEQAGVWLT-LDP 294
QY 217 RNNVKVWENKNGHATSSP-----LNVINNAILRANLOKGENPSHYG 258
Db 295 KPTEGDW-NGAGCHTNYSTKSMREGGFVTKKAILNLSLRHKEHISAYG 343

RESULT 12
T42737
gp330 protein precursor - rat
N;Alternate names: megalin
C;Species: Rattus norvegicus (Norway rat)
C;Date: 11-Jan-2000 #sequence_revision 11-Jan-2000 #text_change 04-Mar-2000
C;Accession: T42737
R;Saito, A.; Pietromonaco, S.; Loo, A.K.C.; Farquhar, M.G.
Proc. Natl. Acad. Sci. U.S.A. 91, 9725-9729, 1994
A;Title: Complete cloning and sequencing of rat gp330/megalin, a distinctive member of t

A;Reference number: A58173; MUID:95024033; PMID:7937880
A;Accession: T42737
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-4660 <SAI>
A;Cross-references: EMBL:L34049; NID:9561852; PID:9561853; PIDN:AAAS1369.1
A;Experimental source: strain Sprague-Dawley; kidney
C;Superfamily: alpha-2-macroglobulin receptor; EGF homology; LDL receptor ligand-bind
F;1-25/Domain: signal sequence #status predicted <SIG>
F;26-4660/Product: gp330 protein #status predicted <MAT>
Query Match 6.2%; Score 94.5; DB 2; Length 4660;
Best Local Similarity 23.6%; Pred. No. 1.4e+02;
Matches 70; Conservative 37; Mismatches 111; Indels 79; Gaps 19;
QY 1 FGKYP-----LEIQPM-----YNEQYTFVSNADPDTGTLELLNALTDPGFGTR 47
Db 4302 FGKENKEKVLVNVNPLTQVRIFHQLRYNQ-----VSNPCKQVCSHLCLL----RPGGYSCA 4354
QY 48 CMEGNPI---PDTFCQAGEEWTAPVPQTIMDLFQNGN-WTMQNPSACQCSSDKIKKM 103
Db 4355 CPQGSDFVTGSTVQCDAASELPVTMPPPCRM---HGGNCYFDENELPKCKCSGYSGE- 4410
QY 104 LPVCPFG-AGGLPPQPRKQNTADILQDLTGRNISDYLVTYVQIIAKSLKNIWNEFRY 162
Db 4411 --YCEVGLSRGIPP-----GTMA-VLLTFVIVILVGL--VVLVGLFHY 4449
QY 163 GFSLGVSNTQALPPSQEVNDAIKQMKHLKLAKDSSADRFLNSLG-RFMTGLDTRNNVK 221
Db 4450 -----RKTGSLTPT-----LPKLPSLSLAKPSE-----NGNGVTFRSGADV--NMD 4489
QY 222 VWFNKNKGWHAISSFLNVINNAILRANLOKGENPSHYGTAFNHPLNLTKQOLSEVAL 278
Db 4490 IGVSFPGPETIDRSMAHNEFV---MEVGKQP-----VIFENPMYAAKDNSTKVAL 4538
RESULT 13
AJR20D
glutamate-ammonia ligase (EC 6.3.1.2) delta precursor, chloroplast - rice
N;Alternate names: glutamine synthetase delta
C;Species: Oryza sativa (rice)
C;Date: 30-Sep-1991 #sequence_revision 30-Sep-1991 #text_change 03-Jun-2002
C;Accession: S07471
R;Sakamoto, A.; Ogawa, M.; Masumura, T.; Shibata, D.; Takeba, G.; Tanaka, K.; Fujii,
Plant Mol. Biol. 13, 611-614, 1989
A;Title: Three cDNA sequences coding for glutamine synthetase polypeptides in Oryza
A;Reference number: S07469; MUID:91370845; PMID:2577497
A;Molecule type: mRNA
A;Accession: S07471
A;Residues: 1-428 <SAK>
A;Cross-references: GB:X14246; NID:g20369; PIDN:CAA32462.1; PID:g20370
C;Superfamily: glutamate-ammonia ligase
C;Keywords: chloroplast; ligase
Query Match 6.1%; Score 92.5; DB 1; Length 428;
Best Local Similarity 23.6%; Pred. No. 8.5;
Matches 67; Conservative 30; Mismatches 112; Indels 75; Gaps 14;
QY 5 PSLELPQWYNEQYTFVSNADP-EDTGTLELLNALTDPGFG-----TRCMEGNPI 54
Db 103 PS-ELPKWNYDGSST---GQAPGEDSEVILYPQAFIRDPFRGNNILVMCDTWTTPAGEPI 158
QY 55 P-----DTPCQAGEEWTAPVP-----QTIMDLFQNGNWTMQNPSPACQCSSDKIKKM 105
Db 159 PTNKRRAAQVFSDPKVVSVQVPWFGEIYTLQRDVNWPLGWP----- 202
QY 106 VCPFGAGLPPQPRKQNTADILQDLTGRNISDYLVTYVQIIAKSLKNIWNEFRYGGF 165
Db 203 -----VGGYPGQGPYYCAVGSKDSFGDRISDAHAKCL-----YAGI 240
QY 166 SLGVSNTQALPPSQE--VNDAIK-QMKKHLKLAKDSSADRFLNSLGRFMTGLDTRNNVK 222
Db 241 NISGTNGEVMFGQWFOGFSVGIEAGDHIWISR-YILERITEQAGVWLT-LDPKPIQGD 298

Db 241 NISGTNGEYMPQGWFOVSGVTEAGDHVWCAR-YLLERITEQAGVVLT-LDPKPIEGD 298

QY 223 WFNNKGWHAISF-----LNVINNAILRLANLQGENPSHYG 258

Db 299 W-NGACHTNYKTSKMRDGGFEVKKAILNLRLHMEHISAYG 341

Search completed: February 4, 2003, 09:40:38
Job time : 25 secs

```

Qy  223 WFNKNGHWTSSF-----LVNNNAILRANLQGNPSHYG 258
      | | | | | | | | | | | | | | | | | | | |
Db  299 W-NGAGCHTWNYSKSMREDGGSFEVIKKAILNLSLRHDLHSAYG 341

RESULT 14
B83793
hypothetical protein BHL146 [Imported] - Bacillus halodurans (strain C-125)
C:Species: Bacillus halodurans
C:Date: 01-Dec-2000 #sequence_revision 01-Dec-2000 #text_change 15-Jun-2001
C:Accession: B83793
R:Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fujii, F.; Hira-
Nucleic Acids Res. 28, 4317-4331, 2000
A:Title: Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans and
A:Reference number: A83650; MUID:20512582; PMID:11058132
A:Accession: B83793
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-459 <SPOT>
A:Cross-references: GB:AP001511; GB:BA000004; NID:gl0173727; PIDN:BAB04865.1; GSPDB:GN00
A:Experimental source: strain C-125
C:Genetics:
A:Gene: BHL146

```

Query Match 6.0%; Score 91; DB 2; Length 459;
Best Local Similarity 33.3%; Pred. No. 12;
Matches 32; Conservative 11; Mismatches 29; Indels 24; Gaps 6;

Qy	180	EVDIAIQMKK---HLKANDSSADRELNSLGRPMRTGLDTRNNVYKWF----	NNKGWHAIS	233
		: : : :	: : :	:
Dd	366	.EKHESVRLLKAAQLSLADESLDGTEIGE-FDLGLD--ESGRVWLLEANSKPRAI-		421
		: : : :	: : :	:
Qy	234	SFLNVINAILRANLOGEN-----PSHYGITAFNH	264	
		: : : :	: : :	:
Dd	422	-----FRHPNLOKEERTLRLPHYGTFFLAKH	448	

RESULT 15
S32228 glutamate-ammonia ligase (EC 6.3.1.2) precursor - rape
C;Species: Brassica napus (rape)
C;Date: 07-Dec-1994 #sequence_revision 10-Nov-1995 #text_change 03-Jun-2002
C;Accession: S32228; S32686
R;Ochs, G.; Schock, G.; Wild, A.
submitted to the EMBL Data Library, March 1993
A;Description: Nucleotide sequence of a cDNA encoding chloroplastic glutamine synthetase
A;Reference number: S32228
A;Accession: S32228
A;Molecule type: mRNA
A;Residues: 1-428 <OCH>
A;Cross-references: EMBL:X72751; NID:g296222; PIDN:CAA51280.1; PID:g296223
C;Superfamily: glutamate-ammonia ligase
C;Keywords: ligase

Query Match 5.9%; Score 90.5; DB 2; Length 428;
Best Local Similarity 23.9%; Pred. No.12;
Matches 68; Conservative 28; Mismatches 113; Indels 75; Gaps 14;

```

Qy      5 PSLELPWMYNEQVTFVSNDAP-EDTGTLELLNALTVDPGEG-----TRCMEGNPI   54
       ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db     103 PS-ELPKWNYDGSST---GQAPEGSDVILYPQAIFRDPFRGGNNILVICDTYTPAGEPI  158
       ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Qy     55 P-DTPCQAGE-----EEWTTAPVPQTIMDLFQNGNWMTMQNPSPACQCSSDIKKMLP  105
       ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db     159 PTNKRRAAAEIFSNNKVNEEIFPWFGIEQEYVTLLOPNVNWPLGW------  202
       ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Qy     106 VCPGAGGLPPQKQNTADILQDLTGRTNSDYLVKYTVQLIAKSLKNKIWNVEFRYGGF  165
       ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db     203 -----VGAYPGPGPYCYCGVAEKSWGDRISDAHYKACL-----YAGI    240
       ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Qy     166 SLGVSNYQALPPSQE--VNDAIK-QMKKHKLKLAKDSSADRFLNSLGRFMWTGLDTRNNVKV  222
       ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |

```

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 4, 2003, 09:38:24 ; Search time 11 Seconds
(without alignments)
1070.843 Million cell updates/sec

Title: US-09-704-272-6

Perfect score: 1525
Sequence: 1 FGKYPSELPQWPMYNEQYTF.....PLNLTKQQLSEVALMTTSVD 284

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 112892 seqs, 41476328 residues

Total number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Swissprot_40:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Query %	ID	Description
1	1513	99.2		ABC1_HUMAN	O95477 homo sapien
2	1423	93.3		ABC1_MOUSE	P41233 mus musculus
3	733.5	48.1		ABCR_HUMAN	P78363 homo sapien
4	267	17.5		ABC2_HUMAN	Q9bzc7 homo sapien
5	264	17.3		ABC2_MOUSE	P41234 mus musculus
6	108.5	7.1		GLN2_DAUCA	O22506 daucus caro
7	98.5	6.5		GLN2_HORVU	P13564 hordeum vul
8	98.5	6.5		DYSF_MOUSE	Q9esd7 mus musculus
9	95.5	6.3		GLN4_PHAVU	P35102 phasolus v
10	94.5	6.2		Y314_METJA	Q57762 methanococc
11	94.5	6.2		GLN2_ARATH	Q43127 arabidopsis
12	94.5	6.2		DYSF_HUMAN	O75923 homo sapien
13	94.5	6.2		LRP2_RAT	P98158 rattus norv
14	92.5	6.1		GLN2_ORYSA	P14655 oryza sativ
15	90.5	5.9		GLNC_BRANA	Q42624 brassica na
16	89.5	5.9		GLNC_MAIZE	P25462 zea mays (m
17	89.5	5.9		PPOB_LYCES	Q08304 lycopersico
18	89	5.8		VGLB_HSVIF	P06436 herpes simp
19	89	5.8		GTFL_STRDO	P11001 streptococc
20	88.5	5.8		YK57_YEAST	P36157 saccharomyc
21	88.5	5.8		HBL1_CAEEL	Q9xyd3 caenorhabdi
22	88	5.8		YD13_AGRHH	P13463 agrobacteri
23	88	5.8		YGB4_YEAST	P25339 saccharomyc
24	87.5	5.7		GLN2_MEDSA	Q9xq94 medicago sa
25	87.5	5.7		HD_FUGRU	P51112 fugu rubrip
26	87	5.7		THYG_HUMAN	P01266 homo sapien
27	86.5	5.7		Y166_UREPA	Q9pqx7 ureaplasma
28	86	5.6		BZL1_YEAST	P38822 saccharomyc
29	86	5.6		RD9_YEAST	P14737 saccharomyc
30	85.5	5.6		GLN2_PEA	P08281 pisum sativ
31	85.5	5.6		RRPL_EBOZM	Q05318 ebola virus
32	85.5	5.6		YLJ6_CAEEL	P34369 caenorhabdi
33	85	5.6		OCT1_MOUSE	P25425 mus musculus

34	84	5.5	322	1	ACT_PROCL	P45521 procambarus
35	83.5	5.5	353	1	VM17_BORHE	P32777 borrelia he
36	83.5	5.5	356	1	GLN3_ORYSA	P14656 oryza sativ
37	83.5	5.5	966	1	AMPN_HUMAN	P15144 homo sapien
38	83.5	5.5	1377	1	CID_DROME	P19538 drosophila
39	83.5	5.5	3224	1	RBP2_HUMAN	P49792 homo sapien
40	83	5.4	559	1	3BP2_MOUSE	Q06649 mus musculu
41	83	5.4	795	1	SYFB_BUCAI	P57230 buchnera ap
42	83	5.4	913	1	VGLB_PRVIF	P08355 pseudorabie
43	82.5	5.4	355	1	GLN4_MAIZE	P38562 zea mays (m
44	82.5	5.4	356	1	GLN3_MAIZE	P38561 zea mays (m
45	82.5	5.4	522	1	INA_DROME	P52235 drosophila

ALIGNMENTS

RESULT 1
ABCL_HUMAN
ID ABC1_HUMAN STANDARD: PRT; 2261 AA.
AC O95477; Q9UN08; Q9UN07; Q9UN06; Q9NQV4; Q9UN09; Q96785; Q96S56;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE ATP-binding cassette, sub-family A, member 1 (ATP-binding cassette transporter 1) (ABC-1) (Cholesterol efflux regulatory protein).
DE ABCA1 OR ABC1 OR CERP.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
SEQUENCE FROM N.A.
RX MEDLINE=20345099; PubMed=10884428;
RA Santamarina-Fojo S., Peterson K.M., Knapper C.L., Qiu Y., Freeman L.A., Cheng J.-P., Osorio J., Remaley A.T., Yang X.-P., Haudenschild C.C., Prades C., Chimini G., Blackmon E.E., Francols T.L., Duverger N., Rubin E.M., Rosier M., Deneffe P., Fredrickson D.S., Brewer H.B. Jr.;
RT "Complete genomic sequence of the human ABCA1 gene: analysis of the human and mouse ATP-binding cassette A promoter."; Proc. Natl. Acad. Sci. U.S.A. 97:7987-7992(2000).
RN [2]
SEQUENCE FROM N.A.
RC TISSUE=Skin;
RA Schwartz K., Lawn R.M., Wade D.P.;
RT "ABCA1 gene expression and apoA-I-mediated cholesterol efflux are regulated by LXR.";
RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.
RN [3]
SEQUENCE FROM N.A.
RX MEDLINE=11352567;
RA Qiu Y., Cavellier L., Chiu S., Yang X., Rubin E., Cheng J.-F.;
RT "Human and mouse ABCA1 comparative sequencing and transgenesis studies revealing novel regulatory sequences."; Genomics 73:66-76(2001).
RN [4]
SEQUENCE FROM N.A.
RA Tanaka A.R., Abe-Dohmae S., Arakawa R., Sadanami K., Kidera A., Kioka N., Amachi T., Yokoyama S., Ueda K.;
RT "A new topological model of functional human ABCA1-signal peptide cleavage and glycosylation of a large extracellular domain."; Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.
RN [5]
SEQUENCE OF 21-2261 FROM N.A.
RX MEDLINE=99194549; PubMed=10092505;
RA Langmann T., Klucken J., Reil M., Liebisch G., Luciani M.F., Chimini G., Kaminski W.E., Schmitz G.;
RT "Molecular cloning of the human ATP-binding cassette transporter 1 (ABCA1): evidence for sterol-dependent regulation in macrophages."; Biochem. Biophys. Res. Commun. 257:29-33(1999).
RN [6]

RP SEQUENCE OF 21-2261 FROM N.A.
RX MEDLINE=99364413; PubMed=10431238;
RA Rust S., Rosier M., Funke H., Real J., Amoura Z., Piette J.-C.,
RA Deleuze J.-F., Brewer H.B., Duverger N., Deneffe P., Assmann G.;
RT "Tangier disease is caused by mutations in the gene encoding
RT ATP-binding cassette transporter 1";
RL Nat. Genet. 22:352-355(1999).
RN [7]
RP VARIANTS FHA THR-1091 AND 1893-GLU-ASP-1894 DEL.
RX MEDLINE=20001430; PubMed=10533863;
RA Marcell M., Brooks-Wilson A., Clee S.M., Roomp K., Zhang L.-H., Yu L.,
RA Collins J.A., van Dam M., Molhuizen H.O.F., Loubser O.,
RA Ouellette B.F.F., Sengen C.W., Fichter K., Mott S., Denis M.,
RA Boucher B., Pinstone S., Genest J. Jr., Kastelein J.J.P., Hayden M.R.;
RT "Mutations in the ABC1 gene in familial HDL deficiency with defective
RT cholesterol efflux";
RL Lancet 354:1341-1346(1999).
RN [8]
RP VARIANTS TD ARG-597 AND ARG-1477, AND VARIANT FHA LEU-693 DEL.
RX MEDLINE=99364411; PubMed=10431236;
RA Brooks-Wilson A., Marcell M., Clee S.M., Zhang L.-H., Roomp K.,
RA van Dam M., Yu L., Brewer C., Collins J.A., Molhuizen H.O.F.,
RA Loubser O., Ouellette B.F.F., Fichter K., Ashbourne-Excoffon K.J.D.,
RA Sengen C.W., Scherer S., Mott S., Denis M., Martindale D.,
RA Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J.P.,
RA Hayden M.R.;
RT "Mutations in ABC1 in Tangier disease and familial high-density
RT lipoprotein deficiency";
RL Nat. Genet. 22:336-345(1999).
RN [9]
RP VARIANTS TD SER-590; SER-935 AND VAL-937, AND VARIANTS ALA-399 AND
RP MET-883.
RX MEDLINE=99364412; PubMed=10431237;
RA Bodzioch M., Orso E., Klucken J., Langmann T., Boettcher A.,
RA Diederich W., Drobnik W., Barlage S., Buechler C.,
RA Porsch-Oezuermez M., Kaminski W.E., Hahmann H.W., Oette K.,
RA Rothe G., Aslanidis C., Lackner K.J., Schmitz G.;
RT "The gene encoding ATP-binding cassette transporter 1 is mutated in
RT Tangier disease";
RL Nat. Genet. 22:347-351(1999).
RN [10]
RP VARIANTS TD ILE-929; ARG-597 AND ARG-1477, AND VARIANTS FHA LEU-693
RP DEL; THR-1091; 1893-GLU-ASP-1894 DEL AND LEU-2150.
RX MEDLINE=20540002; PubMed=11086027;
RA Clee S.M., Kastelein J.J.P., van Dam M., Marcell M., Roomp K.,
RA Zwarts K.J., Collins J.A., Roelants R., Tamasawa N., Stulic T.,
RA Suda T., Ceska R., Boucher B., Rondeau C., Desouich C.,
RA Brooks-Wilson A., Molhuizen H.O.F., Frohlich J., Genest J. Jr.,
RA Hayden M.R.;
RT "Age and residual cholesterol efflux affect HDL cholesterol levels and
RT coronary artery disease in ABCAL heterozygotes";
RL J. Clin. Invest. 106:1263-1270(2000).
RN [11]
RP VARIANTS TD ASN-1289 AND HIS-1800.
RX MEDLINE=20171564; PubMed=10706591;
RA Brousseau M.E., Schaefer E.J., Dupuis J., Eustace B.,
RA Van Beredwegh P., Goldkamp A.L., Thurston L.M., FitzGerald M.G.,
RA Yasek-McKenna D., O'Neill G., Eberhart G.P., Weiffenbach B.,
RA Ordoas J.M., Freeman M.W., Brown R.H. Jr., Gu J.Z.;
RT "Novel mutations in the gene encoding ATP-binding cassette 1 in four
RT tangier disease kindreds";
RL J. Lipid Res. 41:433-441(2000).
RN [12]
RP VARIANT TD ASP-1046, VARIANT FHA CYS-230, AND VARIANTS LYS-219;
RX ILE-825; MET-883 AND LYS-1587.
RX MEDLINE=20396633; PubMed=10938021;
RA Wang J., Burnett J.R., Near S., Young K., Zinman B., Hanley A.J.G.,
RA Connelly P.W., Harris S.B., Hegde R.A.;
RT "Common and rare ABCAL variants affecting plasma HDL cholesterol";
RL Arterioscler. Thromb. Vasc. Biol. 20:1983-1989(2000).
RN [13]
RP VARIANT TD TRP-587, AND VARIANT LEU-2168.
RX MEDLINE=21157002; PubMed=11257260;

Bertolini S., Pisciotto L., Seri M., Cusano R., Cantafora A.,
RA Calabresi L., Franceschini G., Ravazzolo R., Calandra S.;
RT "A point mutation in ABC1 gene in a patient with severe premature
RT coronary heart disease and mild clinical phenotype of Tangier
RT disease";
RL Atherosclerosis 154:599-605(2001).
RN [14]
RP VARIANTS LYS-219; MET-883 AND ASP-1172.
RX MEDLINE=21157003; PubMed=11257261;
RA Brousseau M.E., Bodzioch M., Schaefer E.J., Goldkamp A.L., Kielar D.,
RA Probst M., Ordoas J.M., Aslanidis C., Lackner K.J.,
RA Bloomfield Rubins H., Collins D., Robins S.J., Wilson P.W.F.,
RA Schmitz G.;
RT "Common variants in the gene encoding ATP-binding cassette transporter
RT 1 in men with low HDL cholesterol levels and coronary heart disease";
RL Atherosclerosis 154:607-611(2001).
RN [15]
RP VARIANT TD LEU-1506.
RX MEDLINE=21369429; PubMed=11476961;
RA Lapicka-Bodzioch K., Bodzioch M., Kruehl M., Kielar D., Probst M.,
RA Klec B., Andrikovics H., Boettcher A., Hubacek J., Aslanidis C.,
RA Suttorp N., Schmitz G.;
RT "Homogeneous assay based on 52 primer sets to scan for mutations of
RT the ABCAL gene and its application in genetic analysis of a new
RT patient with familial high-density lipoprotein deficiency syndrome";
RL Biochim. Biophys. Acta 1537:42-48(2001).
RN [16]
RP VARIANTS TD ASN-1289 AND TRP-2081, AND VARIANT LYS-219.
RX MEDLINE=21369433; PubMed=11476965;
RA Huang W., Moriyama K., Koga T., Hua H., Ageta M., Kawabata S.,
RA Kawatari K., Imamura T., Eto T., Kawamura M., Teramoto T., Sasaki J.;
RT "Novel mutations in ABCAL gene in Japanese patients with Tangier
RT disease and familial high density lipoprotein deficiency with
RT coronary heart disease";
RL Biochim. Biophys. Acta 1537:71-78(2001).
RN [17]
RP VARIANTS LYS-219; ALA-399; MET-771; PRO-774; ASN-776; ILE-825;
RX MET-883; ASP-1172; LYS-1587 AND CYS-1731.
RX MEDLINE=21138379; PubMed=11238261;
RA Clee S.M., Zwienderman A.H., Genest J.C., Zwarts K.Y.,
RA Molhuizen H.O.F., Roomp K., Jukema J.W., van Wijkland M., van Dam M.,
RA Hudson T.J., Brooks-Wilson A., Genest J. Jr., Kastelein J.J.P.,
RA Hayden M.R.;
RT "Common genetic variation in ABCAL is associated with altered
RT lipoprotein levels and a modified risk for coronary artery disease";
RL Circulation 103:1198-1205(2001).
RN [18]
RP VARIANT TD THR-255, AND VARIANT ATHEROSCLEROSIS ASP-1611.
RX MEDLINE=21645894; PubMed=11785958;
RA Nishida Y., Hirano K., Tsukamoto K., Nagano M., Ikegami C., Roomp K.,
RA Ishihara M., Sakane N., Zhang Z., Tsujii K., Matsuyama A., Ohama T.,
RA Matsura F., Ishigami M., Sakai N., Hiraoka H., Hattori H.,
RA Weilington C., Yoshida Y., Misugi S., Hayden M.R., Egashira T.,
RA Yamashita S., Matsuzawa Y.;
RT "Expression and functional analyses of novel mutations of ATP-binding
RT cassette transporter-1 in Japanese patients with high-density
RT lipoprotein deficiency";
RL Biochem. Biophys. Res. Commun. 290:713-721(2002).
CC -1- FUNCTION: CAMP-DEPENDENT AND SULFONYLUREA-SENSITIVE ANION
CC TRANSPORTER. KEY GATEKEEPER INFLUENCING INTRACELLULAR CHOLESTEROL
CC TRANSPORT.
CC -1- TISSUE SPECIFICITY: WIDELY EXPRESSED, BUT MOST ABUNDANT IN
CC MACROPHAGES.
CC -1- DOMAIN: MULTIFUNCTIONAL POLYPEPTIDE WITH TWO HOMOLOGOUS HALVES,
CC EACH CONTAINING AN HYDROPHOBIC MEMBRANE-ANCHORING DOMAIN AND AN
CC ATP BINDING CASSETTE (ABC) DOMAIN.
CC -1- DISEASE: DEFECTS IN ABCAL ARE A CAUSE OF HIGH DENSITY LIPOPROTEIN
CC DEFICIENCY TYPE I (HDLI), ALSO KNOWN AS TANGIER DISEASE (TD). TD
CC IS A RECESSIVE DISORDER CHARACTERIZED BY ABSENCE OF HIGH DENSITY
CC LIPOPROTEIN (HDL) CHOLESTEROL FROM PLASMA, HEPATOSPLENOMEGALY,
CC PERIPHERAL NEUROPATHY, AND FREQUENTLY PREMATURE CORONARY ARTERY
CC DISEASE (CAD).
CC -1- DISEASE: Defects in ABCAL are a cause of high density lipoprotein

Query Match 99.2%; Score 1513; DB 1; Length 2261;
Best Local Similarity 99.3%; Pred. No. 7.5e-120;
Matches 282; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 FGKPSLELPQWYNEQYTFVSNDAEDTGTLELLNALT KDPGFGTRCMEGNPIDPTPCQ 60
Db 1371 FGKPSLELPQWYNEQYTFVSNDAEDTGTLELLNALT KDPGFGTRCMEGNPIDPTPCQ 1430
QY 61 AGEEWTTAPVPTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
Db 1431 AGEEWTTAPVPTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 1490
QY 121 QNTADILQDLTGRNISDYLVKTVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
Db 1491 QNTADILQDLTGRNISDYLVKTVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 1550
QY 181 VNDAIKQMKKHLKADSSADRFNLNSLGRFMTGLDTRNNKVKWNNKGWHAISSEFLNVIN 240
Db 1551 VNDATKQMKKHLKADSSADRFNLNSLGRFMTGLDTRNNKVKWNNKGWHAISSEFLNVIN 1610
QY 241 NALIRANLQGENPSHYGITAFNHPNLTKQOLSEVALMTTSVD 284
Db 1611 NALIRANLQGENPSHYGITAFNHPNLTKQOLSEVALMTTSVD 1654

RESULT 2
ID ABC1_MOUSE STANDARD; PRT; 2261 AA.
AC P41233;
DT 01-FEB-1995 (Rel. 31, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE ATP-binding cassette, sub-family A, member 1 (ATP-binding cassette transporter 1) (ATP-binding cassette 1) (ABC-1).
GN ABCA1 OR ABC1
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=DBA/2; TISSUE=Macrophage;
RX MEDLINE=94375008; PubMed=8088782;
RA Luciani M.F., Denizot F., Savary S., Mattei M.-G., Chimini G.;
RT "Cloning of two novel ABC transporters mapping on human chromosome 9";
RL Genomics 21:150-159(1994).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J;
RA Qiu Y., Cavelier L., Chiu S., Rubin E., Cheng J.-F.;
RT "Human and mouse ABCA1 comparative sequencing and transgenesis studies identify potential regulatory sequences";
RL Submitted (JUL-2000) to the EMBL/Genbank/DBJ databases.

CC -!- FUNCTION: CAMP-DEPENDENT AND SULFONYLUREA-SENSITIVE ANION TRANSPORT. KEY GATEKEEPER INFLUENCING INTRACELLULAR CHOLESTEROL TRANSPORT (BY SIMILARITY).
CC -!- TISSUE SPECIFICITY: WIDELY EXPRESSED IN ADULT TISSUES. HIGHEST LEVELS ARE FOUND IN PREGNANT UTERUS AND UTERUS.
CC -!- DOMAIN: MULTIFUNCTIONAL POLYPEPTIDE WITH TWO HOMOLOGOUS HALVES, EACH CONTAINING AN HYDROPHOBIC MEMBRANE-ANCHORING DOMAIN AND AN ATP BINDING CASSETTE (ABC) DOMAIN.
CC -!- SIMILARITY: BELONGS TO THE ABC TRANSPORTER FAMILY. ABCA SUBFAMILY.

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

DR EMBL; X75926; CAA53530.1; ALT_INIT.
DR EMBL; AF287263; AAG39073.1; ALT_INIT.
DR MGD; MGI:99607; Abcal.
DR InterPro; IPR003593; AAA_ATPase.
DR InterPro; IPR003439; ABC_transportr.
DR Pfam; PF00005; ABC_tran; 2.
DR ProDom; PD000006; ABC_transportr; 2.
DR SMART; SM00382; AAA; 1.
DR PROSITE; PS00211; ABC_TRANSPORTER; 1.
KW ATP-binding; Glycoprotein; Transmembrane; Transport.
FT TRANSMEM 26
FT TRANSMEM 42
FT TRANSMEM 640
FT TRANSMEM 656
FT TRANSMEM 690
FT TRANSMEM 706
FT TRANSMEM 717
FT TRANSMEM 733
FT TRANSMEM 749
FT TRANSMEM 765
FT TRANSMEM 771
FT TRANSMEM 787
FT TRANSMEM 1041
FT TRANSMEM 1057
FT TRANSMEM 1351
FT TRANSMEM 1367
FT TRANSMEM 1661
FT TRANSMEM 1677
FT TRANSMEM 1708
FT TRANSMEM 1724
FT TRANSMEM 1737
FT TRANSMEM 1753
FT TRANSMEM 1775
FT TRANSMEM 1791
FT TRANSMEM 1854
FT TRANSMEM 1870
FT NP_BIND 933
FT NP_BIND 940
FT CARBOHYD 1946
FT CARBOHYD 1953
FT CARBOHYD 14
FT CARBOHYD 14
FT CARBOHYD 98
FT CARBOHYD 151
FT CARBOHYD 151
FT CARBOHYD 161
FT CARBOHYD 161
FT CARBOHYD 196
FT CARBOHYD 196
FT CARBOHYD 244
FT CARBOHYD 244
FT CARBOHYD 292
FT CARBOHYD 292
FT CARBOHYD 337
FT CARBOHYD 337
FT CARBOHYD 349
FT CARBOHYD 400
FT CARBOHYD 400
FT CARBOHYD 478
FT CARBOHYD 478
FT CARBOHYD 489
FT CARBOHYD 521
FT CARBOHYD 521
FT CARBOHYD 820
FT CARBOHYD 820
FT CARBOHYD 1144
FT CARBOHYD 1144
FT CARBOHYD 1294
FT CARBOHYD 1294
FT CARBOHYD 1453
FT CARBOHYD 1453
FT CARBOHYD 1499
FT CARBOHYD 1499
FT CARBOHYD 1504
FT CARBOHYD 1504
FT CARBOHYD 1637
FT CARBOHYD 1637
FT CARBOHYD 2044
FT CARBOHYD 2044
FT CARBOHYD 2238
FT CARBOHYD 2238
FT CONFLICT 1567
FT CONFLICT 1568
FT CONFLICT 2024
FT CONFLICT 2024
SQ SEQUENCE 2261 AA; 254011 MW; FAE62B21FD1D09F9 CRC64;

Query Match 93.3%; Score 1423; DB 1; Length 2261;
Best Local Similarity 93.0%; Pred. No. 3.2e-112;
Matches 264; Conservative 10; Mismatches 10; Indels 0; Gaps 0;

QY 1 FGKPSLELPQWYNEQYTFVSNDAEDTGTLELLNALT KDPGFGTRCMEGNPIDPTPCQ 60
Db 1371 FGKPSLELPQWYNEQYTFVSNDAEDTGTLELLNALT KDPGFGTRCMEGNPIDPTPCQ 1430
QY 61 AGEEWTTAPVPTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
Db 1431 AGEEDWTSPVQSIDVLFQNGNWTMKNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 1490
QY 121 QNTADILQDLTGRNISDYLVKTVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
Db 1491 QNTADILQDLTGRNISDYLVKTVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 1550
QY 181 VNDAIKQMKKHLKADSSADRFNLNSLGRFMTGLDTRNNKVKWNNKGWHAISSEFLNVIN 240
Db 1551 VNDAIKQMKKHLKADSSADRFNLNSLGRFMTGLDTRNNKVKWNNKGWHAISSEFLNVIN 1610
QY 241 NALIRANLQGENPSHYGITAFNHPNLTKQOLSEVALMTTSVD 284
Db 1611 NALIRANLQGENPSHYGITAFNHPNLTKQOLSEVALMTTSVD 1654

Db 1611 NAILRANLQGENPSQVIGITAFNHLNLTQQLSEVALMTTSD 1654

RESULT 3

ABCR_HUMAN

ID ABCR_HUMAN STANDARD; PRT: 2273 AA.

AC P78363; O60438; O60915; O15112;

DT 30-MAY-2000 (Rel. 39, Last sequence update)

DT 30-MAY-2000 (Rel. 39, Last annotation update)

DE 15-JUN-2002 (Rel. 41, Last sequence update)

DE Retinal-specific ATP-binding cassette transporter (RIM ABC

DE transporter) (RIM protein) (RMP) (Stargardt disease protein).

GN ABCA4 OR ABCR.

OS Homo sapiens (human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI_TaxID=9606;

RNA

[1]

SEQUENCE FROM N.A., VARIANTS STGD, AND VARIANTS HIS-846 AND GLN-943.

RX MEDLINE=97207641; PubMed=9054934;

RA Allikmets R., Singh N., Sun H., Shroyer N.F., Hutchinson A.,

RA Chidambaram A., Gerrard B., Baird L., Stauffer D., Peiffer A.,

RA Rattner A., Smallwood P.M., Li Y., Anderson K.L., Lewis R.A.,

RA Nathans J., Leppert M., Dean M., Lupski J.R.;

RA "A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is

RT mutated in recessive Stargardt macular dystrophy.";

RL Nat. Genet. 15:236-246(1997).

RNA

[2]

SEQUENCE FROM N.A.

RX MEDLINE=97345663; PubMed=9202155;

RA Azarian S.M., Travis G.H.;

RA "The photoreceptor rim protein is an ABC transporter encoded by the

RT gene for recessive Stargardt's disease (ABCR).";

RL FEBS Lett. 409:247-252(1997).

RNA

[3]

SEQUENCE FROM N.A., AND VARIANTS STGD TRP-18 AND CYS-212.

RX MEDLINE=98163759; PubMed=9503029;

RA Gerber S., Rozet J.-M., van de Pol T.J.R., Hoyng C.B., Munnich A.,

RA Blankenagel A., Kaplan J., Cremers F.P.M.;

RA "Complete exon-intron structure of the retina-specific ATP binding

RT transporter gene (ABCR) allows the identification of novel mutations

RL underlying Stargardt disease.";

RL Genomics 48:139-142(1998).

RNA

[4]

SEQUENCE FROM N.A., AND VARIANTS STGD.

RX MEDLINE=98141123; PubMed=9490294;

RA Nasonkin I., Illing M., Koehler M.R., Schmid M., Molday R.S.,

RA Weber B.H.F.;

RA "Mapping of the rod photoreceptor ABC transporter (ABCR) to 1p21-p22.1

RT and identification of novel mutations in Stargardt's disease.";

RL Hum. Genet. 102:21-26(1998).

RNA

[5]

CHARACTERIZATION.

RX MEDLINE=99175213; PubMed=10075733;

RA Sun H., Molday R.S., Nathans J.;

RT "Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR,

RT the photoreceptor-specific ATP-binding cassette transporter

RT responsible for Stargardt disease.";

RL J. Biol. Chem. 274:8269-8281(1999).

RNA

[6]

DISEASE.

RX MEDLINE=98133912; PubMed=9466990;

RA Cremers F.P.M., van de Pol D.J.R., van Driel M.A., den Hollander A.I.,

RA van Haren F.J.J., Koeners N.V.A.M., Tijmes N., Bergen A.A.B.,

RA Rohrschneider K., Blankenagel A., Pinckers A.J.L.G., Deutman A.F.,

RA Hoyng C.B.;

RA "Autosomal recessive retinitis pigmentosa and cone-rod dystrophy

RT caused by splice site mutations in the Stargardt's disease gene

RT ABCR.";

RL Hum. Mol. Genet. 7:355-362(1998).

RNA

[7]

VARIANTS ARM2, AND VARIANTS.

RX MEDLINE=97442530; PubMed=9295268;

RA

RA Allikmets R., Shroyer N.F., Seddon J.M., Lewis R.A.,

RA Bernstein P.S., Peiffer A., Zabarskie N.A., Li Y., Hutchinson A.,

RA Dean M., Lupski J.R., Leppert M.;

RT "Mutation of the Stargardt disease gene (ABCR) in age-related macular

RT degeneration.";

RL Science 277:1805-1807(1997).

RNA

[8]

VARIANTS STGD W-18; C-212; H-636; M-1019; V-1038; C-1108; W-1640;

RP S-1977 AND H-2107, AND VARIANTS FFM P-11; P-541; V-1038; E-1091;

RP C-1508; F-1970 AND R-1971.

RX MEDLINE=98454319; PubMed=9781034;

RA Rozet J.-M., Gerber S., Souled E., Perrault I., Chatelin S., Ghazi I.,

RA Leowski C., Dufier J.-L., Munnich A., Kaplan J.;

RA "Spectrum of ABCR gene mutations in autosomal recessive macular

RT dystrophies.";

RT Eur. J. Hum. Genet. 6:291-295(1998).

RNA

[9]

VARIANTS STGD.

RP MEDLINE=99138655; PubMed=9973280;

RA Lewis R.A., Shroyer N.F., Singh N., Allikmets R., Hutchinson A.,

RA Li Y., Lupski J.R., Leppert M., Dean M.;

RT "Genotype/phenotype analysis of a photoreceptor-specific ATP-binding

RT cassette transporter gene, ABCR, in Stargardt disease.";

RL Am. J. Hum. Genet. 64:422-434(1999).

RNA

[10]

VARIANTS STGD, AND VARIANTS.

RX MEDLINE=9912348; PubMed=10090887;

RA Maugeri A., van Driel M.A., van de Pol D.J.R., Klevering B.J.,

RA van Haren F.J.J., Tijmes N., Bergen A.A.B., Rohrschneider K.,

RA Blankenagel A., Pinckers A.J.L.G., Dahl N., Brunner H.G.,

RA Deutman A.F., Hoyng C.B., Cremers F.P.M.;

RA "The 2598G-->C mutation in the ABCR gene is a mild frequent founder

RT mutation in the western European population and allows the

RT classification of ABCR Mutations in patients with Stargardt disease.";

RL Am. J. Hum. Genet. 64:1024-1035(1999).

RNA

[11]

VARIANT STGD TYR-54, AND VARIANT ALA-863.

RX MEDLINE=20077755; PubMed=10612508;

RA Zhang K., Caribaldi D.C., Kniazeva M., Albini T., Chiang M.F.,

RA Kerrigan M., Sunness J.S., Han M., Allikmets R.;

RA "A novel mutation in the ABCR gene in four patients with autosomal

RT recessive Stargardt disease.";

RL Am. J. Ophthalmol. 128:720-724(1999).

RNA

[12]

VARIANTS STGD V-60; R-206; N-300; P-541; A-849; P-974; V-1038; C-1108;

RP L-1408; R-1488; D-1652; P-1729; E-1961; W-2038; W-2077; H-2107; R-2128

RP AND Y-2150.

RX MEDLINE=99221420; PubMed=10206579;

RA Fishman G.A., Stone E.M., Grover S., Derlacki D.J., Haines H.L.,

RA Hockey R.R.;

RT "Variation of clinical expression in patients with Stargardt dystrophy

RT and sequence variations in the ABCR gene.";

RL Arch. Ophthalmol. 117:504-510(1999).

RNA

[13]

VARIANTS GLU-1961 AND ASN-2177.

RX MEDLINE=20349288; PubMed=10880298;

RA Allikmets R., Tammur J., Hutchinson A., Lewis R.A., Shroyer N.F.,

RA Dalakishvili K., Lupski J.R., Steiner K., Pauleikhoff D., Holz F.G.,

RA Weber B.H.F., Dean M., Atkinson A., Gail M.H., Bernstein P.S.,

RA Singh N., Peiffer A., Zabarskie N.A., Leppert M., Seddon J.M.,

RA Zhang K., Sunness J.S., Udar N.S., Velchits S., Silva-Garcia R.,

RA Small K.W., Simonelli F., Testa F., D'Urso M., Brancato R.,

RA Rinaldi E., Ingavast S., Taube A., Wadelius C., Souled E., Ducroq D.,

RA Kaplan J., Assink J.J.M., ten Brink J.B., de Jong P.T.V.M.,

RA Bergen A.A.B., Maugeri A., van Driel M.A., Hoyng C.B., Cremers F.P.M.,

RA Paloma E., Coco R., Balcells S., Gonzalez-Duarte R., Kermani S.,

RA Stanga P., Bhattacharya S., Bird A.C.;

RT "Further evidence for an association of ABCR alleles with age-related

RT macular degeneration.";

RL Am. J. Hum. Genet. 67:487-491(2000).

RNA

[14]

VARIANTS STGD E-60; T-60; E-65; L-68; R-72; C-212; S-230; S-247;

RP V-328; K-471; P-541; Q-572; R-607; K-635; C-653; Y-764; R-765; A-901;

RP

RP I-959; K-1036; V-1038; P-1063; D-1087; C-1097; C-1108; L-1380; K-1399;
 RP P-1430; V-1440; L-1443; L-1486; Y-1488; M-1537; P-1689; L-1705;
 RP T-1733; R-1748; P-1763; K-1885; H-1898; R-1961; R-1975; S-1977; G-2077
 RP W-2077 AND V-2241, AND VARIANTS Q-152; H-212; R-423; I-552; R-914;
 RP Q-943; T-1562; I-1868; V-1921; L-1948; F-1970; A-2059; N-2177 AND
 RP V-2216.
 RX MEDLINE-20442027; PubMed=10958763;
 RA Rivera A., White K., Stoehr H., Steiner K., Hemmrich N., Grimm T.,
 RA Jurklics B., Lorenz B., Scholl H.P.N., Apfelstedt-Sylla E.,
 RA Weber B.H.F.;
 RT "A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene
 RT in Stargardt disease and age-related macular degeneration.";
 RL Am. J. Hum. Genet. 67:800-813(2000).
 RN [15]
 RP VARIANTS CORD3 GLU-65; CYS-212; PRO-541; ALA-863; GLY-863 DEL;
 RP VAL-1038; LYS-1122; TYR-1490 AND ASP-1598.
 RX MEDLINE-20442040; PubMed=10958761;
 RA Maugeri A., Klevering B.J., Rohrschneider K., Blankenagel A.,
 RA Brunner H.G., Deutman A.F., Hoyng C.B., Cremers F.P.M.;
 RT "Mutations in the ABCA4 (ABCR) gene are the major cause of autosomal
 RT recessive cone-rod dystrophy.";
 RL Am. J. Hum. Genet. 67:960-966(2000).
 RN [16]
 RP VARIANTS STGD ASP-340; GLN-572; ALA-863; SER-965; VAL-1038; ALA-1780
 RP AND HIS-1898, AND VARIANT GLN-943;
 RX MEDLINE-20208356; PubMed=10746567;
 RA Shroyer N.F., Lewis R.A., Lupski J.R.;
 RT "Complex inheritance of ABCR mutations in Stargardt disease: linkage
 RT disequilibrium, complex alleles, and pseudodominance.";
 RL Hum. Genet. 106:244-248(2000).
 RN [17]
 RP VARIANTS STGD.
 RX MEDLINE-20098082; PubMed=10634594;
 RA Papaioannou M., Oaka L., Bessant D., Lois N., Bird A.C., Payne A.,
 RA Bhattacharya S.S.;
 RT "An analysis of ABCR mutations in British patients with recessive
 RT retinal dystrophies.";
 RL Invest. Ophthalmol. Vis. Sci. 41:16-19(2000).
 RN [18]
 RP VARIANTS STGD C-212; D-767; I-897; V-1038; K-1087; K-1399; Q-1640 AND
 RP E-1961, AND VARIANT HIS-212.
 RX MEDLINE-20174852; PubMed=10711710;
 RA Simonelli F., Testa F., de Crecchio G., Rinaldi E., Hutchinson A.,
 RA Atkinson A., Dean M., D'Urso M., Allikmets R.;
 RT "New ABCR mutations and clinical phenotype in Italian patients with
 RT Stargardt disease.";
 RL Invest. Ophthalmol. Vis. Sci. 41:892-897(2000).
 RN [19]
 RP CHARACTERIZATION OF VARIANTS, AND MUTAGENESIS OF GLY-966; LYS-969;
 RP GLY-1975 AND LYS-1978.
 RX MEDLINE-20472331; PubMed=11017087;
 RA Sun H., Smallwood P.M., Nathans J.;
 RT "Biochemical defects in ABCR protein variants associated with human
 RT retinopathies.";
 RL Nat. Genet. 26:242-246(2000).
 RN [20]
 RP VARIANT STGD ASN-972, AND VARIANTS GLN-943; ILE-1868 AND LEU-1948.
 RX MEDLINE-21478761; PubMed=11594993;
 RA Eksandh L., Ekstroem U., Abrahamson M., Bauer B., Andreasson S.;
 RT "The ABCR gene is a candidate for the gene responsible for the
 RT retinopathy associated with human
 RL Nat. Genet. 26:242-246(2000).
 RN [21]
 RP Query Match 48.1%; Score 733.5; DB 1; Length 2273;
 RP Best Local Similarity 48.2%; Pred. No. 9.1e-54;
 RP Matches 146; Conservative 35; Mismatches 83; Indels 39; Gaps 4;
 QY 1 FGKPSLELOPMWYNYQYTFVNDAPEDGTGTELLNALTDPGFGTRCMGNPIPTPCQ 60
 DB 1397 FGEYPAITLHPWYQYQYTFVNDAPEDGTGTELLNALTDPGFGTRCMGNPIPTPCQ 60
 QY 61 AGEBEWTTAPVQTIIMDLFONGWNTMONPSPACQSSDKIKKMLPVCPGAGGLPPQPK 120
 DB 1456 GNSTPHKTVSPVSNITQLFQKQKTVQNPSPSCRCSTREKTLMLPECPGAGGLPPQPK 1515
 QY 121 QNTADILQDITGRNISDYLVKTYVQIIAKSLKNKIWNFNYGGFSLGSVNTQALPPSQE 180

DB 1516 QRSEIILQDITGRNISDYLVKTYVQIIAKSLKNKIWNFNYGGFSLGSVNTQALPPSQE 1571
 QY 181 VNDRAIKQKHLKHLAKDSSADRFNLISGR-----FMTGLDTRNNVK 221
 DB 1572 TGEALV-----GFLSLGRIMNVSGGPTITREASKEIPDFLKHLETONIK 1616
 QY 222 VWFNNKGWHAISSFLNINAILRANLQGENPSHYGITAFAFNHPLNLTQKQSLSEVALMTT 281
 DB 1617 VWFNNKGWHAISFLNINAILRANLQGENPSHYGITAFAFNHPLNLTQKQSLSEVALMTT 1676
 QY 282 SVD 284
 DB 1677 SVD 1679
 RESULT 4
 ABC2_HUMAN
 ID ABC2_HUMAN STANDARD; PRT; 2436 AA.
 AC Q9BZC7;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)
 DE ATP-binding cassette, sub-family A, member 2 (ATP-binding cassette
 DE transporter 2) (ATP-binding cassette 2).
 GN ABCA2 OR ABC2.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX PubMed=11178988;
 RA Kaminski W.E., Piehler A., Pullmann K., Porsch-Ozcurumez M., Duong C.,
 RA Bared G.M., Buchler C., Schmitz G.;
 RT "Complete coding sequence, promoter region, and genomic structure of
 RT the human ABCA2 gene and evidence for sterol-dependent regulation in
 RT macrophages.";
 RL Biochem. Biophys. Res. Commun. 281:249-258(2001).
 CC -1- FUNCTION: PROBABLE TRANSPORTER, ITS NATURAL SUBSTRATE HAS NOT BEEN
 CC FOUND YET. MAY HAVE A ROLE IN MACROPHAGE LIPID METABOLISM AND
 CC NEURAL DEVELOPMENT.
 CC -1- SUBCELLULAR LOCATION: Integral membrane protein (potential).
 CC -1- SIMILARITY: BELONGS TO THE ABC TRANSPORTER FAMILY. ABCA SUBFAMILY.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; AF327705; AAK14335.1; JOINED.
 DR EMBL; AF327658; AAK14335.1; JOINED.
 DR EMBL; AF327659; AAK14335.1; JOINED.
 DR EMBL; AF327660; AAK14335.1; JOINED.
 DR EMBL; AF327661; AAK14335.1; JOINED.
 DR EMBL; AF327662; AAK14335.1; JOINED.
 DR EMBL; AF327663; AAK14335.1; JOINED.
 DR EMBL; AF327664; AAK14335.1; JOINED.
 DR EMBL; AF327665; AAK14335.1; JOINED.
 DR EMBL; AF327666; AAK14335.1; JOINED.
 DR EMBL; AF327667; AAK14335.1; JOINED.
 DR EMBL; AF327668; AAK14335.1; JOINED.
 DR EMBL; AF327669; AAK14335.1; JOINED.
 DR EMBL; AF327670; AAK14335.1; JOINED.
 DR EMBL; AF327671; AAK14335.1; JOINED.
 DR EMBL; AF327672; AAK14335.1; JOINED.
 DR EMBL; AF327673; AAK14335.1; JOINED.
 DR EMBL; AF327674; AAK14335.1; JOINED.
 DR EMBL; AF327675; AAK14335.1; JOINED.
 DR EMBL; AF327676; AAK14335.1; JOINED.

```
DR EMBL: AF327677: AAK14335.1; JOINED.
DR EMBL: AF327678: AAK14335.1; JOINED.
DR EMBL: AF327679: AAK14335.1; JOINED.
DR EMBL: AF327680: AAK14335.1; JOINED.
DR EMBL: AF327681: AAK14335.1; JOINED.
DR EMBL: AF327682: AAK14335.1; JOINED.
DR EMBL: AF327683: AAK14335.1; JOINED.
DR EMBL: AF327684: AAK14335.1; JOINED.
DR EMBL: AF327685: AAK14335.1; JOINED.
DR EMBL: AF327686: AAK14335.1; JOINED.
DR EMBL: AF327687: AAK14335.1; JOINED.
DR EMBL: AF327688: AAK14335.1; JOINED.
DR EMBL: AF327689: AAK14335.1; JOINED.
DR EMBL: AF327690: AAK14335.1; JOINED.
DR EMBL: AF327691: AAK14335.1; JOINED.
DR EMBL: AF327692: AAK14335.1; JOINED.
DR EMBL: AF327693: AAK14335.1; JOINED.
DR EMBL: AF327694: AAK14335.1; JOINED.
DR EMBL: AF327695: AAK14335.1; JOINED.
DR EMBL: AF327696: AAK14335.1; JOINED.
DR EMBL: AF327697: AAK14335.1; JOINED.
DR EMBL: AF327698: AAK14335.1; JOINED.
DR EMBL: AF327699: AAK14335.1; JOINED.
DR EMBL: AF327700: AAK14335.1; JOINED.
DR EMBL: AF327701: AAK14335.1; JOINED.
DR EMBL: AF327702: AAK14335.1; JOINED.
DR EMBL: AF327703: AAK14335.1; JOINED.
DR EMBL: AF327704: AAK14335.1; JOINED.
DR Genew: HGNC:32; ABCA2.
DR MTM: 600047.
DR InterPro: IPR003593; AAA_ATPase.
DR InterPro: IPR003439; ABC_transporter.
DR Pfam: PF00005; ABC_tran; 2.
DR ProDom: PD000006; ABC_transportr; 2.
DR SMART: SM00382; AAA; 2.
DR PROSITE: PS00211; ABC_TRANSPORTER; 1.
DR ATP-binding; Transport; Transmembrane; Repeat; Glycoprotein.
FT TRANSMEM 21 40 POTENTIAL.
FT TRANSMEM 706 728 POTENTIAL.
FT TRANSMEM 749 771 POTENTIAL.
FT TRANSMEM 786 808 POTENTIAL.
FT TRANSMEM 813 835 POTENTIAL.
FT TRANSMEM 850 872 POTENTIAL.
FT TRANSMEM 892 914 POTENTIAL.
FT TRANSMEM 1793 1815 POTENTIAL.
FT TRANSMEM 1846 1865 POTENTIAL.
FT TRANSMEM 1875 1897 POTENTIAL.
FT TRANSMEM 1904 1926 POTENTIAL.
FT TRANSMEM 1988 2010 POTENTIAL.
FT NP_BIND 1025 1032 ATP (POTENTIAL).
FT NP_BIND 2088 2095 ATP (POTENTIAL).
FT CARBOHYD 14 14 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 90 90 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 169 169 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 174 174 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 306 306 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 369 369 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 380 380 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 421 421 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 433 433 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 477 477 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 485 485 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 495 495 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 531 531 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 545 545 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 591 591 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 601 601 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 629 629 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 1409 1409 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 1497 1497 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 1550 1550 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 1558 1558 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 1613 1613 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT CARBOHYD 1678 1678 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 1776 1776 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 2055 2055 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ SEQUENCE 2436 AA; 269971 MW; 9E6688D8615DE06D CRC64;

Query Match 17.5%; Score 267; DB 1; Length 2436;
Best Local Similarity 29.2%; Pred No. 3.5e-14;
Matches 80; Conservative 35; Mismatches 73; Indels 86; Gaps 12;

QY 44 FGTRCMEG-----NPIP-DTPCQ-----AGEEWTPAP-V 71
| : | : |
Db 1572 FDSMCLESETQGLPLSNFVPPSPAPSDPSAPDQLQAWNVSLPPTAGPEMWTSAPSL 1631
| : | : |
QY 72 POTIMDLFONGNWTQNPSPACQSSDKIKMLPVCAGAGLPPPOKONTADILQDLT 131
| : | : |
Db 1632 PRUVREPVR-----CTCSAQGTGFS--CPSVVG-HPQMRVVTGDLIDIT 1675
| : | : |
QY 132 GRNISDYLVKTVYQIIAKSLKNKIWNFEYRGFGSLGSVNTQALPPSQEVNDIAKOMKKH 191
| : | : |
Db 1676 GHNVSLEYLLFTSDRF-----RLHRYGAITFG--NVLKSIPTASFGTRAPPMVRK- 1721
| : | : |
QY 192 LKLAQSSADRELNSLGRFMTGLDTRNNVKNKNGHAISSPLNVINNAIRLANLQKG 251
| : | : |
Db 1722 -----IAVRAAQVFNKNGHSHMPTYLNSLNAILRANLPKS 1759
| : | : |
QY 252 E-NPSHYGITAFNHPNLTKQOLS-EVALMTTSV 283
| : | : |
Db 1760 KGNPAAYGITVTNHPNMKTSASLSLDYLIQGTDV 1793

RESULT 5
ABCA2_MOUSE STANDARD; PRT; 2434 AA.
ID ABC2_MOUSE
AC P41234;
DT 01-FEB-1995 (Rel. 31, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE ATP-binding cassette, sub-family A, member 2 (ATP-binding cassette
DE transporter 2) (ATP-binding cassette 2).
GN ABCA2 OR ABC2.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A., AND REVISIONS.
RC STRAIN=DBA/2;
RA Chimini G.;
RL Submitted (DEC-2000) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE OF 964-2434 FROM N.A.
RC STRAIN=DBA/2; TISSUE=Macrophage;
MEDLINE=94375008; PubMed=8088782;
Luciani M.F., Denizot F., Savary S., Mattei M.-G., Chimini G.;
"Cloning of two novel ABC transporters mapping on human chromosome
9.;"
RT Genomics 21:150-159(1994).
CC -! FUNCTION: PROBABLE TRANSPORTER, ITS NATURAL SUBSTRATE HAS NOT BEEN
CC FOUND YET. MAY HAVE A ROLE IN MACROPHAGE LIPID METABOLISM AND
CC NEURAL DEVELOPMENT.
CC -! SUBCELLULAR LOCATION: Integral membrane protein (Potential).
CC -! TISSUE SPECIFICITY: WIDELY EXPRESSED IN ADULT TISSUES. HIGHEST
CC LEVELS ARE FOUND IN BRAIN AND PREGNANT UTERUS.
CC -! SIMILARITY: BELONGS TO THE ABC TRANSPORTER FAMILY. ABCA SUBFAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
```

```
DR EMBL; X75927; CAA53531.2; -.
DR MGD; MGI:99606; Abca2.
DR InterPro; IPR003593; AAA_AtpPase.
DR InterPro; IPR003439; ABC_transportr.
DR Pfam; PF00005; ABC_tran; 2.
DR ProDom; PD000006; ABC_transportr; 2.
DR SMART; SM00382; AAA; 2.
DR PROSITE; PS00211; ABC_TRANSPORTER; 1.
KW ATP-binding; Transport; Transmembrane; Repeat; Glycoprotein.
FT TRANSMEM 21 40 POTENTIAL.
FT TRANSMEM 705 727 POTENTIAL.
FT TRANSMEM 748 770 POTENTIAL.
FT TRANSMEM 780 802 POTENTIAL.
FT TRANSMEM 809 831 POTENTIAL.
FT TRANSMEM 1793 1815 POTENTIAL.
FT TRANSMEM 1846 1865 POTENTIAL.
FT TRANSMEM 1875 1897 POTENTIAL.
FT TRANSMEM 1904 1926 POTENTIAL.
FT NP_BIND 1024 1031 ATP (POTENTIAL).
FT NP_BIND 2088 2095 ATP (POTENTIAL).
FT CARBOHYD 14 14 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 89 89 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 168 168 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 173 173 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 305 305 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 368 368 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 379 379 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 420 420 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 432 432 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 476 476 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 484 484 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 494 494 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 530 530 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 548 548 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 589 589 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 599 599 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 627 627 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1408 1408 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1496 1496 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1549 1549 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1557 1557 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1613 1613 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1678 1678 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1776 1776 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 2055 2055 N-LINKED (GLCNAC. .) (POTENTIAL).
SQ SEQUENCE 2434 AA; 270582 MW; 3CEDD48ED5692005 CRC64;

Query Match 17.3%; Score 264; DB 1; Length 2434;
Best Local Similarity 25.2%; Pred. No. 6.3e-14;
Matches 92; Conservative 40; Mismatches 97; Indels 136; Gaps 15;

QY 2 GKPSLELPWMYNEQY-----FVSNDAPE-----DTGTELLNLTAKDPGFGT 46
DB 1482 GDLPELVLPQYH-NVTPGRGNFIPYANEEQEVRLRLSPDASPOQLVSTFRLPVGVA 1540
QY 47 RCM-----EGNPI----- 54
DB 1541 TCVLKSPANGSLGPMNLSSGESRLAARFFDSMCLESTQGLPLSNVFPVPPSPARSDS 1600
QY 55 ---PD-----TPCQAGEEWTAP-VPQIMDLFQNGNWTWQNPSPACQCSSDKI 100
DB 1601 PVXPDEDSLQANNLSLPTAGPETWTSAPSLPLVHEPVR-----CTCSAGGT 1648
QY 101 KMLPVCPPGAGLPPPPQKQNTADILDTGRNISDYLVKTYVQIIAKSLKNKIWNNEF 160
DB 1649 GFS---CPSSVGG-HPPQMRVVTGDILDTIGHNVSEYLLFTSDFR-----RLH 1693
QY 161 RYGFSLGVSNTQALPPSOEVNDAIKQMKKHLKAKDSSADRLNSLGRFMTGLDTRNV 220
DB 1694 RGAITFG--NVQSIAS-----FGARVPMVRKTAVRVA 1728
QY 221 KVFNNKGWHAISFLVNNAILRANLPKSGNPAAYGITVTNHPMNKTSASLSLDYLL 1788
DB 1729 QVLYNNKGYSMPTYLNSLNNAILRANLPKSGNPAAYGITVTNHPMNKTSASLSLDYLL 1788
QY 279 MTTSV 283
DB 1789 QGTDV 1793

RESULT 6
ID GLN2_DAUCA STANDARD; PRT; 432 AA.
AC O22506;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DE 16-OCT-2001 (Rel. 40, Last annotation update)
DE Glutamine synthetase, chloroplast precursor (EC 6.3.1.2) (Glutamate--
DE ammonia ligase) (GS2).
GN GLN2.
OS Daucus carota (Carrot).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
OC Asteridae; euasterids II; Apiales; Apiaceae; Daucus.
OC NCBI_TaxID=4039;
OX [1]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. US-Harumakigosun; TISSUE=Leaf;
RA Higashi K., Kanada H.;
RL Submitted (AUG-1997) to the EMBL/GenBank/DBJ databases.
CC -!- FUNCTION: THE LIGHT-MODULATED CHLOROPLAST ENZYME, ENCODED BY A
CC NUCLEAR GENE AND EXPRESSED PRIMARILY IN LEAVES, IS RESPONSIBLE FOR
CC THE REASSIMILATION OF THE AMMONIA GENERATED BY PHOTORESPIRATION
CC (BY SIMILARITY).
CC -!- CATALYTIC ACTIVITY: ATP + L-glutamate + NH(3) = ADP + phosphate +
CC L-glutamine.
CC -!- SUBUNIT: HOMODIMER (BY SIMILARITY).
CC -!- SUBCELLULAR LOCATION: Chloroplast (By similarity).
CC -!- SIMILARITY: BELONGS TO THE GLUTAMINE SYNTHETASE FAMILY.
CC -----
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AF019561; AAB71693.1; -.
DR InterPro; IPR001691; GLN_synth.
DR Pfam; PF00120; glb-synt; 1.
DR PROSITE; PS00180; GLNA_1; 1.
DR PROSITE; PS00181; GLNA_ATP; 1.
KW Ligase; Multigene family; Chloroplast; Transit peptide.
FT TRANSIT 1 ? CHLOROPLAST (POTENTIAL).
FT CHAIN 1 ? 432 GLUTAMINE SYNTHETASE.
SQ SEQUENCE 432 AA; 47763 MW; 20BC0A4CF8E35345 CRC64;

Query Match 7.1%; Score 108.5; DB 1; Length 432;
Best Local Similarity 24.5%; Pred. No. 0.092;
Matches 71; Conservative 26; Mismatches 110; Indels 83; Gaps 15;

QY 3 KYPSELPQWYNEQYTFVSNDAPEDTGTELL-NALTKDPGFG-----TRCMEGN 52
DB 105 EHPS-ELPKWYDGSST---GQAPGDDSEVILYPOAIFKDPFGGNNILVICDTYTPQE 160
QY 53 PIPOTPCQ-----AGEEWTAPVPQIMDLFQNGNWTWQNPSPACQCSSDKI 101
DB 161 PIPTNKRHKAQIFSADKVLGVPWFGEYTLMO--ODVNW----- 201
QY 102 KMLPVCPPG--AGGLPPPPQKQNTADILDTGRNISDYLVKTYVQIIAKSLKNKIWNNE 159
DB 202 -----PLGNVGVGPQPGPYCAAGADKSGFRDISDAHYKACL----- 240
QY 160 FRYGFSLGVSNTQALPPSOE--VNDAIK-QMKKHLKAKDSSADRLNSLGRFMTGLDT 216
DB 160 FRYGFSLGVSNTQALPPSOE--VNDAIK-QMKKHLKAKDSSADRLNSLGRFMTGLDT 216
```

```
Db 241 --YAGINTSGTNGEVMFGQMEFOVGSVGTAGDHIWCAR-YLLBRITTEQAGVVLTP-LDP 296
QY 217 RNNKWNKNGHAISSF-----LNVNNAILRANLQKGENPSHYG 258
SQ 297 KPIDGDW-NGAGCHTNTYTKSMREEGFVEIKKAILNLSLRHKEHISAYG 345

RESULT 7
GLN2_HORVU STANDARD; PRT; 434 AA.
AC P13564;
DT 01-JAN-1990 (Rel. 13, Created)
DT 01-JAN-1990 (Rel. 16, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Glutamine synthetase leaf isozyme, chloroplast precursor (EC 6.3.1.2)
DE (Glutamate--ammonia ligase) (Chloroplast GS2).
OS Hordeum vulgare (Barley).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Poideae;
OC Triticeae; Hordeum.
OX NCBI_TaxID=4513;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=91355850; PubMed=1983297;
RA Stroman P., Balma S., Casadoro G.;
RT "A cDNA sequence coding for glutamine synthetase in Hordeum vulgare
L.";
RL Plant Mol. Biol. 15:161-163(1990).
RN [2]
RP SEQUENCE OF 9-434 FROM N.A.
RX STRAIN=cv. Maris Mink; TISSUE=leaf;
RX MEDLINE=91346618; PubMed=1983286;
RA Freeman J., Marquez A.J., Wallsgrove R.M., Saarelainen R.,
RA Forde B.G.;
RT "Molecular analysis of barley mutants deficient in chloroplast
glutamine synthetase.";
RL Plant Mol. Biol. 14:297-311(1990).
RN [3]
RP SEQUENCE OF 48-434 FROM N.A.
RX MEDLINE=89322552; PubMed=2473765;
RA Balma S., Haegi A., Stroman P., Casadoro G.;
RT "Characterization of a cDNA clone for barley leaf glutamine
synthetase.";
RL Carlsberg Res. Commun. 54:1-9(1989).
CC -!- FUNCTION: THE LIGHT-MODULATED CHLOROPLAST ENZYME, ENCODED BY A
CC NUCLEAR GENE AND EXPRESSED PRIMARILY IN LEAVES, IS RESPONSIBLE FOR
CC THE REASSIMILATION OF THE AMMONIA GENERATED BY PHOTORESPIRATION.
CC -!- CATALYTIC ACTIVITY: ATP + L-glutamate + NH(3) = ADP + phosphate +
CC L-glutamine.
CC -!- SUBUNIT: HOMOOCTAMER.
CC -!- SUBCELLULAR LOCATION: Chloroplast.
CC -!- MISCELLANEOUS: IN BARLEY, THERE ARE DISTINCT ISOZYMES IN THE
CC CHLOROPLAST, AND CYTOPLASM.
CC -!- SIMILARITY: BELONGS TO THE GLUTAMINE SYNTHETASE FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
DR EMBL; X53580; CAA37643.1; -;
DR EMBL; X16000; CAA34131.1; -;
DR PIR; S11865; AJBHQ.
DR InterPro; IPR001691; GLN_synth.
DR Pfam; PF00120; gln-synt; 1.
DR PROSITE; PS00180; GLNA_1; 1.
DR PROSITE; PS00181; GLNA_ATP; 1.
KW Ligase; Multigene family; Chloroplast; Transit peptide.
FT TRANSIT 1 54 CHLOROPLAST.
FT CHAIN 55 434 GLUTAMINE SYNTHETASE LEAF ISOZYME.
```

```
FT CONFLICT 9 27 GAGCAGDAVPGGGGGDG ->
FT FT AAVVQAMQCVGVRGRTA (IN REF. 2).
SQ SEQUENCE 41 41 S -> R (IN REF. 2).
SQ SEQUENCE 434 AA; 47094 MW; FC47F5685EFC0D1E CRC64;

Query Match 6.5%; Score 98.5; DB 1; Length 434;
Best Local Similarity 23.8%; Pred. No. 0.65;
Matches 68; Conservative 29; Mismatches 110; Indels 79; Gaps 14;

QY 5 PSLELPWMYNEQYTFVSNAP-EDTGTLELLNALTKDQFG------TRCMEGNPI 54
Db 109 PS-ELPKWNYDGSST---GOAPGEDSEVILYQAIFKDPFRGGNNILVICDTYTPQGEPI 164
QY 55 PDT----PCQAGEEWTAPVP-----QTJMDLFQNGNMTMQNPSPACQCSSDKIKM 103
Db 165 PTNRHMAAQIFSDPKVTSQVPMFGEIEQYETLMQ--RDVNWPLGW----- 208
QY 104 LPVPPGAGGLPPQPKONTADILQTLGRNISD--YLVKTYVQIIAKSLKNIWVNEFR 161
Db 209 -----VGGYPGPQGPYYCAVGSKSGFRDISDAHYRACLYAGTETSGTNGEVPQWE 261
QY 162 YG-GFSLGVSNTQALPSPQEVNDIAIKMKKHLKLAKDSSADRFNLNLSGRFMTGLDTRNV 220
Db 262 YQVPSVGVGDAGDHINASRYI-----LERTEQAGVVLTP-LDPRPIQ 302
QY 221 KWFNNKGHAISSFL-----NVNNAILRANLQKGENPSHYG 258
Db 303 GDW-NGAGCHTNTYSLSMREDGGFDVKKAILNLSLRHDLHIAAYG 347

RESULT 8
DYSE_MOUSE
ID DYSEF_MOUSE STANDARD; PRT; 2083 AA.
AC Q9ESD7; Q9QXC0;
DT 15-JUN-2002 (Rel. 41, Created)
DT 15-JUN-2002 (Rel. 41, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Dysferlin (Dystrophy associated fer-1 like protein) (Fer-1 like
DE protein 1).
GN DYSF OR FER1L.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=BALB/c, C57BL/10, and SJL/J; TISSUE=Skeletal muscle;
RX MEDLINE=21129430; PubMed=11234777;
RA Vafiadaki E., Reis A., Keers S., Harrison R., Anderson L.V.B.,
RA Raifelsberger T., Ivanova S., Hoeger H., Bittner R.E., Bushby K.M.D.,
RA Bashir R.;
RT "Cloning of the mouse dysferlin gene and genomic characterization of
RT the SJL-Dysf mutation.";
RL NeuroReport 12:625-629(2001).
RN [2]
RP SEQUENCE OF 468-2083 FROM N.A.
RX STRAIN=BALB/c, C57BL/10, C57BL/6, C3H, and B6C3F1;
RX MEDLINE=94438383; PubMed=10508505;
RA Bittner R.E., Anderson L.V.B., Burkhardt E., Bashir R., Vafiadaki E.,
RA Ivanova S., Raifelsberger T., Maerk I., Hoeger H., Jung M.,
RA Karbaslyan M., Storch M., Lassmann H., Moss J.A., Davison K.,
RA Harrison R., Bushby K.M.D., Reis A.;
RT "Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for
RT limb girdle muscular dystrophy 2B.";
RL Nat. Genet. 23:141-142(1999).
CC -!- SUBCELLULAR LOCATION: Type II membrane protein. Localizes to the
CC sarcolemma (By similarity).
CC -!- TISSUE SPECIFICITY: Expressed in skeletal and cardiac muscle. Also
CC found in brain, liver, and kidney.
CC -!- DISEASE: Defects in Dysf are the cause of a slowly progressive
CC muscular dystrophy observed in SJL mice. It affects primarily the
CC proximal muscles and it is inherited as autosomal recessive trait.
CC -!- SIMILARITY: BELONGS TO THE FERLIN FAMILY.
```

```

Db      1630  FCKMFLCTTLEPKDLKITLYD--YDLLSKDKIGETWIDLENRLLSK--FGARC----- 1681
QY      53  PIPDTFCOAGEEW-----TTAPVQPTIMDLFQNGWNMTQN----- 88
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db     1682  GLPOTCCVSGPNKWRDKLRPSQLLHFCQHRIKAPVYTRDRTVFDKDYTIEEAGRL 1741
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY      89  PSPAC-----QCSSDKIKKMLPVCPPGAGGLP 115
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db     1742  PPHLGPVEERLAHVLOQOGLVPEHVESRPLVSPLOPDTQCKLQMWIDIPKVLGSPG 1801
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY     116  PP-----QRRQ-----NTADILOD---LTGRNISDYLVKTYV----- 144
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

QY	145	-----OIIAKSLUKNIWNEFRYGFSGVSNTOALPPSOEV	181
		: : : : : : : :	
Db	1862	RSLGGEGNNRFFVPFDYPAEQVCVAKKDAFW	1910
		-----RLDKTESKIPARW	
QY	182	-----ND	222
		: : : : : : : :	
Db	1911	FQIWNDRKFSFDDFGSLQLDLNRMPKPATAEKCSLDLDDTFHPMEWVSLEQOKTVKG	1970

Q#	225	11	224																																																																	
Db	1971	WW	1972																																																																	
<p>RESULT 9</p> <p>GLN4_PHAVU</p> <table border="1"> <thead> <tr> <th>ID</th> <th>GLN4_PHAVU</th> <th>STANDARD;</th> <th>PRT;</th> <th>429 AA.</th> </tr> </thead> <tbody> <tr> <td>DT</td> <td>01-APR-1990</td> <td>(Rel. 14, Created)</td> <td></td> <td></td> </tr> <tr> <td>DT</td> <td>01-APR-1990</td> <td>(Rel. 14, Last sequence update)</td> <td></td> <td></td> </tr> <tr> <td>DT</td> <td>15-JUN-2002</td> <td>(Rel. 41, Last annotation update)</td> <td></td> <td></td> </tr> <tr> <td>DE</td> <td colspan="4">Glutamine synthetase, leaf isozyme, chloroplast precursor (EC 6.3.1.2)</td> </tr> <tr> <td>DE</td> <td colspan="4">(isozyme delta) (Glutamate--ammonia ligase).</td> </tr> <tr> <td>DE</td> <td colspan="4">Phaseolus vulgaris (Kidney bean) (French bean).</td> </tr> <tr> <td>OC</td> <td>Eukaryota;</td> <td>Viridiplantae;</td> <td>Streptophyta;</td> <td>Embryophyta; Tracheophyta;</td> </tr> <tr> <td>OC</td> <td>Spermatophyta;</td> <td>Magnoliophyta;</td> <td>eudicotyledons;</td> <td>core eudicots; Rosidae;</td> </tr> <tr> <td>OC</td> <td>eurosids I;</td> <td>Fabales;</td> <td>Fabaceae;</td> <td>Papilionoideae; Phaseoleae; Phaseolus.</td> </tr> <tr> <td>OC</td> <td>NCBI_TaxID=3885;</td> <td></td> <td></td> <td></td> </tr> <tr> <td>RP</td> <td>[1]</td> <td></td> <td></td> <td></td> </tr> <tr> <td>RP</td> <td colspan="4">SEQUENCE FROM N.A.</td> </tr> </tbody> </table>				ID	GLN4_PHAVU	STANDARD;	PRT;	429 AA.	DT	01-APR-1990	(Rel. 14, Created)			DT	01-APR-1990	(Rel. 14, Last sequence update)			DT	15-JUN-2002	(Rel. 41, Last annotation update)			DE	Glutamine synthetase, leaf isozyme, chloroplast precursor (EC 6.3.1.2)				DE	(isozyme delta) (Glutamate--ammonia ligase).				DE	Phaseolus vulgaris (Kidney bean) (French bean).				OC	Eukaryota;	Viridiplantae;	Streptophyta;	Embryophyta; Tracheophyta;	OC	Spermatophyta;	Magnoliophyta;	eudicotyledons;	core eudicots; Rosidae;	OC	eurosids I;	Fabales;	Fabaceae;	Papilionoideae; Phaseoleae; Phaseolus.	OC	NCBI_TaxID=3885;				RP	[1]				RP	SEQUENCE FROM N.A.			
ID	GLN4_PHAVU	STANDARD;	PRT;	429 AA.																																																																
DT	01-APR-1990	(Rel. 14, Created)																																																																		
DT	01-APR-1990	(Rel. 14, Last sequence update)																																																																		
DT	15-JUN-2002	(Rel. 41, Last annotation update)																																																																		
DE	Glutamine synthetase, leaf isozyme, chloroplast precursor (EC 6.3.1.2)																																																																			
DE	(isozyme delta) (Glutamate--ammonia ligase).																																																																			
DE	Phaseolus vulgaris (Kidney bean) (French bean).																																																																			
OC	Eukaryota;	Viridiplantae;	Streptophyta;	Embryophyta; Tracheophyta;																																																																
OC	Spermatophyta;	Magnoliophyta;	eudicotyledons;	core eudicots; Rosidae;																																																																
OC	eurosids I;	Fabales;	Fabaceae;	Papilionoideae; Phaseoleae; Phaseolus.																																																																
OC	NCBI_TaxID=3885;																																																																			
RP	[1]																																																																			
RP	SEQUENCE FROM N.A.																																																																			

STRAIN=cv. Tendergreen; TISSUE=Leaf;
RA Lightfoot D. A., Green N.K., Cullimore J. V.;
RC "The chloroplast-located glutamine synthetase of Phaseolus vulgaris
RT L.: nucleotide sequence, expression in different organs and uptake
RT in isolated chloroplasts.";
RL Plant Mol. Biol. 11:191-202(1988).
CC -1- FUNCTION: THE LIGHT-MODULATED CHLOROPLAST ENZYME, ENCODED BY A
CC NUCLEAR GENE AND EXPRESSED PRIMARILY IN LEAVES, IS RESPONSIBLE FOR
CC THE REASSIMILATION OF THE AMMONIA GENERATED BY PHOTORESPIRATION.
CC -1- CATALYTIC ACTIVITY: ATP + L-glutamate + NH(3) = ADP + phosphate +
CC L-glutamine.
CC -1- SUBUNIT: HOMOOCTAMER.
CC -1- SUBCELLULAR LOCATION: Chloroplast.
CC -1- MISCELLANEOUS: THERE ARE AT LEAST FOUR ISOZYMES OF THIS ENZYME IN
CC P. VULGARIS.
CC -1- MISCELLANEOUS: IRREVERSIBLE INHIBITED BY THE HERBICIDE
CC L-PHOSPHINOTHICIN (PPT).
CC -1- SIMILARITY: BELONGS TO THE GLUTAMINE SYNTHETASE FAMILY.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC at the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Source: <http://www.isb-sib.ch/announcement/>
CC entities requires a license agreement (See <http://www.isb-sib.ch/>
CC or send an email to license@isb-sib.ch).
CC -----
CC
DR EMBL; X12738; CAA31234.1; -
DR PIR; S04031; AJFQD.
DR InterPro; IPR001691; GIN_synth.
DR

```
DR InterPro: IPR001637; GlnA_adenyltn.
DR Pfam: PF00120; gln-synt; 1.
DR PROSITE: PS00180; GLNA_1; 1.
DR PROSITE: PS00181; GLNA_Atp; 1.
KW Nitrogen fixation; Ligase; Multigene family; Chloroplast;
KW Transist peptide.
FT TRANSIT 1 57 CHLOROPLAST.
SQ CHAIN 58 429 GLUTAMINE SYNTHETASE LEAF ISOZYME.
SQ SEQUENCE 429 AA; 47246 MW; 0CA55G24B1118AF8 CRC64;

Query Match 6.3%; Score 95.5; DB 1; Length 429;
Best Local Similarity 24.1%; Pred. No. 1.2;
Matches 69; Conservative 26; Mismatches 116; Indels 75; Gaps 14;

QY 3 KPSLEQPMWNYQYTFVNDAP-EDTGTLELLNALTKDQGFGRCM-----EGN 52
DB 102 EHPs-ELPKWNYDGSST---GQAPGEDSEVILYPAIFKDPFRGNNLTVCDAITPAGE 157
QY 53 PIPDTPCQAGEEWT-----APVP-----QTIMDLFONGNWTMQNPSACQSSDKIKM 103
DB 158 PIPTNKRHRAAEVFSNPRVIAEVPWFGEIYETLLQTNVNWPLGW----- 203
QY 104 LPVCPGAGGLPPQKQNTADILQDLTGRTSD--YLVKTYVQIIIAKSLKNIWNEFR 161
DB 204 -----VGGYPGGQPYVYCSAGADRSFGDISDAHYKACLFAGINISGTNGEYMPQWE 256
QY 162 YG-GFSLGVSNTQALPPSQEVNDIAIKQMKHLKLAKDSADRLNSLGRFTGLDTRNNV 220
DB 257 YQVGPVSGI-----EAGDHIWASRYL-----ERITEQAG-VVLSLDPKPIE 297
QY 221 KWFNKGWHAISF-----LNVNNAILRANLQKGNPSHYG 258
DB 298 GDW-NGAGCHTNYSTKSMREDGGFEVVKAILNLSLRKEHISAYG 342

RESULT 10
Y314_METJA
ID Y314_METJA STANDARD; PRT; 263 AA.
AC Q57762;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Hypothetical protein M30314.
GN M30314.
OS Methanococcus jannaschii.
OC Archaea; Euryarchaeota; Methanococci; Methanococcales;
OC Methanocaldococcaceae; Methanocaldococcus.
OX NCBI_TaxID=2190;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=JAL-1 / DSM 2661 / ATCC 43067;
RX MEDLINE=96337999; PubMed=8688087;
RA Bult C.J., White O., Olsen G.J., Zhou L., Fleischmann R.D.,
RA Sutton G.G., Blake J.A., Fitzgerald L.M., Clayton R.A., Gocayne J.D.,
RA Kerlavage A.R., Dougherty B.A., Tomb J.-F., Adams M.D., Reich C.L.,
RA Overbeek R., Kirkness E.F., Weinstock K.G., Merrick J.M., Glodek A.,
RA Scott J.L., Geoghagen N.S.M., Weidman J.F., Fuhrmann J.L., Nguyen D.,
RA Uitterback T.R., Kelley J.M., Peterson J.D., Sadow P.W., Hanna M.C.,
RA Cotton M.D., Roberts K.M., Hurst M.A., Kaine B.P., Borodovsky M.,
RA Klenk H.-P., Fraser C.M., Smith H.O., Woese C.R., Venter J.C.;
RT "Complete genome sequence of the methanogenic archaeon, Methanococcus
jannaschii."
RL Science 273:1058-1073(1996).
CC -1- SIMILARITY: SOME, TO M.JANNASCHII M30398.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----

DR EMBL: U67486; AAB98310.1; -.
DR TIGR: MJ0314; -.
DR InterPro: IPR002197; HTH_Fis.
DR InterPro: IPR000792; HTH_LuxR.
DR InterPro: IPR004042; Intein_endonuc.
DR PROSITE: PS50819; INTEIN_ENDONUCLEASE; 1.
KW Hypothetical protein; Complete proteome.
SQ SEQUENCE 263 AA; 30804 MW; A7520A3BBE0CC5CD CRC64;

Query Match 6.2%; Score 94.5; DB 1; Length 263;
Best Local Similarity 24.6%; Pred. No. 0.73;
Matches 49; Conservative 32; Mismatches 61; Indels 57; Gaps 11;

QY 72 PQTIMDLFONGNWTMQNPSACQSSDKIKMLPVCPCGAGGLPPQKQNTADILQDLT 131
DB 43 PQEIIKYQNG-YTTTEIAIKMKCSHETIRRL-----RNNNIDI----- 81
QY 132 GRNISDLYVTYVQIIIAKSLKN--KIWNNEFRYGGFSLGVSNTQALPPSQEVN----- 182
DB 82 -RKSESLI-----IKNPKKINLNPSESLAYILGLVNGDGSVNKQESNVIELKV 130
QY 183 ---DAIKQMKHLKLAKDSADRLNSLGRFTGLDTRNNKVFNNKG---WHA---IS 233
DB 131 TDKDFIEEFARNL-----ENIGFYINNEYVKFENKKDQYVVRV---RSKGFYYWTKSLNVD 184
QY 234 SFLNVI--NNAILRANLQK 251
DB 185 YVMNVIGNNEKLMISWLKG 203

RESULT 11
GLN2_ARATH
ID GLN2_ARATH STANDARD; PRT; 430 AA.
AC Q43127;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Glutamine synthetase, chloroplast precursor (EC 6.3.1.2) (Glutamate--
ammonia ligase) (GS2).
GN GLN2 OR GS2L OR A75G35630 OR MJE4.9.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
OC eurosids II; Brassicales; Brassicaceae; Arabidopsids.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92079889; PubMed=1684022;
RA Peterman T.K., Goodman H.M.;
RT "The glutamine synthetase gene family of Arabidopsis thaliana: light-
regulation and differential expression in leaves, roots and seeds.";
RL Mol. Gen. Genet. 230:145-154(1991).
RN [2]
RP SEQUENCE FROM N.A.
RA Arimura G., Fujii M., Takahashi M., Goshima N., Morikawa H.;
RT "Nucleotide sequences of genes for cytosolic and chloroplastic
glutamine synthetase from Arabidopsis thaliana.";
RN Submitted (WAY-1998) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. Columbia;
RX MEDLINE=98403884; PubMed=9734815;
RA Kotani H., Nakamura Y., Sato S., Asamizu E., Kaneko T., Miyajima N.,
RA Tabata S.;
RT "Structural analysis of Arabidopsis thaliana chromosome 5. VI.
Sequence features of the regions of 1,367,185 bp covered by 19
physically assigned pl and TAC clones.";
RL DNA Res. 5:203-216(1998).
CC -1- FUNCTION: THE LIGHT-MODULATED CHLOROPLAST ENZYME, ENCODED BY A
CC NUCLEAR GENE AND EXPRESSED PRIMARILY IN LEAVES, IS RESPONSIBLE FOR
CC THE REASSIMILATION OF THE AMMONIA GENERATED BY PHOTORESPIRATION
CC (BY SIMILARITY).
CC
CC -1- CATALYTIC ACTIVITY: ATP + L-glutamate + NH(3) = ADP + phosphate +
```

```

CC L-glutamine.
CC -1- SUBUNIT: HOMOCYTAMER (BY SIMILARITY).
CC -1- SUBCELLULAR LOCATION: Chloroplast.
CC -1- SIMILARITY: BELONGS TO THE GLUTAMINE SYNTHETASE FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; S6727; AAB20558.1; -.
CC EMBL; AB015045; BAA88761.1; -.
CC EMBL; AB013393; BAB09304.1; -.
CC SWISS-2DPAGE; Q43127; ARATH.
CC InterPro; IPR001691; Gln_synth.
CC Pfam; PF00120; gln-synt; 1.
CC PROSITE; PS00180; GLNA_1; 1.
CC PROSITE; PS00181; GLNA_ATP; 1.
CC Ligase; Multigene family; Chloroplast; Transit peptide.
CC TRANSIT 1 51 CHLOROPLAST (POTENTIAL).
CC FT CHAIN 52 430 GLUTAMINE SYNTHETASE.
CC ST 1 51
CC FT CHAIN 52 430
CC ST 1 51
CC SQ SEQUENCE 430 AA; 47410 MW; 564029BC06572295 CRC64;

Query Match 6.2%; Score 94.5; DB 1; Length 430;
Best Local Similarity 23.1%; Pred. No. 1.4;
Matches 67; Conservative 25; Mismatches 111; Indels 87; Gaps 14;

QY 5 PSLELPQWNYNEQYTFVSNADP-EDTGLELLNALTQDPGF-----TROMENPI 54
Db 105 PS-ELPKWNYDGSST---GQAGEDSEVILYPPQAFIRPFRGNNILVICDTWTPAGEPI 160
QY 55 P-----DPPCGAEEWTTAPVPOTIMDLFONGNWTQNPSPACQCSDDKTKM 103
Db 161 PTNKRAAEAFSNKYSGEVWFGIGQEYTLQ--QNVKPLGWP----- 204
QY 104 LPVCPGAGGLPPQPKQNTADILQDLTGRNISDYLVKTYVQITAKSLKNKIWNPEFYG 163
Db 205 -----VGAPFGPGPGPYCGVGADKIWRDISDAHYKACL-----YA 240
QY 164 GFSLGVSNTQALPPSQEVN-----DAIKQMKHLKLAKDSSADRFNLISGRFMTGLDT 216
Db 241 GINISGTNGEVMFGQWFGVQPSYGVDA---GDHVMCAR-YLLERITEQAGVVL-TDP 294
QY 217 RNNYKVFNNKGWHAISSF-----LVNINNAILRANLQKGNPSHYG 258
Db 295 KPTEGDW-NGAGCHTNYSTKSMREEGGFVFIKAILNLSLRHKEITSAYG 343

RESULT 12.
DYSF_HUMAN
ID DYSF_HUMAN STANDARD; PRT; 2080 AA.
AC Q75923; O75696; Q9UEN7;
DT 15-JUN-2002 (Rel. 41, Created)
DT 15-JUN-2002 (Rel. 41, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Dysferlin (Dystrophy associated fer-1-like protein) (Fer-1 like
DE protein 1)
GN DYSF OR FER1L1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A., VARIANTS MM V-1298; R-1857 AND C-2042, AND
RP VARIANTS LGMD2B V-1298 AND C-2042.
RC TISSUE=Skeletal muscle;
RC MEDLINE=98400252; PubMed=9731526;
RA Liu J., Aoki M., Illa I., Wu C., Fardeau M., Angelini C., Serrano C.,
RA Urtizberea J.A., Hentati F., Hamida M.B., Bohlega S., Culper E.J.,
RA Amato A.A., Bossie K., Oelftjen J., Bejaoui K., McKenna-Yasek D.,

```

```
WWW="http://www.dmd.nl/dysf_home.html".
-----
This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
-----
CC EMBL; AF075575; AAC63519.1; -
CC EMBL; AJ007670; CAA07603.1; ALT_SEQ.
CC EMBL; AJ007973; CAA07800.1; -
CC HSSP; P21707; 1RSY.
CC Genew; HGNC:3097; DYSF.
CC MIM; 603009; -
CC MIM; 253601; -
CC MIM; 254130; -
CC MIM; 606768; -
CC InterPro; IPR000008; C2.
CC Pfam; PF00168; C2; 7.
CC SMART; SM00239; C2; 7.
CC PROSITE; PS00499; C2_DOMAIN_1; FALSE_NEG.
CC PROSITE; PS00004; C2_DOMAIN_2; 5.
CC Transmembrane; Repeat; Disease mutation.
CC DOMAIN 1 2046 CYTOPLASMIC (POTENTIAL).
CC TRANSMEM 2047 2067 POTENTIAL.
CC DOMAIN 2068 2080 EXTRACELLULAR (POTENTIAL).
CC DOMAIN 1 85 C2 DOMAIN 1.
CC DOMAIN 207 302 C2 DOMAIN 2.
CC DOMAIN 366 479 C2 DOMAIN 3.
CC DOMAIN 1139 1244 C2 DOMAIN 4.
CC DOMAIN 1565 1663 C2 DOMAIN 5.
CC DOMAIN 1038 1097 ARG-RICH.
CC VARIANT 791 791 P -> R (IN MM AND LGMD2B).
CC /FTID=VAR_012308.
CC VARIANT 1298 1298 I -> V (IN MM AND LGMD2B).
CC /FTID=VAR_012309.
CC VARIANT 1857 1857 H -> R (IN MM).
CC /FTID=VAR_012310.
CC VARIANT 2042 2042 R -> C (IN MM AND LGMD2B).
CC /FTID=VAR_012311.
CC SEQUENCE 2080 AA; 237293 MW; 376E25A5AB9BE398 CRC64;
Query Match 6.28; Score 94.5; DB 1; Length 2080;
Best Local Similarity 18.08; Pred. No. 12;
Matches 65; Conservative 45; Mismatches 95; Indels 157; Gaps 15;
QY 1 FGKPSL-----ELQPMWYNEQYTFVSDAPEDTGTLELLNALTGDPGFGTRCMGN 52
DB 1627 FGKMFELTCTLPLEKDKLITYD---YDLISKDEKIGETVVDLENRLLSK--FGARC--- 1678
QY 53 PIPDTPCOAGEW-----TTAPVPTIMDLFQNGNWTMN----- 88
DB 1679 GLPQTYCYSGPNQWRDLRPSOLLHLFCQOHRVKAPVYTRDVMFQDKEYSIEIEAGRI 1738
QY 89 PSPAC-----QCSDKIKMLPVCPCGAGGLP 115
DB 1739 PNPGLGPVEERLALHVOQOGLVPEHVESRPLYSPLQPDIEQGLQMWVDLPFKALRGP 1798
QY 116 P-----PQRKQ-----NTADILQD---LTGRNISDYLKTVV----- 144
DB 1799 PFNITPRARRFFLRCIITWNTROVILDDLSLTGKMSDIYVKGWMIQFEHKQKTDVHY 1858
QY 145 -----QIIAKSLKNKIWNVEFRYGGFSLGVSNTQALPPSQEV 181
DB 1859 RSLGGEGNFRFIIPFDYLPQAVCTIAKDAFW-----RLDKTESKIPARVY 1907
QY 182 -----NDA-----TKMKKHLKLKADSSADRFNLNL-GRFMTGLDTRNNVKV 222
DB 1908 FQIWDNKFSDDFLGLSLQDLNMRPKPAKTAKGSLDQLDDAFHPFWFVSLFEQTKVG 1967
QY 223 WF 224
```

```
Db 1968 WW 1969
RESULT 13
LRP2_RAT STANDARD; PRT; 4660 AA.
AC P98158;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Low-density lipoprotein receptor-related protein 2 precursor (Megalin)
DE (Glycoprotein 330).
DE LRP2.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Sprague-Dawley; TISSUE=Kidney;
RX MEDLINE=95024033; PubMed=7937880;
RA Saito A., Pietromaco S., Loo A.K.C., Farguher M.G.;
RT "Complete cloning and sequencing of rat gp330/megalin, a
RT distinctive member of the low density lipoprotein receptor gene
RT family";
RL Proc. Natl. Acad. Sci. U.S.A. 91:9725-9729(1994).
RN [2]
RP FUNCTION.
RX MEDLINE=95386696; PubMed=7544804;
RA Moestrup S.K., Cui S., Vorum H., Bregengaard C., Bjorn S.E.,
RA Norris K., Gliemann J., Christensen E.I.;
RT "Evidence that epithelial glycoprotein 330/megalin mediates uptake of
RT polybasic drugs.";
RL J. Clin. Invest. 96:1404-1413(1995).
RN [3]
RP TISSUE SPECIFICITY.
RX MEDLINE=94172242; PubMed=7510321;
RA Zheng G., Bachinsky D.R., Stamenkovic I., Strickland D.K., Brown D.,
RA Andres G., McCluskey R.T.;
RT "Organ distribution in rats of two members of the low-density
RT lipoprotein receptor gene family, gp330 and LRP/alpa 2MR, and the
RT receptor-associated protein (RAP).";
RL J. Histochem. Cytochem. 42:531-542(1994).
CC -!- FUNCTION: BINDS PLASMINOGEN, EXTRACELLULAR MATRIX COMPONENTS,
CC PLASMINOGEN ACTIVATOR-PLASMINOGEN ACTIVATOR INHIBITOR TYPE I
CC COMPLEX, APOLIPOPROTEIN E-ENRICHED BETA-VLDL, LIPOPROTEIN LIPASE,
CC LACTOFERRIN, CLUSTERIN AND CALCIUM.
CC -!- FUNCTION: RECEPTOR-MEDIATED UPTAKE OF POLYBASIC DRUGS SUCH AS
CC APROTININ, AMINOGLYCOSIDES AND POLYMYXIN B.
CC -!- SUBUNIT: FORMS A MULTIMERIC COMPLEX TOGETHER WITH A RECEPTOR-
CC ASSOCIATED PROTEIN (RAP).
CC -!- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN. EXPRESSED IN
CC CLATHRIN-COATED PITS; A SOLUBLE FORM IS POSSIBLY DERIVED BY
CC CLEAVAGE AT THE CELL SURFACE.
CC -!- TISSUE SPECIFICITY: EPITHELIAL CELLS OF KIDNEY GLOMERULUS AND
CC PROXIMAL TUBULE, LUNG, EPIDIDYMIS, YOLK SAC, AMONG OTHERS.
CC -!- SIMILARITY: CONTAINS 36 LDL-RECEPTOR CLASS A DOMAINS.
CC -!- SIMILARITY: CONTAINS 37 LDL-RECEPTOR CLASS B DOMAINS.
CC -!- SIMILARITY: CONTAINS 17 EGF-LIKE DOMAINS.
-----
This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
-----
CC EMBL; L34049; AAA51369.1; -
CC HSSP; Q07954; 1CR8.
CC GlycoSuiteDB; P98158; -
CC InterPro; IPR000152; Asx_hydroxyl.
```



```

DR InterPro; IPR000561; EGF-like.
DR InterPro; IPR001881; EGF-like.
DR InterPro; IPR002172; LDL_recept_A.
DR InterPro; IPR000033; ldl_receptor_rep.
DR Pfam; PF00057; ldl_recept_a; 36.
DR Pfam; PF00058; ldl_recept_b; 33.
DR PRINTS; PR00261; LDLRECEPTOR.
DR SMART; SM00179; EGF_CA; 3.
DR SMART; SM00001; EGF_Like; 15.
DR SMART; SM00192; LDLra; 36.
DR SMART; SM00135; LY; 35.
DR PROSITE; PS00010; ASX_HYDROXYL; 4.
DR PROSITE; PS00022; EGF_1; 1.
DR PROSITE; PS00022; EGF_2; 8.
DR PROSITE; PS01186; EGF_CA; 3.
DR PROSITE; PS01187; EGF_CA; 3.
DR PROSITE; PS01209; LDLRA_1; 31.
DR PROSITE; PS00068; LDLRA_2; 36.
KW Glycoprotein; Repeat; Endocytosis; Coated pits; Transmembrane;
KW Receptor; EGF-like domain; SH3-binding; Signal.
FT SIGNAL 1 25 POTENTIAL.
FT CHAIN 26 4660
FT FT
FT FT
FT DOMAIN 26 4425
FT TRANSMEM 4426 4446
FT DOMAIN 4447 4660
FT DOMAIN 26 64
FT DOMAIN 65 105
FT DOMAIN 106 144
FT DOMAIN 145 181
FT DOMAIN 181 219
FT DOMAIN 220 258
FT DOMAIN 263 307
FT DOMAIN 308 346
FT DOMAIN 347 385
FT DOMAIN 347 385
FT DOMAIN 435 476
FT DOMAIN 478 519
FT DOMAIN 521 566
FT DOMAIN 568 611
FT DOMAIN 612 652
FT DOMAIN 658 704
FT DOMAIN 752 793
FT DOMAIN 795 835
FT DOMAIN 837 879
FT DOMAIN 881 923
FT DOMAIN 969 1013
FT DOMAIN 1023 1061
FT DOMAIN 1064 1103
FT DOMAIN 1108 1146
FT DOMAIN 1148 1186
FT DOMAIN 1186 1225
FT DOMAIN 1229 1269
FT DOMAIN 1270 1308
FT DOMAIN 1311 1351
FT DOMAIN 1350 1390
FT DOMAIN 1391 1430
FT DOMAIN 1479 1520
FT DOMAIN 1522 1563
FT DOMAIN 1567 1609
FT DOMAIN 1611 1654
FT DOMAIN 1656 1696
FT DOMAIN 1701 1742
FT DOMAIN 1791 1832
FT DOMAIN 1834 1882
FT DOMAIN 1884 1930
FT DOMAIN 1932 1972
FT DOMAIN 1973 2013
FT DOMAIN 2019 2060
FT DOMAIN 2108 2156
FT DOMAIN 2158 2201
FT DOMAIN 2203 2245
FT DOMAIN 2247 2289
FT DOMAIN 2291 2332
FT DOMAIN 2343 2384
InterPro; IPR000561; EGF-like.
InterPro; IPR001881; EGF-like.
InterPro; IPR002172; LDL_recept_A.
InterPro; IPR000033; ldl_receptor_rep.
Pfam; PF00057; ldl_recept_a; 36.
Pfam; PF00058; ldl_recept_b; 33.
PRINTS; PR00261; LDLRECEPTOR.
SMART; SM00179; EGF_CA; 3.
SMART; SM00001; EGF_Like; 15.
SMART; SM00192; LDLra; 36.
SMART; SM00135; LY; 35.
PROSITE; PS00010; ASX_HYDROXYL; 4.
PROSITE; PS00022; EGF_1; 1.
PROSITE; PS00022; EGF_2; 8.
PROSITE; PS01186; EGF_CA; 3.
PROSITE; PS01187; EGF_CA; 3.
PROSITE; PS01209; LDLRA_1; 31.
PROSITE; PS00068; LDLRA_2; 36.
Glycoprotein; Repeat; Endocytosis; Coated pits; Transmembrane;
Receptor; EGF-like domain; SH3-binding; Signal.
SIGNAL 1 25 POTENTIAL.
CHAIN 26 4660
DOMAIN 26 4425
TRANSMEM 4426 4446
DOMAIN 4447 4660
DOMAIN 26 64
DOMAIN 65 105
DOMAIN 106 144
DOMAIN 145 181
DOMAIN 181 219
DOMAIN 220 258
DOMAIN 263 307
DOMAIN 308 346
DOMAIN 347 385
DOMAIN 347 385
DOMAIN 435 476
DOMAIN 478 519
DOMAIN 521 566
DOMAIN 568 611
DOMAIN 612 652
DOMAIN 658 704
DOMAIN 752 793
DOMAIN 795 835
DOMAIN 837 879
DOMAIN 881 923
DOMAIN 969 1013
DOMAIN 1023 1061
DOMAIN 1064 1103
DOMAIN 1108 1146
DOMAIN 1148 1186
DOMAIN 1186 1225
DOMAIN 1229 1269
DOMAIN 1270 1308
DOMAIN 1311 1351
DOMAIN 1350 1390
DOMAIN 1391 1430
DOMAIN 1479 1520
DOMAIN 1522 1563
DOMAIN 1567 1609
DOMAIN 1611 1654
DOMAIN 1656 1696
DOMAIN 1701 1742
DOMAIN 1791 1832
DOMAIN 1834 1882
DOMAIN 1884 1930
DOMAIN 1932 1972
DOMAIN 1973 2013
DOMAIN 2019 2060
DOMAIN 2108 2156
DOMAIN 2158 2201
DOMAIN 2203 2245
DOMAIN 2247 2289
DOMAIN 2291 2332
DOMAIN 2343 2384

```

```

FT DOMAIN 2432
FT DOMAIN 2477
FT DOMAIN 2518
FT DOMAIN 2520
FT DOMAIN 2562
FT DOMAIN 2604
FT DOMAIN 2647
FT DOMAIN 2699
FT DOMAIN 2739
FT DOMAIN 2779
FT DOMAIN 2820
FT DOMAIN 2862
FT DOMAIN 2903
FT DOMAIN 2947
FT DOMAIN 2992
FT DOMAIN 3031
FT DOMAIN 3072
FT DOMAIN 3112
FT DOMAIN 3153
FT DOMAIN 3154
FT DOMAIN 3194
FT DOMAIN 3241
FT DOMAIN 3282
FT DOMAIN 3324
FT DOMAIN 3363
FT DOMAIN 3402
FT DOMAIN 3461
FT DOMAIN 3511
FT DOMAIN 3552
FT DOMAIN 3593
FT DOMAIN 3634
FT DOMAIN 3675
FT DOMAIN 3718
FT DOMAIN 3758
FT DOMAIN 3797
FT DOMAIN 3836
FT DOMAIN 3882
FT DOMAIN 3924
FT DOMAIN 3966
FT DOMAIN 4008
FT DOMAIN 4050
FT DOMAIN 4197
FT DOMAIN 4241
FT DOMAIN 4284
FT DOMAIN 4332
FT DOMAIN 4379
FT DOMAIN 4413
FT SITE 4454
FT SITE 4457
FT SITE 4606
FT SITE 4619
FT SITE 4625
FT SITE 4630
FT SITE 1743
FT SITE 4522
FT SITE 4527
FT SITE 4601
FT DISULFID 28
FT DISULFID 35
FT DISULFID 47
FT DISULFID 67
FT DISULFID 74
FT DISULFID 87
FT DISULFID 108
FT DISULFID 115
FT DISULFID 127
FT DISULFID 142
FT DISULFID 147
LDL-RECEPTOR CLASS B 25.
LDL-RECEPTOR CLASS B 26.
LDL-RECEPTOR CLASS B 27.
LDL-RECEPTOR CLASS B 28.
LDL-RECEPTOR CLASS B 29.
EGF-LIKE 10.
LDL-RECEPTOR CLASS A 16.
LDL-RECEPTOR CLASS A 17.
LDL-RECEPTOR CLASS A 18.
LDL-RECEPTOR CLASS A 19.
LDL-RECEPTOR CLASS A 20.
LDL-RECEPTOR CLASS A 21.
LDL-RECEPTOR CLASS A 22.
LDL-RECEPTOR CLASS A 23.
LDL-RECEPTOR CLASS A 24.
LDL-RECEPTOR CLASS A 25.
EGF-LIKE 11.
CALCIUM-BINDING (POTENTIAL).
EGF-LIKE 12.
LDL-RECEPTOR CLASS B 30.
LDL-RECEPTOR CLASS B 31.
LDL-RECEPTOR CLASS B 32.
LDL-RECEPTOR CLASS B 33.
LDL-RECEPTOR CLASS B 34.
EGF-LIKE 13.
LDL-RECEPTOR CLASS A 26.
LDL-RECEPTOR CLASS A 27.
LDL-RECEPTOR CLASS A 28.
LDL-RECEPTOR CLASS A 29.
LDL-RECEPTOR CLASS A 30.
LDL-RECEPTOR CLASS A 31.
LDL-RECEPTOR CLASS A 32.
LDL-RECEPTOR CLASS A 33.
LDL-RECEPTOR CLASS A 34.
LDL-RECEPTOR CLASS A 35.
LDL-RECEPTOR CLASS A 36.
EGF-LIKE 14.
CALCIUM-BINDING (POTENTIAL).
EGF-LIKE 15.
LDL-RECEPTOR CLASS B 35.
LDL-RECEPTOR CLASS B 36.
LDL-RECEPTOR CLASS B 37.
EGF-LIKE 16.
EGF-LIKE 17.
SH3-BINDING (POTENTIAL).
SH3-BINDING (POTENTIAL).
SH2-BINDING (POTENTIAL).
SH3-BINDING (POTENTIAL).
SH3-BINDING (POTENTIAL).
CELL ATTACHMENT SITE (POTENTIAL).
ENDOCYTOSIS SIGNAL (POTENTIAL).
ENDOCYTOSIS SIGNAL (POTENTIAL).
BY SIMILARITY.
BY SIMILARITY.
BY SIMILARITY.
BY SIMILARITY.
BY SIMILARITY.
BY SIMILARITY.
BY SIMILARITY.
BY SIMILARITY.

```

```

Query Match 6.2%; Score 94.5; DB 1; Length 4660;
Best Local Similarity 23.6%; Pred. No. 35;
Matches 70; Conservative 37; Mismatches 111; Indels 79; Gaps 19;
Qy 1 FGKYP-----LELQPM-----YNEQYTFVSNDAPEDTGTLELLNALTDPGFGTR 47
Db 4302 FGKENKEKVLVNPWLQVRIFHLQRYNQS---VSNPKQVCVSHLCLL---RPGGYSCA 4354
Qy 48 CMENGPIT---PDTFCQAGEEHWTTAPVPTQITMDLFQNGN-WTMONPSPACQSSDITKKM 103
Db 4355 CPOGSDFTVGTSTVQCDAASELPVTMPPPFCM---HGGNGCYFDENELPKCKSSGYSGE- 4410

```

QY 104 LPVCPGP-AGGLPPPKQNTADILQDLTGRNISDYLVKTYVOIIAKSLKNIWNEFRY 162
 Db 4411 --YCEVGLSRGIPP-----GTTWA-VLLTFVIVIGAL-----VLVGLFHY 4449
 QY 163 GGFSLGVNTQALPPSQEVNDAIKQMKHLKLAKDSSADRLNSLG-RWMTGLDTRNNVK 221
 Db 4450 -----RKTGSLPT-----LPKLPSSLSLAKPSE-----NGNGVTRFSGADV--NMD 4489
 QY 222 VWFNKKGWAISFLNINNAIRLANLOKGENPSHYGITAFNHLNLTQKQSEVAL 278
 Db 4490 IGVSPPGPEIIDRSMAHNEHV---MEVGKQP-----VIFENPMYAAKDNSTSKVAL 4538
 RESULT 14
 GLN2_ORYSA
 ID GLN2_ORYSA STANDARD; PRT; 428 AA.
 AC P14655;
 DT 01-APR-1990 (Rel. 14, Created)
 DT 01-APR-1990 (Rel. 14, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Glutamine synthetase shoot isozyme, chloroplast precursor (EC 6.3.1.2)
 DE (Glutamate--ammonia ligase) (Clone lambda-GS31).
 OS Oryza sativa (Rice).
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 OC Ehrhartoideae; Oryzeae; Oryza.
 OC NCBI_TaxID=4530;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=cv. Kinmaze; TISSUE=Shoot;
 RX MEDLINE=91370845; PubMed=2577497;
 RA Sakamoto A., Ogawa M., Masumura T., Shibata D., Takeba G.,
 RA Tanaka K., Fujii S.;
 RT "Three cDNA sequences coding for glutamine synthetase polypeptides in
 RT Oryza sativa L." 13:611-614(1989).
 RL Plant Mol. Biol. 13:611-614(1989).
 CC -!- FUNCTION: THE LIGHT-MODULATED CHLOROPLAST ENZYME, ENCODED BY A
 CC NUCLEAR GENE AND EXPRESSED PRIMARILY IN LEAVES, IS RESPONSIBLE FOR
 CC THE REASSIMILATION OF THE AMMONIA GENERATED BY PHOTORESPIRATION.
 CC -!- CATALYTIC ACTIVITY: ATP + L-glutamate + NH(3) = ADP + phosphate +
 CC L-glutamine.
 CC -!- SUBUNIT: HOMOOCTAMER.
 CC -!- SUBCELLULAR LOCATION: Chloroplast.
 CC -!- SIMILARITY: BELONGS TO THE GLUTAMINE SYNTHETASE FAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC EMBL; X14246; CAA32462.1; -;
 CC PIR; S07471; AJRZQD.
 CC InterPro; IPR001691; GLN_synth.
 CC Pfam; PF00120; gln-synt; 1.
 CC PROSITE; PS00180; GLNA.1; 1.
 CC PROSITE; PS00181; GLNA_ATP; 1.
 KW Ligase; Multigene family; Chloroplast; Transit peptide.
 FT TRANSIT 1 56 CHLOROPLAST (POTENTIAL).
 FT CHAIN 57 428 GLUTAMINE SYNTHETASE SHOOT ISOZYME.
 SQ SEQUENCE 428 AA; 46642 MW; DFF1B39BFC5921FE CRC64;
 Query Match 6.1%; Score 92.5; DB 1; Length 428;
 Best Local Similarity 23.6%; Pred. No. 2, 1;
 Matches 67; Conservative 30; Mismatches 112; Indels 75; Gaps 14;
 QY 5 PSLELPWMYNEQYTFVSNDAPE-EDTGTLELLNALTKDPFG-----TRCMGNGPI 54
 Db 103 PS-ELPKWYDGSST---GQAFGESEVILYQPAIFKDPFRGNGNLLVMCDTYTPAGEPI 158
 QY 55 P-----DTPCQAGEEETATPVP-----QTIMDLFQNGNWTMONPSPACOCSSDKIKKMLP 105

Db 159 PTNKRNRQAQVSPKVSQVPWFGEIQEYETLLQDYNWPLGWP----- 202
 QY 106 VCPPGAGGLPPPKQNTADILQDLTGRNISDYLVKTYVOIIAKSLKNIWNEFRYGGF 165
 Db 203 -----VCGYPGPGPYCAVGSXSKSFGDRDISDAHYKACL-----YAGI 240
 QY 166 SLGVSNTQALPPSQE--VYDAIK-QMKHLKLAKDSSADRLNSLGFRMTGLDTRNNVKV 222
 Db 241 NISGTNGEVPQGWYQVGPVGVIEAGDHIWISR-YILERITEQAGVVLT-LDPKPIQGD 298
 QY 223 WFNKKGWAISF-----LNVINNAIRLANLOKGENPSHYG 258
 Db 299 W-NGAGCHTNTSKSMREDGGFEVKKAILNLSLRHDLHISAYG 341
 RESULT 15
 GLNC_BRANA
 ID GLNC_BRANA STANDARD; PRT; 428 AA.
 AC Q42624; Q9M429;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DE Glutamine synthetase, chloroplast precursor (EC 6.3.1.2) (Glutamate--
 DE ammonia ligase) (GS2).
 GN GLN2 OR GLN.
 OS Brassica napus (Rape).
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
 OC eurosids II; Brassicales; Brassicaceae; Brassica.
 OC NCBI_TaxID=3708;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Leaf;
 RX MEDLINE=94269200; PubMed=7911583;
 RA Ochs G., Schock G., Wild A.;
 RT "Chloroplastic glutamine synthetase from Brassica napus.";
 RL Plant Physiol. 103:303-304(1993).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=cv. Drakkar; TISSUE=Leaf;
 RT "Cloning and Sequencing of genomic fragments coding for glutamine
 RT synthetase of Brassica napus.";
 RL Submitted (FEB-2000) to the EMBL/Genbank/DBJ databases.
 CC -!- FUNCTION: THE LIGHT-MODULATED CHLOROPLAST ENZYME, ENCODED BY A
 CC NUCLEAR GENE AND EXPRESSED PRIMARILY IN LEAVES, IS RESPONSIBLE FOR
 CC THE REASSIMILATION OF THE AMMONIA GENERATED BY PHOTORESPIRATION
 CC (BY SIMILARITY).
 CC -!- CATALYTIC ACTIVITY: ATP + L-glutamate + NH(3) = ADP + phosphate +
 CC L-glutamine.
 CC -!- SUBUNIT: HOMOOCTAMER (BY SIMILARITY).
 CC -!- SUBCELLULAR LOCATION: Chloroplast.
 CC -!- SIMILARITY: BELONGS TO THE GLUTAMINE SYNTHETASE FAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC EMBL; X72751; CAA51280.1; -;
 CC EMBL; AJ271909; CAB72423.1; -;
 CC InterPro; IPR001691; GLN_synth.
 CC Pfam; PF00120; gln-synt; 1.
 CC PROSITE; PS00180; GLNA.1; 1.
 CC PROSITE; PS00181; GLNA_ATP; 1.
 KW Ligase; Multigene family; Chloroplast; Transit peptide.
 FT TRANSIT 1 49 CHLOROPLAST (POTENTIAL).
 FT CHAIN 50 428 GLUTAMINE SYNTHETASE.
 FT CONFLICT 50 50 L -> I (IN REF. 2).


```
Db 1371 FGKYPSELQPMWYDEQYTFISNDAPEDAGTOKLIDALLNKPGFGTRCMQCHSIPDTPCT 1430
QY 61 AGESEWTTAPVPTIMDLFQNGWNTWNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
Db 1431 VQKEWTTASVDSVLEILR-GNWSMENSPSCSEKIKKMLPVCPPGAGGLPPQRE 1489
QY 121 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
Db 1490 QDTADILQNLTRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSNE 1549
QY 181 VNDATKQMKHKLAKDSSADRELSNIGRPMGLDPRNNKVFNNKNGHAISSFLANVIN 240
Db 1550 VYDAIKQVKKLELAQSSGDRLENNLASFMKGLDPRNNKVFNNKNGHAISSFLANVIN 1609
QY 241 NAILRANLQKGNPSHYGITAFNHPNLNTKQQLSEVALMTTSD 284
Db 1610 NAILRANLQKGNPSHYGITAFNHPNLNTKQQLSEVALMTTSD 1653

RESULT 2
002698 PRELIMINARY; PRT: 2281 AA.
AC 002698;
DT 01-JUL-1997 (TrEMBLrel. 04, Created)
DT 01-JUL-1997 (TrEMBLrel. 04, Last sequence update)
DE ABC transporter.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN 1;
RP SEQUENCE FROM N.A.
RC TISSUE=RETINAL ROD CELL;
RX MEDLINE=97248596; PubMed=9092582;
RA Illing M., Molday L.L., Molday R.S.;
RT "The 220-kDa rim protein of retinal rod outer segments is a member of
the ABC transporter superfamily."
RL J. Biol. Chem. 272:10303-10310(1997).
DR EMBL; 090126; AAC48716.1; -.
DR InterPro; IPR003593; AAA_ATPase.
DR InterPro; IPR003439; ABC_transporter.
DR Pfam; PF00005; ABC_tran; 2.
DR ProDom; PD000006; ABC_transporter; 2.
DR SMART; SM00382; AAA; 1.
DR TIGRFAMs; TIGR01257; rim_protein; 1.
KW ATP-binding.
SQ SEQUENCE 2281 AA; 257228 MW; 71CD404C98F7A079 CRC64;

Query Match 48.0%; Score 731.5; DB 6; Length 2281;
Best Local Similarity 47.2%; Pred. No. 1.4e-53;
Matches 143; Conservative 38; Mismatches 83; Indels 39; Gaps 4;

QY 1 FGKYPSELQPMWYDEQYTFISNDAPEDGTLELLNALTQDPGFGTRCMGNPIPDTPCQ 60
Db 1395 FGEPALTLPFWMYGQYTFESMDQDSEWLSALADVLNKGFGNRCLEWLPPEPC- 1453
QY 61 AGESEWTTAPVPTIMDLFQNGWNTWNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
Db 1454 GNSSPWKTPTSPVSDVTHLQOQQKWDQDPSRCSTREKLTMLPECEGAGGLPPQRI 1513
QY 121 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
Db 1514 QRSTELQDLTDRNVDFLVKTYPALIRSLSKSKFWNEQRYGGSVG---GKLPAPPF 1569
QY 181 VNDATKQMKHKLAKDSSADRELSNIGR- - - - - FMTGLDTRNNVK 221
Db 1570 TGEALV- - - - - GFSLDGLQMLNVSGGPMTRAAKEMPAFLKQLETDNIK 1614
QY 222 VWFNKGWHAISFLNINNAIRANLQKGNPSHYGITAFNHPNLNTKQQLSEVALMTT 281
Db 1615 VWFNKGWHAISFLNVAHNAIRASLRKDKNPGEYGITVISQPLNLTKEQLSEITVLT 1674
```

```
QY 282 SVD 284
Db 1675 SVD 1677

RESULT 3
035600 PRELIMINARY; PRT: 2310 AA.
AC 035600;
DT 01-JAN-1998 (TrEMBLrel. 05, Created)
DT 01-JAN-1998 (TrEMBLrel. 05, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE ATP-binding cassette transporter.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN 1;
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RX MEDLINE=97345663; PubMed=9202155;
RA Azarian S.M., Travis G.H.;
RT "The photoreceptor rim protein is an ABC transporter encoded by the
gene for recessive Stargardt's disease (ABCR).";
RL FEBS Lett. 409:247-252(1997).
RN 2;
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RA Azarian S.M., Travis G.H.;
RL Submitted (JUN-1998) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF000149; AAC23916.1; -.
DR MGI; MGI:109424; Abca4.
DR InterPro; IPR003593; AAA_ATPase.
DR InterPro; IPR003439; ABC_transporter.
DR Pfam; PF00005; ABC_tran; 2.
DR ProDom; PD000006; ABC_transporter; 2.
DR SMART; SM00382; AAA; 1.
DR TIGRFAMs; TIGR01257; rim_protein; 1.
DR PROSITE; PS00211; ABC_TRANSPORTER; UNKNOWN_1.
KW ATP-binding.
SQ SEQUENCE 2310 AA; 260207 MW; 8370C6C8A62EF294 CRC64;

Query Match 47.5%; Score 724.5; DB 11; Length 2310;
Best Local Similarity 47.2%; Pred. No. 5.8e-53;
Matches 143; Conservative 39; Mismatches 82; Indels 39; Gaps 4;

QY 1 FGKYPSELQPMWYDEQYTFVSNDAPEDTGTELLNALTQDPGFGTRCMGNPIPDTPCQ 60
Db 1396 FGEPALTLPFWMYGQYTFESMDENNEHLEVLADVLNKGFGNRCLEWLPPEPC- 1454
QY 61 AGESEWTTAPVPTIMDLFQNGWNTWNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
Db 1455 INATSWKTPTSPVSPNITHLFQKQKWTAAHPSKCGSTREKLTMLPECEGAGGLPPQRT 1514
QY 121 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
Db 1515 QRSTEVLDLTNRNISDYLVKTYPALIRSLSKSKFWNEQRYGGSIG-GKLPAPISGE 1573
QY 181 VNDATKQMKHKLAKDSSADRELSNIGR- - - - - FMTGLDTRNNVK 221
Db 1574 - - - - - ALVGLSLGOMNVSGPVTREASKEMDLDLKHLETONIK 1615
QY 222 VWFNKGWHAISFLNINNAIRANLQKGNPSHYGITAFNHPNLNTKQQLSEVALMTT 281
Db 1616 VWFNKGWHAISFLNVAHNAIRASLR- - - - - FMTGLDTRNNVK 1675

QY 282 SVD 284
Db 1676 SVD 1678
```

```

RESULT 4
ID Q91V24 PRELIMINARY; PRT; 2159 AA.
AC Q91V24;
DT 01-DEC-2001 (TREMBLrel. 19, Created)
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
DT 01-JUN-2002 (TREMBLrel. 21, Last annotation update)
DE ATP-binding cassette transporter sub-family A member 7.
GN ABCA7.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=OL129, AND DBA/2;
RX MEDLINE=2132888; PubMed=11435699;
RA Broccardo C., Osorio J., Luciani M.-F., Schriml L.M., Prades C.,
RA Shulenin S., Osoroldo I., Naudin I., Lafargue C., Rosier M., Jordan B.,
RA Mattei M.G., Dean M., Denefle P., Chimini G.;
RT "Comparative analysis of the promoter structure and genomic
RT organization of the human and mouse ABCA7 gene encoding a novel ABCA
RT transporter."
RL Cytochrome Cell Genet. 92:264-270(2001).
DR EMBL; AF287142; AAK56863.1; -
DR EMBL; AF287141; AAK56862.1; -
DR MGD; MGI:1351646; Abca7.
DR InterPro; IPR003439; ABC_transportr.
DR InterPro; IPR002016; Peroxidase.
DR Pfam; PF00005; ABC_tran; 2.
DR ProDom; PD000006; ABC_Transporter; 2.
DR PROSITE; PS00211; ABC_TRANSPORTER; UNKNOWN_1.
DR PROSITE; PS00435; PEROXIDASE_1; UNKNOWN_1.
KW ATP-binding.
SQ
SEQUENCE 2159 AA; 236882 MW; CD2BE3FE0D8B822B CRC64;

Query Match 43.5%; Score 664; DB 11; Length 2159;
Best Local Similarity 45.3%; Pred. No. 8.3e-48;
Matches 129; Conservative 47; Mismatches 107; Indels 2; Gaps 2;

QY 1 FCKYPSLEOPWNYNEQTFYSNDAPETGCTLELLNALTDPGFGTRMGEGNPIDPTCCQ 60
DB 1266 FGQIPLQLSPAMYGFQVSFFSEADPGPNRMKLEALLGEALGPESMODKDARGSECT 1325
QY 61 AGEEEWTTP-VPTQIMDLFONGNTWMONPSPACQSSDKIKKMLPVCPPGAGLPPOP 119
DB 1326 HSLACYFTVPPEPPDVASILASGNWTPESPSPACQSCQPQARGLLPCDPAGAGPPPOA 1385
QY 120 KONTADLODLGRNISDYLVKTVYOIIIAKSLLKNWNFRYGGFSLGVSNQTALPPSQ 179
DB 1386 VAGLGEVQNLIQRNVSDFLVKTFPSLRGLTKTKWVDVRVGGSFLG-GRDPOLPTCH 1444
QY 180 EVNDALKMKHLKLAKDOSSADRFLNSIGRMTGLDRFNKVWFNNKGHWAISSFLNVI 239
DB 1445 EYVRTLAETRALLSPQNGNALDRILNNLTOWALGEDARNSLKTWFNNKGHWAMVAFNRA 1504
QY 240 NNAILRANLQGENPSHYGTAFNHPLNLTKOOLSEVALMTTSD 284
DB 1505 NGLLHALLPSPVRHANSITLNHPLNLTKEQLEATLASSVD 1549

RESULT 5
ID Q9BZC4 PRELIMINARY; PRT; 2146 AA.
AC Q9BZC4;
DT 01-JUN-2001 (TREMBLrel. 17, Created)
DT 01-JUN-2001 (TREMBLrel. 17, Last sequence update)
DE ATP-binding cassette transporter sub-family A member 7.
GN ABCA7.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.

```

OX	NCBI_TaxID=9606;
RN	[1]
RP	SEQUENCE FROM N.A.
RM	MEDLINE=2132888; PubMed=11435699;
RX	Broccardo C., Osorio J., Luciani M.-F., Schriml L.M., Prades C.,
RA	Shullen S., Arnold I., Naudin L., Lafargue C., Rosier M., Jordan B.,
RA	Mullen M.G., Dean M., Deneffe P., Chimini G.
RA	"Comparative analysis of the promoter structure and genomic
RT	organization of the human and mouse ABCA7 gene encoding a novel ABCA
RT	transporter.";
RL	Cytogenet. Cell Genet. 92:264-270(2001).
RL	EMBL; AF328787; AAK00959.1; -
DR	InterPro; IPR003593; AAA_Afpase.
DR	InterPro; IPR003439; ABC_transporter.
DR	InterPro; IPR001899; Gram_pos_anchor.
DR	Pfam; PF00005; ABC_tran; 2
DR	ProDom; PD000006; ABC_transporter; 2.
DR	SMART; SM00382; AAA; 2.
DR	PROSITE; PS00211; ABC_TRANSPORTER; UNKNOWN_1.
DR	PROSITE; PS00343; GRAM_POS_ANCHORING; UNKNOWN_1.
KW	ATP-binding.
SQ	SEQUENCE 2146 AA; 234306 MW; 23917285AD97E75 CRC64;
Query Match 43.4%; Score 662.5; DB 4; Length 2146;	
Best Local Similarity 44.7%; Pred: No. 1.e-47;	
Matches 127; Conservative 50; Mismatches 96; Indels 11; Gaps	
QY	1 FGKYSLEQPMWYNEQYTFVSNADPTGTLELLNALTKDGGFTRCMESNPIPTPCQ 60
Db	1263 FGHYFALRLSTMYGAQVSPFSEDAPGPGRRALLEALLOEAG-----LEPPVQ 1312
QY	61 AGESEETTPAPPTIMDLFONGNWTMONPSPACOCSSDKIKMLPVCPPGAGGLPPQPK 120
Db	1313 HSHRFSAPEVAEVAKVLASGNWTFSPSPACQCSRPGARRLLDPCPAAGPPPPQAV 1372
QY	121 QNTADILQDGRNISDYLVKTYQIIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
Db	1373 TGSGEVQNLTRGRLSDFLVKTYPRVLQGLTKKWKNEVRYGGFSLG-GRDPLGPSQE 1431
QY	181 VNDATKMKHKILKAKDSSADRLNSLGRFMTGLDTRNNKVFNNKNGKWHATSSFLNVIN 240
Db	1432 LGRSVEELWALLSPDGCALDRVLKMLTAWAHSLDQDLSKIFNNKNGKHSWVAFVNRAS 1491
QY	241 NAILRANLOKGNPSHYGITAFNHPNLTKQOLSEVALMTTSVD 284
Db	1492 NAILRAHLPFGPARHAHSITTLNHPNLTKQOLSEALMASSVD 1535
RESULT 6	
Q96S58	PRELIMINARY; PRT: 2008 AA.
ID	Q96S58
AC	Q96S58;
DT	01-DEC-2001 (TrEMBLrel. 19, Created)
DT	01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT	01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE	ABCA7-SSN.
GN	ABCA7/ABCA7-SSN.
OS	Homo sapiens (Human).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX	[1]
RN	NCBI_TaxID=9606;
RP	SEQUENCE FROM N.A.
RM	MEDLINE=21255283; PubMed=11355874;
RX	Tanaka A., Ikeda Y., Abe-Dohmae S., Arakawa R., Sadanami K.,
RA	Kidera A., Nakagawa S., Nagase T., Aoki R., Kioka N., Amachi T.,
RA	Yokoyama S., Ueda K.;
RT	"Human ABCA1 Contains a Large Amino-Terminal Extracellular Domain
RT	Homologous to an Epitope of Sjogren's Syndrome.";
RL	Biochem. Biophys. Res. Commun. 283:1019-1025(2001).
RL	EMBL; AB055390; BAB62294.1; -
DR	InterPro; IPR003439; ABC_transporter.
DR	InterPro; IPR001899; Gram_pos_anchor.

[illegible]


```
QY 192 LKLAKDSSADRFNSLGRFMTGLDTRNNVYWFNNKGWHAISSFLNINNAILRANLQKG 251
Db 815 -----IAVRRAAQVFNKNGYHSMPTYLNSLNAILRANLPKS 852
QY 252 E-NPSHYGITAFNHPNLTKQOLS-EVALMTTSV 283
Db 853 KGNPAAYGITTNHPMKNKSASLSLDYLLQGTDV 886

RESULT 9
Q9HC28 PRELIMINARY; PRT; 2436 AA.
AC Q9HC28;
DT 01-MAR-2001 (Tremblrel. 16, Created)
DT 01-MAR-2001 (Tremblrel. 16, Last sequence update)
DE Similar to KIAA1062 protein (Fragment).
DE ATP-binding cassette sub-family A member 2 (ABC transporter
DE ABCA2).
GN ABCA2.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=BRAIN;
RA Vulevic B., Chen Z., Davis W. Jr., Walsh E.S., Tew K.D.;
RT "Cloning and characterization of human ABCA2.";
RL Submitted (AUG-1999) to the EMBL/GenBank/DBJ databases.
[2]
RN SEQUENCE FROM N.A.
RX PubMed=11178988;
RA Kaminski W.E., Piehler A., Pullmann K., Porsch-Ozcuremez M., Duong C.,
RA Bared G.M., Buchler C., Schmitz G.;
RT "Complete Coding Sequence, Promoter Region, and Genomic Structure of
RT the Human ABCA2 Gene and Evidence for Sterol-Dependent Regulation in
RT Macrophages.";
RL Biochem. Biophys. Res. Commun. 281:249-258(2001).
DR EMBL; AF178941; AAG09372.1; -.
DR EMBL; AF327657; AAK14334.1; -.
DR InterPro; IPR003593; AAA_ATPase.
DR InterPro; IPR003439; ABC_transportr.
DR InterPro; IPR000561; EGF-like.
DR InterPro; IPR000572; Euk_Mb_Oxred.
DR Pfam; PF000056; Lipocln_cytFABP.
DR Pfam; PF00005; ABC_tran; 2.
DR ProDom; PD000006; ABC_transportr; 2.
DR SMART; SM00382; AAA; 2.
DR PROSITE; PS00211; ABC_TRANSPORTER; UNKNOWN_1.
DR PROSITE; PS00022; EGF_1; UNKNOWN_1.
DR PROSITE; PS00213; LIPOCALIN; UNKNOWN_1.
DR PROSITE; PS00559; MOLYBDOPTERIN_EUK; UNKNOWN_1.
KW ATP-binding.
SQ SEQUENCE 2436 AA; 269955 MW; E04A43AF14EA25D1 CRC64;

Query Match 17.5%; Score 267; DB 4; Length 2436;
Best Local Similarity 29.2%; Pred. No. 1.2e-13;
Matches 80; Conservative 35; Mismatches 73; Indels 86; Gaps 12;

QY 44 FGTRCMEG-----NPIT-DTPCQ-----AGEEWTAP-V 71
Db 1572 FDSMCLESTQGLPLSNFVPPSPAPSDPELDQAWNVSLLPPTAGPEMWTSPSL 1631
QY 72 POTIMDLFQNGNWTMONPSAPCQSSDKIKMLPVCPCAGGLPPPKQNTADILQDILT 131
Db 1632 PRLVREPVR-----CTCSAQGTGFS---CPSSVGG-HPQMRVVTGDIITDIT 1675
QY 132 GRNISDYLVKTVYQIIAKSLKNIWNEFRYGGFSLGSVNTQALPPSQEVNDAIKQMKKH 191
Db 1676 GHNVSLEYLLFTSDRF-----RLHRYGAITFG--NVLKSIPIASEFGTRAPPMVRK- 1721
QY 192 LKLAKDSSADRFNSLGRFMTGLDTRNNVYWFNNKGWHAISSFLNINNAILRANLQKG 251

Query Match 17.5%; Score 267; DB 4; Length 2436;
Best Local Similarity 29.2%; Pred. No. 1.2e-13;
Matches 80; Conservative 35; Mismatches 73; Indels 86; Gaps 12;

QY 44 FGTRCMEG-----NPIT-DTPCQ-----AGEEWTAP-V 71
Db 1572 FDSMCLESTQGLPLSNFVPPSPAPSDPELDQAWNVSLLPPTAGPEMWTSPSL 1631
QY 72 POTIMDLFQNGNWTMONPSAPCQSSDKIKMLPVCPCAGGLPPPKQNTADILQDILT 131
Db 1632 PRLVREPVR-----CTCSAQGTGFS---CPSSVGG-HPQMRVVTGDIITDIT 1675
QY 132 GRNISDYLVKTVYQIIAKSLKNIWNEFRYGGFSLGSVNTQALPPSQEVNDAIKQMKKH 191
Db 1676 GHNVSLEYLLFTSDRF-----RLHRYGAITFG--NVLKSIPIASEFGTRAPPMVRK- 1721
QY 192 LKLAKDSSADRFNSLGRFMTGLDTRNNVYWFNNKGWHAISSFLNINNAILRANLQKG 251
```

```
Db 1722 -----IAVRRAAQVFNKNGYHSMPTYLNSLNAILRANLPKS 1759
QY 252 E-NPSHYGITAFNHPNLTKQOLS-EVALMTTSV 283
Db 1760 KGNPAAYGITTNHPMKNKSASLSLDYLLQGTDV 1793

RESULT 10
Q96HC2 PRELIMINARY; PRT; 867 AA.
AC Q96HC2;
DT 01-DEC-2001 (Tremblrel. 19, Created)
DT 01-DEC-2001 (Tremblrel. 19, Last sequence update)
DE Similar to KIAA1062 protein (Fragment).
DE Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=EYE;
RA Strausberg R.;
RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC008755; AAH08755.1; -.
DR InterPro; IPR003439; ABC_transportr.
DR InterPro; IPR000561; EGF-like.
DR Pfam; PF00005; ABC_tran; 1.
DR ProDom; PD000006; ABC_transportr; 1.
DR PROSITE; PS00022; EGF_1; UNKNOWN_1.
FT NON_TER
SQ SEQUENCE 867 AA; 96734 MW; DCF6B6A90074C085 CRC64;

Query Match 17.2%; Score 262; DB 4; Length 867;
Best Local Similarity 28.8%; Pred. No. 8e-14;
Matches 79; Conservative 35; Mismatches 74; Indels 86; Gaps 12;

QY 44 FGTRCMEG-----NPIT-DTPCQ-----AGEEWTAP-V 71
Db 3 FDSMCLESTQGLPLSNFVPPSPAPSDPELDQAWNVSLLPPTAGPEMWTSPSL 62
QY 72 POTIMDLFQNGNWTMONPSAPCQSSDKIKMLPVCPCAGGLPPPKQNTADILQDILT 131
Db 63 PRLVREPVR-----CTCSAQGTGFS---CPSSVGG-HPQMRVVTGDIITDIT 106
QY 132 GRNISDYLVKTVYQIIAKSLKNIWNEFRYGGFSLGSVNTQALPPSQEVNDAIKQMKKH 191
Db 107 GHNVSLEYLLFTSDRF-----RLHRYGAITFG--NVLKSIPIASEFGTRAPPMVRK- 152
QY 192 LKLAKDSSADRFNSLGRFMTGLDTRNNVYWFNNKGWHAISSFLNINNAILRANLQKG 251
Db 153 -----IAVRRAAQVFNKNGYHSMPTYLNSLNAILRANLPKS 190

QY 252 E-NPSHYGITAFNHPNLTKQOLS-EVALMTTSV 283
Db 191 KGNPAAYGITTNHPMKNKSASLSLDYLLQGTDV 224

RESULT 11
Q9ESR9 PRELIMINARY; PRT; 2434 AA.
AC Q9ESR9;
DT 01-MAR-2001 (Tremblrel. 16, Created)
DT 01-MAR-2001 (Tremblrel. 16, Last sequence update)
DE Similar to KIAA1062 protein (Fragment).
DE Homo sapiens (Human).
GN ABC2.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Rodentia; Sclurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
```

```
RP SEQUENCE FROM N.A.
RC TISSUE=BRAIN;
RX MEDLINE=20427713; PubMed=10570803;
RA Zhao L., Zhou C., Tanaka A., Nakata M., Hirabayashi T., Amachi T.,
RA Shioda S., Ueda K., Inagaki N.;
RT "Cloning, characterization and tissue distribution of the rat ATP-
RT binding cassette (ABC) transporter ABC2/ABCA2.";
RL Biochem. J. 350:865-872(2000).
DR EMBL: AB037937; BAB16596.1; -.
DR InterPro: IPR003593; AAA_Atpase.
DR InterPro: IPR003439; ABC_transporter.
DR InterPro: IPR000561; EGF-like.
DR InterPro: IPR000566; Lipocin_cytfABP.
DR Pfam: PF00005; ABC_tran; 2.
DR ProDom: PD000006; ABC_transporter; 2.
DR SMART: SM00382; AAA; 2.
DR PROSITE: PS00211; ABC_TRANSPORTER; UNKNOWN_1.
DR PROSITE: PS00222; EGF_1; UNKNOWN_1.
DR PROSITE: PS00213; LIPOCALIN; UNKNOWN_1.
KW ATP-binding.
SQ SEQUENCE 2434 AA; 270925 MW; CD424A9C4FG3513F CRC64;

Query Match 17.0%; Score 259.5; DB 11; Length 2434;
Best Local Similarity 32.3%; Pred. No. 5,2e-13;
Matches 74; Conservative 29; Mismatches 71; Indels 55; Gaps 9;

QY 58 PCOAGEEWTAP-VFOTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPP 116
DB 1617 PTAGPETWTWAPSLPRLVHEPVR-----CTCSAQGTGFS---CPSSVGG-HP 1660

QY 117 POKQNTADLTDLTGRTNSDYLKTVQVQIIAKSLKKNKWNVEFFYGGFSLGVSNTQALP 176
DB 1661 PQMRVVTGDLDTITGHNVSEYLLFTSDRF-----RLHRYGAITFG--NIQKSI 1707

QY 177 PSEVNDIAIKQMKHKLAKDSSADRFNLGLRGFTGLDTRNNVKNVFNKNGHAISSF 236
DB 1708 PAPIGTRTLPWVRK-----IAVRVAQVLYNNKGYHSMPTYL 1744

QY 237 NVINNAILRANLQGE-NPSHYGITAFAFNHPLNLTKQOLS-EVALMTTSV 283
DB 1745 NSLNNAILRANLPKSGNPAAYGITVTNHPMKNKSASLSLDYLOGTDV 1793

RESULT 12
Q96JT3 PRELIMINARY; PRT; 2277 AA.
AC Q96JT3;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE ATP-binding cassette transporter family A member 12.
GN ABCA12.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=RETINA;
RA Bonner T.I., Moses T., Detera-Wadleigh S.;
RT "A retinal cDNA for the ATP-binding cassette transporter ABCA12.";
RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY033486; AAK54355.1; -.
DR InterPro: IPR003439; ABC_transporter.
DR Pfam: PF00005; ABC_tran; 1.
DR ProDom: PD000006; ABC_transporter; 2.
DR SMART: SM00278; HHH1; 1.
DR PROSITE: PS00211; ABC_TRANSPORTER; UNKNOWN_1.
KW ATP-binding.
SQ SEQUENCE 2277 AA; 256970 MW; EDA2F00280361E2D CRC64;

Query Match 16.4%; Score 250; DB 4; Length 2277;
```

```
Best Local Similarity 26.0%; Pred. No. 3.le-12;
Matches 75; Conservative 49; Mismatches 81; Indels 84; Gaps 14;

QY 4 YPSLELOPMWY--NEQYTFVSNDAPEDTGTELLNALTKDPGFGTRCMENPIPTPC-- 59
DB 1456 YPIQISPLSYGTSEQTAFAYNHP---STEALVSAMWDFGIDNMLNTS---DLQCLN 1509

QY 60 QAGEEWTAPVPQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQR 119
DB 1510 KDSLEKNWTSGEPIITNGV-----CSCSEN-----VQECP---KENYSPPHR 1548

QY 120 KQNTADLTDLTGRTNSDYLKTVQVQIIAKSLKKNKWNVEF---RYGGFSLGVSNTQALP 176
DB 1549 RYSSQVYINLTGQRVENYLIST-----ANEFFVKRYGWSFG----- 1586

QY 177 PSEVNDIAIKQMKHKLAKDSSADRFNLGLRGFTGLDTRNNVKNVFNKNGHAISSF 235
DB 1587 -----LPTKDLRF-----ITGVPANRTLAKVWYDEGYHSLPAY 1622

QY 236 LNVINNAILRANLQGENSPSHYGITAFNHPNLTKQOLSEVALMTTSVD 284
DB 1623 LNSLNNAILRANVMSKYDAARH-GIIMYSHPYPGVQDQ--EQATISSLID 1668

RESULT 13
Q01790 PRELIMINARY; PRT; 1547 AA.
AC Q01790;
DT 01-JUL-1997 (TrEMBLrel. 04, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Hypothetical 173.7 kDa protein.
GN F12B6.1.
OS Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;
OC Rhabditidae; Pelodierinae; Caenorhabditis.
OX NCBI_TaxID=6239;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=BRISTOL N2;
RX MEDLINE=99069613; PubMed=9851916;
RA Waterston R.;
RT "Genome sequence of the nematode C. elegans: a platform for
RT investigating biology. The C. elegans Sequencing Consortium.";
RL Science 282:2012-2018(1998).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=BRISTOL N2;
RA Pauley A., Maggi L.;
RT "The sequence of C. elegans cosmid F12B6.";
RL Submitted (MAY-1997) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=BRISTOL N2;
RA Waterston R.;
RL Submitted (APR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL: AF003138; AAK21369.2; -.
KW Hypothetical protein.
SQ SEQUENCE 1547 AA; 173682 MW; A532D93977006C67 CRC64;

Query Match 14.1%; Score 215.5; DB 5; Length 1547;
Best Local Similarity 24.2%; Pred. No. 1.7e-09;
Matches 86; Conservative 44; Mismatches 105; Indels 121; Gaps 15;

QY 5 PSLELOPMWYNEQYTFVSN--DAPEDTGTELLNALTKDPGFGTRCMEG--NPYPDT--- 57
DB 605 PPLPLETSTINGNSDFYVNSWDTAENSTANDILHAMFSPGTPGRCADVPNDLLDTMR 664

QY 58 -----PCQ--AGEEWT-----TAPVPQTIMDL- 78
DB 665 ELMFRNRYGFRNKPAGPVKDSVDNEYQCNIQGEFYDTEDISNATYNAPIYGCEDFG 724

QY 79 ----FQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQRKQNTADLTDLQLTGRN 134
```



```
Qy 117 POKONTADILDLTGRN--ISDYLKVKTYVQIIAKSL-----KNKIWNNEFR 161
Db 698 -----DPIFKIGVNEIPGEHYLNNYLKRIVLVSACQVGSDDCYNQSANL--SEYL 747
Qy 162 YGFSGLGVS-NTQALPPS--QEVNDAIKQMKHLKAKDSSADR--FLNSLG----- 208
Db 748 YNGTAIEATLKTQAYCAGLRSTTNEIYSRVQSDL-LSSSDSTDRLSFISLGCSTSQL 806
Qy 209 ---RPMTGLDTRNNYKVMFNKNGWHAISSEFLNVINNALRANLOKGENPSHYGITA 261
Db 807 LDFLRSLDTNNSL-----SYSERTSLLNSAYSR-----SEIGLTA 842
```

Search completed: February 4, 2003, 09:40:17
Job time : 43 secs